The development of functionalised stapled peptides as chemical tools to modulate biological processes in platelets and as novel antimicrobial therapeutics targeting Pseudomonas aeruginosa by Gaynord, Josephine





The development of functionalised 
stapled peptides as chemical tools to 
modulate biological processes in 
platelets and as novel antimicrobial 






University of Cambridge 
July 2020 
 
Supervised by Professor David R. Spring 
 





Peptides are useful modulators of protein-protein interactions (PPIs) and cellular membranes, 
both of which are traditionally challenging to target using small molecules. Often therapeutic 
peptides suffer from issues including poor proteolytic stability. Two-component peptide 
stapling can improve stability and enable facile peptide functionalisation. This thesis describes 
the development of functionalised stapled peptides for two biological applications.   
 
1. The development of stapled peptides as chemical tools to investigate PPIs in human 
platelets  
Platelets are a vital, anuclear component of blood. The Bcl-2 family of proteins are known to 
be key mediators of apoptosis in nucleated cells, however the role of each Bcl-2 protein in 
platelet apoptosis and activation is unknown. Recently, stapled peptides were deemed useful 
chemical tools for studying PPIs in platelets. In this section, three polyarginine-functionalised 
stapled peptides were developed as Bcl-2 PPI inhibitors. These novel chemical tools are 
anticipated to provide valuable insight into the roles of Bcl-2 PPIs in platelet modulation, which 
could ultimately lead to new therapeutic targets. 
 
2. The development of cleavable stapled peptide-drug conjugates to target 
Pseudomonas aeruginosa 
Antimicrobial resistance (AMR) is a major healthcare threat, and Gram-negative bacteria such 
as Pseudomonas aeruginosa pose a significant therapeutic challenge. Antimicrobial peptides 
disrupt bacterial membranes, however functionalised two-component stapled antimicrobial 
peptides (STAMPs) are underexplored. This section describes the development of a STAMP-
drug conjugate, constructed by functionalisation of the STAMP staple with a small molecule 
antibiotic, attached via a β-lactamase-cleavable motif. The resulting conjugate combines two 
mechanisms of action, which is a validated strategy for overcoming AMR. To this end, two 
novel, unfunctionalised STAMPs were identified that exhibited good minimum inhibitory 
concentrations against P. aeruginosa (64 µg/mL) and selectivity over a Gram-positive strain, 
from a panel of seven novel STAMPs. Subsequently, a tractable synthesis of the proposed 
functionalised STAMP was investigated. It is hypothesised that the cleavable STAMP-drug 




Figure 0 A summary of functionalised stapled peptides as both chemical tools to study protein-protein interactions 
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1. Chapter 1 - Introduction 
1.1 Peptides as drugs and tool compounds: pros and cons 
Historically, drug discovery has focused on small molecule therapies, which typically bind to 
well-defined pockets on proteins. At the other end of the scale with respect to size, biologics 
(e.g. monoclonal antibodies) are primarily used to target protein-protein interactions (PPIs), 
which are usually shallow and cover a comparatively large surface area, however they lack 
cellular penetration.1 Peptides occupy the space between these two extremes in terms of their 
size and properties as biologically active chemicals (Table 1).2 Peptides can access a range 
of different biological targets, including PPIs, and display distinct pharmacologic profiles.3 A 
comparison of these three classes of therapeutics is drawn in Table 1.  
Table 1 A comparison of small molecules, peptides and biologics looking at typical characteristics of each class of 
drugs. Adapted from Passioura.4 

























Plasma half life Hours Minutes-hours Weeks 
Membrane 
permeable? 
Yes Sometimes No 
Orally 
bioavailable? 
Usually Sometimes No 
Specificity for 
target 
Moderate High High 
Insulin became the first peptide drug to enter the market in 1923 for the treatment of diabetes; 
today there are over 150 peptide-based drugs in clinical trials, with around 60 on the market.5 
The first peptide drugs targeted extracellular hormone receptors, and it is still the case that 
most peptides in the clinic have extracellular targets, including G-protein coupled receptors, 
immunoglobulin family receptors and ion channels.2 Today, the variety of targets accessed by 
peptides has increased, with intracellular targets no longer off limits.6,7  
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Aside from their uses as disease-modifying therapeutics, peptides can also be used as 
chemical tools (or ‘probes’). A chemical tool is any compound with high affinity and specificity 
for its target that can be used to study a biological system; it may not have the appropriate 
physicochemical properties or pharmacokinetics to be developed into a drug. As chemical 
tools, peptides enable biological investigations of targets that were previously inaccessible 
with small molecule probes.8  
Due to their unique size and composition, peptides have a number of advantages and 
disadvantages which are summarised in Table 2. 
Table 2 A summary of key advantages and disadvantages of peptides as drugs. 
Advantages of peptides  Disadvantages of peptides 
High potency and selectivity 
Applicable to a broad range of targets 
Easy access to chemically and biologically 
diverse therapeutics 
Good safety and efficacy 
Poor proteolytic stability 
Short half-life and fast elimination 
Low membrane permeability 
Usually not orally bioavailable 
Rapid renal clearance 
 
With respect to their disadvantages, peptides suffer from poor absorption, distribution, 
metabolism and excretion (ADME) properties,5 and they often have short half-lives (e.g. 
minutes) due to rapid renal excretion and proteolytic degradation in plasma.9 Additionally, 
peptides are much less likely to be cell permeable than small molecules due to their 
comparatively high molecular weight, numbers of hydrogen bond donors and acceptors and 
high polar surface area.10 Most peptides have extremely low bioavailability (<1%) meaning 
that very few peptide drugs can be taken orally, the more favourable route due to higher patient 
compliance.5 Indeed, analysis of the marketed peptide drugs (Table 4, Section 1.4) shows that 
only one linear peptide (semaglutide) and two cyclic peptides (cyclosporin A and linaclotide) 
can be taken orally.11,12  
Despite these potential disadvantages, peptides offer many advantages over both biologics 
and small molecules. Peptides can give comparable affinity and target selectivity as biologics, 
such as antibodies, however bulk peptide synthesis can be much cheaper.13 Additionally, 
peptides can access intracellular targets and have vastly improved tissue penetration over 
biologics.14 Compared to small molecule drugs, peptides can have much stronger interactions 
with their intended targets and higher specificity as they are comprised of endogenous amino 
acids capable of making high numbers of interactions with target proteins. Finally, peptides 
often display low toxicity and immunogenicity and present a lower risk of drug-drug interactions 




1.2 Overcoming the problems with peptides 
Synthetic modifications can be made to peptides to improve their properties and overcome 
the disadvantages discussed in the previous section. The result of modifying a peptide is a 
peptidomimetic: a molecule which mimics the binding properties of the parent peptide. 
Peptidomimetics can range from peptides with minimal structural alterations to structurally 
unrelated small molecules which mimic the mechanism of action of the parent peptide. A 
modern classification of peptidomimetics is proposed by Grossmann and co-workers:15  
• Class A – peptides where a few amino acids may have been introduced and minor 
modifications made to the backbone, but are mostly unchanged overall. 
• Class B – peptides which have undergone significant backbone modifications, multiple 
amino acid substitutions and/or the incorporation of small molecule fragments (includes 
peptoids). 
• Class C – non-peptidic small molecules where substituents are presented in a similar 
fashion to the key residues of the parent peptide. 
• Class D – small molecules which do not relate to the parent peptide structure, but which 
mimic the mode of action of the peptide. 
Examples of the types of modifications which can be made to peptides are shown in Figure 1. 
To reduce proteolytic degradation L-amino acids (A, Figure 1) can be replaced with D-amino 
acids (B, Figure 1), N-methylation and α-methylation performed (C, Figure 1) or β-amino acids 
or peptoids (D and E respectively, Figure 1) can be introduced into the peptide.16 To avoid 
metabolic instability, specific amino acids which have been identified as metabolically liable 
can be replaced with unnatural analogues.5 
 
Figure 1 Selected strategies for improving the proteolytic stability of peptides. A: A standard L-amino acid, B: A D-
amino acid, C: α-methylation and N-methylation, D: Use of β-amino acids, E: An alanine peptoid.  
Macrocyclisation is another strategy which has the potential to improve multiple properties of 
therapeutic peptides. Macrocyclisation can occur either head-tail, side chain-head, side chain-
tail or side chain-side chain (Figure 2): all of these different connections are represented in 




Figure 2 A cartoon depicting the possible macrocyclisation positions on a linear peptide. Adapted from White and 
Yudin.18 
Peptide cyclisation can be beneficial for:  
1. Constraining the peptide in a biologically relevant conformation such as an α-helix or β-
turn to reduce the entropic penalty upon binding to the target.18–20 
2. Improving the proteolytic stability.21 
3. Improving the cellular permeability.22 
4. Introducing further functionality (e.g. a fluorescent tag for biochemical assays).23–25 
5. Modulating the physicochemical properties of the peptide.18 
The work in this thesis is concerned with side chain-side chain macrocyclisation, often called 
‘stapling’, as it will be referred to from herein. The following section discusses different 
approaches to peptide stapling.  
 
1.2.1 Stapled peptides 
Peptide stapling can be performed in either a one-component or two-component manner. One-
component stapling involves the intramolecular reaction of two amino acid side chains (A, 
Figure 3), whereas two-component stapling involves the reaction of an external linker with two 




Figure 3 A schematic overview of peptide stapling. A) One-component peptide stapling, and B) two-component 
peptide stapling. The peptide is shown as a blue line or helix, amino acid side chains as green rectangles or yellow 
ovals and the reactive handles on the linker as grey triangles.   
Often one of the aims of peptide stapling is to fix the peptide in a particular conformation to 
reduce the entropic penalty associated with re-organisation prior to target-binding.15 In 
particular, peptides are commonly stapled to induce an α-helical conformation as this 
structural motif is of high biological relevance: around 30-40% of the structural features in 
proteins are α-helices.26 Furthermore, PPIs are a common target for peptide therapeutics and 
chemical tools and it has been estimated that α-helices contribute to binding in over 60% of 
PPIs.27 One turn of an α-helix spans 3.6 residues and helices are naturally stabilised by 
intramolecular hydrogen bonding between the carbonyl and peptide backbone NH at positions 
i,i+4.15 If an α-helical peptide is desired, stapling is often performed at i,i+4, 7 or 11 positions 
(Figure 4). However the advantages of peptide stapling go beyond conferring conformational 
rigidity and some of the examples discussed in the following sections involve peptide stapling 
at alternative positions to those which promote α-helicity. In these cases, stapling was 
performed either to achieve different biologically relevant conformations, improve proteolytic 
stability or to introduce functionality to the peptide sequence.  
 
Figure 4 A cartoon of an α-helix showing the optimal staple positions for the stabilisation of the secondary structure. 
Residues at i, i+4, i+7 and i+11 positions span one, two or three turns of the helix, respectively.  
 
1.2.1.1 An overview of one-component peptide stapling 
The earliest reported approach to peptide stapling involved one-component lactamisation 
between acid- and amine-bearing canonical amino acid side chains.28 Another of the first 
methods to be reported was the formation of disulfide bonds, however, due to the chemical 
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instability of the resulting linkage this approach has not been widely adopted.29 In recent years 
the field has advanced significantly, and now unnatural amino acids are frequently employed 
in stapling strategies. The current ‘gold standard’ of one-component peptide stapling is 
hydrocarbon stapling, wherein unnatural alkenyl amino acids are introduced into the peptide 
sequence, which is subsequently cyclised by ring-closing metathesis (RCM). This method 
yields an all-hydrocarbon stapled peptide and was first reported by Blackwell and Grubbs,30 
and later developed by Verdine (Scheme 1).31 RCM stapling is popular due to its synthetic 
simplicity; however, the alkene-containing unnatural amino acids are expensive or can require 
long synthetic routes.  
 
Scheme 1 The initial peptide macrocyclisation via RCM reported by Grubbs and Blackwell.30 
Other one-component stapling methodologies which make use of unnatural amino acids 
include copper-catalysed azide-alkyne cycloadditions (CuAAC),32 UV-promoted 
cycloadditions,33 thiol-ene reactions,34 oxime formation,35 thioether formation,36 and CH 
activation.37,38  
One major downside to one-component peptide stapling is that it does not usually append any 
functionality onto the peptide. A straightforward site of functionalisation is the N-terminus of 
the peptide, or a reactive amino acid side chain residue (e.g. the lysine ε-amino group).39 
Alternatively, the staple linker can be functionalised, which can occur via two different methods 
(Figure 5). Modification of the linker can take place before macrocyclisation, however every 
different analogue would require re-synthesis of the unnatural amino acids and peptide chain. 
Alternatively, once stapled the linker can be modified, although this method of functionalisation 
has seldom been reported in the literature.40 The dual functionalisation of one-component 
stapled peptides poses a significant synthetic challenge and would require a combination of 




Figure 5 A cartoon depicting the functionalisation of a one-component stapled peptide via appendage of the 
functionality onto the staple either pre or post-macrocyclisation. The peptide is shown as a blue line or helix, amino 
acid side chains as green rectangles or yellow ovals and the functionality as red stars. 
 
1.2.1.2 Two-component peptide stapling 
Two-component peptide stapling involves a bimolecular reaction between a linker and two 
amino acid side chain residues. The major advantage of two-component peptide stapling is 
that the linker and peptide can be varied independently of each other and brought together in 
a combinatorial manner. One disadvantage is the possibility of forming double-addition 
products instead of the desired macrocyclic peptides (Figure 6).41 To combat this, two-
component stapling reactions are typically performed at low concentrations with near-
equivalent amounts of peptide and linker.  
 
Figure 6 A cartoon depicting the formation of possible side-products during two-component peptide stapling. The 
peptide is shown as a blue line or helix, amino acid side chains as green rectangles and the linker reactive handles 
as grey triangles. 
Two-component stapling can be performed using natural and unnatural amino acids, and the 
linkers can vary in size from a simple methylene unit to much larger linkers.42  
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1.2.1.2.1 Two-component peptide stapling using unnatural amino acids 
The use of unnatural amino acids in two-component stapling provides excellent 
chemoselectivity, which is important given the number of potentially competing reactive 
groups in a peptide. However, unnatural amino acids must be synthesised or purchased, often 
at a high cost. The most common method of two-component peptide stapling using unnatural 
amino acids is double CuAAC stapling. This involves the incorporation of two azide-containing 
amino acids into the peptide sequence and stapling with a bis-alkynyl linker. This approach 
was initially reported by Bong and co-workers,43 and developed further by the Spring group,44 
Pedersen and co-workers,45 and Thurber and co-workers.46 The conditions developed by the 
Spring group for two-component CuAAC stapling are shown in Scheme 2.44  
 
Scheme 2 The CuAAC stapling of a peptide designed to disrupt the p53/MDM2 PPI under conditions reported by 
Lau et al.44  
A complementary approach was also developed by the Spring group using a strain-promoted 
azide-alkyne cycloaddition (SPAAC), which removes the need for the potentially cytotoxic 
copper catalyst required for CuAAC, thus allowing in situ peptide stapling (Scheme 3).47 
 
Scheme 3 The SPAAC stapling of a peptide a peptide designed to disrupt the p53/MDM2 PPI under conditions 
reported by Lau et al.47 
 
1.2.1.2.2 Two-component peptide stapling using cysteine  
Using natural amino acids for peptide stapling provides the benefits that they are widely 
available and cheap, however, they are more likely to result in issues of chemoselectivity. To 
mitigate this problem, numerous methods based upon the reactivity of the thiol group in 
cysteine have been developed. Cysteine has a relatively low natural abundance in proteins 
and peptides and, under the correct reaction conditions, can display orthogonal reactivity to 
the other functionalities commonly present in peptides, thus making it an ideal candidate for 
peptide stapling methodologies.48  
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The most prolific two-component cysteine stapling reaction is alkylation, which has been 
reported by several groups. The use of benzyl and alkyl halides was developed by Timmerman 
and co-workers, and named chemical linkage of peptides onto scaffolds (CLIPS, A, Figure 
7).49 The CLIPS technology can give mono-, bicyclic and functionalised peptides;50,51 it can 
also be combined with orthogonal ring-forming reactions (such as CuAAC) to give complex tri- 
and tetra-cyclic peptide scaffolds.52,53 Additionally, the CLIPS methodology has been applied 
to the generation of cyclic peptide libraries via phage display by Winter and co-workers.54 
Woolley and co-workers used cysteine alkylation to perform a peptide stapling screen, 
investigating the effect of the linker length and rigidity on the helical content of the resulting 
cyclic peptides.55 The same group used this stapling reaction to introduce diazobenzene 
linkers, allowing photocontrol of the helical content of the stapled peptides (B, Figure 7).56,57 
The simplest staple scaffold for cysteine alkylation was developed by Kourra and co-workers, 
in which diiodomethane is used to introduce a methylene unit (C, Figure 7). This has been 
used to mimic native disulfide bonds, eliminating the potential for disulfide reduction which can 
result in a loss of activity.58 Dawson and co-workers published the stapling of peptides by 
alkylation with 1,3-dichloroacetone (DCA),59 and illustrated that the resulting macrocyclic 
peptides could be functionalised via oxime formation (D, Figure 7). Finally, Bernardes and co-
workers reported the grafting of peptides using a dibromo isobutylene linker (E, Figure 7).60  
 
Figure 7 A cartoon depicting two-component stapling methodologies which use an SN2 reaction to bridge between 
two cysteine residues with an alkyl halide linker. A) alkylation with various alkyl and aryl halides,49 B) incorporation 
of a photo-switchable linker via alkylation,57,56 C) formation of a methylene bridge with diiodomethane,58 D) DCA 
stapling and functionalisation via oxime formation,59 and E) peptide grafting with an isobutylene linker.60 The 
peptide is represented by a blue line, and functionality as a yellow star.  
There are several approaches to peptide stapling based around SNAr reactions with suitable 
aromatic linkers (Figure 8). Pentelute and co-workers published two-component peptide 
stapling between Cys residues with perfluoroaryl linkers (A, Figure 8).61 The lipophilic nature 
of these perfluoroaryl linkers was used to improve the blood-brain-barrier penetration of a Bim 
BH3-only peptide which, once stapled, showed enhanced in vivo brain penetration relative to 
the linear peptide.62 Similarly Derda and co-workers published a similar macrocyclisation, 
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instead using a decafluoro-diphenylsulfone linker (B, Figure 8).63 Finally, Smith and co-
workers published a stapling approach using a dichloro-tetrazine linker (C, Figure 8). The 
resulting stapled peptide could be functionalised via an inverse electron-demand Diels-Alder 
reaction, and the staple could be completely removed in a two-step process involving 
irradiation with UV and treatment with cysteine, returning the linear peptide.64  
 
Figure 8 A cartoon depicting two-component Cys peptide stapling methodologies which use SNAr chemistry. A) 
Stapling with perfluoroaryl linkers,61,62 B) Stapling with a decafluoro-diphenylsulfone linker,63 and C) Stapling with 
a tetrazine linker.64 The peptide is represented by a blue line. 
Thiol-ene reactions have been incorporated into peptide stapling approaches: Chou et al. 
published the reaction between a peptide bearing two Cys residues and a bis-alkenyl linker in 
the presence of a radical initiator and UV irradiation (A, Figure 9).34 There are also multiple 
methods using conjugate addition, and the groups of Keillor and Wilson have published similar 
approaches using maleimide linkers. Keillor and co-workers performed peptide 
macrocyclisation with a bis-maleimide linker, onto which functionality could be appended (B, 
Figure 9).65 Wilson and co-workers used a single dibromomaleimide to bridge between Cys 
residues, and functionality (e.g. a FITC tag or a PEG chain) was added via the nitrogen (C, 
Figure 9).66 This stapling procedure is also reversible, as the addition of excess thiol, such as  
glutathione returns the linear peptide.  
 
Figure 9 A cartoon depicting peptide stapling methodologies involving the conjugate addition, or thiol-ene reactions 
of Cys residues. A) The thiol-ene reaction with bis-alkenyl linkers,34 B) Stapling via conjugate addition with a bis-
maleimide linker,65 C) Stapling via a double conjugate addition into a dibromomaleimide,66 and D) Cyclisation via 
the conjugate addition of Cys residues with divinylheterocycles.67 The peptide is represented by a blue line, variable 
groups as a grey shape, and functionality as a yellow star. 
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The reaction of Cys residues and divinyl heterocycles (DVHs) has been applied to the 
macrocyclisation of unprotected peptides under mild conditions (D, Figure 9).67,68 A peptide 
designed to inhibit the p53/MDM2 PPI was stapled with a divinyl triazine (DVT) linker between 
i,i+7 positions (A, Scheme 4), and the cyclic peptide showed improved serum stability and 
increased α-helicity compared to a linear analogue. In addition to this, fluorescence 
polarisation showed that the Cys-DVT stapling gave Ki = 13 ± 0.7 nM, around a 60-fold 
increase in binding affinity compared to literature values for the wild-type p53 peptide (Ki = 
821 ± 56 nM).23 The same peptide was stapled with a FITC-functionalised divinylpyrimidine 
(DVP) linker, and a polyarginine CPP was appended to the macrocyclic peptide via CuAAC 
(B, Scheme 4).69 Confocal microscopy of the resulting stapled peptide, Pep-FITC-RRR, 
confirmed uptake by U2OS cells, whereas an analogue lacking the polyarginine CPP was not 
cell permeable.   
 
Scheme 4 The Cys-DVH stapling of a p53/MDM2 peptide. A) The literature stapling conditions to give an 
unfunctionalised DVT stapled peptide reported by Robertson et al.67and B) The structure of a dual-functionalised 
DVP stapled peptide reported by Walsh et al.69 The CPP is highlighted in red and FITC in blue.   
Finally, peptide macrocyclisation strategies have been reported which use palladium-
mediated arylation of cysteine. The groups of Pentelute and Buchwald published a two-




Figure 10 A cartoon depicting peptide macrocyclisation via the palladium-mediated arylation of Cys residues.70–72 
The peptide is represented by a blue line. 
 
1.2.1.2.3 Two-component peptide stapling using lysine  
After cysteine, lysine is the next most common amino acid residue for use in peptide stapling, 
due to the high nucleophilicity of the ε-amino group. One of the earliest two-component 
stapling methodologies was published by Phelan and co-workers in 1997.28 They prepared 
macrocyclic peptides via a double lactamisation with two glutamic acid residues and a bis-
amino linker, however, this required an orthogonal protection strategy and often lead to the 
formation of significant side-products (A, Figure 11). This methodology was employed by 
Fujimoto et al. to investigate the effect of different staple lengths and rigidities on the helicity 
of the resulting macrocyclic peptides (B, Figure 11).73 There are several two-component 
stapling technologies which use a combination of different strategies. A recent example was 
published by the groups of Pentelute and Buchwald, wherein an initial palladium-mediated 
Cys arylation introduces a phenyl carbamate, which then reacts with a lysine residue to give 
the cross-linked peptide (C, Figure 11).74  
 
Figure 11 A cartoon depicting the peptide stapling methodologies which incorporate lysine residues. A) Peptide 
stapling via lactamisation between Glu residues with a bis-amino linker,28 B) stapling between Lys residues with a 
bis-carboxylic acid linker,73 C) peptide stapling via Cys arylation and subsequent cyclic urea formation.74 The 
peptide is represented by a blue line. 
 
1.2.1.2.4 Two-component peptide stapling using other amino acids  
Tryptophan is the only other canonical amino acid for which there is a published two-
component stapling methodology. Johannes and co-workers reported a condensation reaction 
between two Trp residues and an aryl aldehyde yielding a macrocyclic peptide (Figure 12).75 
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This method has the potential to allow functionalisation of the cyclic peptide, by modification 
of the aryl bromide.  
 
Figure 12 A cartoon depicting the condensation reaction between two Trp residues and an aryl aldehyde.75 
 
1.2.1.3 Functionalised two-component stapled peptides 
Two-component peptide stapling allows the facile appendage of tags (e.g. fluorescent dyes) 
to the staple itself. The advantages of this approach are two-fold: placing the functionality on 
the staple (rather than the N- or C-terminus of peptide) distances this added group from the 
interacting region of the peptide, thus making it less likely to negatively impact binding. 
Additionally, from one peptide sequence, different analogues can be rapidly produced by 
performing parallel stapling reactions with different linkers (Figure 13).  
 
Figure 13 A cartoon showing the ease of functionalisation for two-component stapled peptides: from one linear 
peptide sequence a library of stapled analogues can be rapidly constructed using different linkers. The peptide is 
shown as a blue line or helix, amino acid side chains as green rectangles and the reactive handles on the linker as 
grey triangles. Functionality on the linker is shown as either yellow or red stars. 
The ability to easily add functionality to peptides is particularly relevant in the development of 
biologically active peptides, which frequently require modification if they are to be studied via 
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biochemical assays: for example the attachment of fluorescent tags onto peptides is often 
required to track their cellular localisation. The ease with which this can be performed was 
demonstrated by Lau et al., who appended a TAMRA dye onto a p53 peptide via two-
component CuAAC stapling (A, Figure 14).23 In the literature there are many other examples 
of fluorescently-labelled stapled peptides where the dye has been appended via stapling.59,76   
Whilst there are some examples in the literature of stapled peptides exhibiting cell penetration, 
it is not the case that stapling a peptide will always confer cellular penetration.18 Therefore, a 
growing area of research includes the appendage of cell penetrating peptides (CPPs) to 
biologically-active peptides to improve their cellular penetration.23,77,78 An illustrative example 
from Dawson and co-workers consists of a polyarginine CPP appended to a model peptide 
using Cys-DCA stapling (B, Figure 14).59 Iegre et al. achieved dual functionalisation of a two-
component CuAAC stapled peptide targeting the protein kinase CK2. Both a polyarginine CPP 
and FITC label were introduced on the staple linker (C, Figure 14), resulting in a cell-
permeable stapled peptide which was significantly more stable in serum than a linear 
analogue.25 This example illustrates the utility of two-component peptide stapling for 
developing useful chemical tools and therapeutics.   
  
Figure 14 Selected examples of functionalised two-component stapled peptides. A: The fluorescent tag TAMRA 
(blue) introduced via CuAAC stapling.23 B: Polyarginine CPP (red) introduced via DCA stapling.59 C: Dual-
functionalisation wherein both a polyarginine CPP (red) and fluorescent tag FITC (blue) are introduced via CuAAC 
stapling.25 Peptide is shown as a blue helix.  
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The appendage of affinity tags to biologically active molecules allows the study of their 
interactions, as well as their isolation from complex mixtures. Dawson et al. introduced biotin, 
a streptavidin-affinity tag, to a model peptide using DCA stapling and oxime functionalisation 
(A, Figure 15).59 Photoaffinity tags (e.g. the benzophenone moiety) form covalent bonds with 
biomolecules upon exposure to UV light, and have previously been incorporated into stapled 
peptides by the introduction of a benzophenone-containing unnatural amino acid.79 However, 
this approach has several disadvantages: the reactive moiety could negatively affect the 
peptide binding and investigating different photoaffinity motifs would require the synthesis of 
multiple different unnatural amino acids and peptides. Introducing the photoaffinity motif via 
peptide stapling circumvents these issues, and was demonstrated by Wu et al., who 
synthesised a p53 CuAAC-stapled peptide bearing a benzophenone photoaffinity motif on the 
peptide staple (B, Figure 15).24  
In the same way, the introduction of an electrophilic motif to a stapled peptide to give a 
covalent inhibitor can be achieved through the introduction of an unnatural amino acid bearing 
the reactive moiety.80 However, for the same reasons as discussed above, it is beneficial to 
introduce the functionality away from the peptide sequence. Charoenpattarapreeda et al. 
demonstrated this, introducing an electrophilic moiety to a p53 peptide via two-component 
CuAAC stapling (C, Figure 15).81 
 
Figure 15 Examples of functionality that can be added via the staple; A) an affinity probe, biotin, introduced via 
DCA stapling,59 B) a benzophenone photoaffinity probe introduced via CuAAC,24 and C) an electrophilic motif 
introduced via CuAAC.81 Peptide is shown as a blue helix.  
 
1.3 Sources of biologically active cyclic peptides 
Biologically active peptides can be sourced from nature, biological and chemical library 
construction, and structure-based design. Each of these approaches will be discussed in this 
section, highlighting notable peptides which have been discovered using each method. 
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1.3.1 Cyclic peptides from natural sources 
Nature provides a vast repertoire of biologically active peptides with different structures and 
functions. For example, mammals produce peptide hormones such as insulin and 
somatostatin,2 and many organisms, including insects and bacteria, produce peptides with 
antimicrobial activity.82 These natural peptides have served as the inspiration for many 
marketed peptide therapeutics, including oxytocin, a natural-hormone used to induce labour,83 
and the antimicrobial colistin (Figure 16). Both of these drugs have been designated essential 
medicines by the World Health Organisation (WHO).84 
 
Figure 16 The structure of oxytocin, a drug derived from a natural peptide hormone, and colistin, a marketed 
antimicrobial peptide which is a natural product first isolated from bacteria. 
 
1.3.2 Cyclic peptides from library screening 
An important approach to identifying target-binding peptides is the screening of chemical 
libraries. In particular, genetically-encoded libraries (GELs) represent an extremely powerful 
method for peptide discovery as vast libraries of high diversity can be rapidly generated and 
screened.85 There are several approaches to the construction of GELs: 
• DNA-encoded libraries (DELs) 
• mRNA display 
• Phage display  
• Split-intein circular ligation of peptides and proteins (SICLOPPS) 
Synthetic DELs can be prepared in a combinatorial manner, wherein each peptide is 
covalently attached to a DNA ‘barcode’ containing genetic information relevant to the amino 
acid sequence.86 Whilst these libraries are relatively cheap and easy to prepare, the possible 
synthetic transformations are limited to those which are compatible with DNA.87  
DELs, phage display and mRNA display libraries share similar screening procedures: once 
synthesised, the peptides remain covalently attached to their coding entity and are screened 
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against an immobilised protein target to identify active binders. The peptide sequence and 
structure can be determined by sequencing the attached genetic information. These methods 
all, therefore, share the potential disadvantage that the affinity of the peptide may be 
negatively affected by the presence of the large encoding moiety.  
mRNA display involves in vitro translation and transcription, thus avoiding the dependency of 
peptide synthesis on E. coli transformation (Figure 17). The Suga group developed de novo 
ribozymes, named the ‘Flexizyme’ technology, which enable the incorporation of unnatural 
amino acids into a growing peptide chain.88 The result of mRNA display is a library of peptides 
linked to their encoding mRNA strand via a puromycin linker. Cyclisation can occur by the 
incorporation of an N-chloroacetyl group and subsequent reaction with a cysteine residue in 
the peptide to form a thioether linkage (Figure 17),89 although several other cyclisation 
techniques have also been reported.90  
 
Figure 17 A cartoon depicting mRNA display for the screening of cyclic peptides. The linear peptide is attached to 
an encoding mRNA strand and then cyclised in situ, often via thioether formation (inset). The cyclic peptide is then 
screened against an immobilised protein target.  
During phage display library construction, bacteriophages are engineered to produce and 
‘display’ peptides on their surface (Figure 18). Among many different cyclisation methods,90 
the most common and straightforward include disulfide formation,91 or cysteine alkylation 
using the proprietary CLIPS technology which was developed by Timmerman and applied to 




Figure 18 A cartoon depicting peptide screening via phage display, wherein bacteriophages are engineered to 
display a peptide on their surface. Peptide macrocyclisation can occur via alkylation of cysteine residues with 
CLIPS reagents (inset), and screening is performed using immobilised protein targets.  
Tavassoli and co-workers have developed an alternative approach, SICLOPPS, wherein 
protein splicing is manipulated for cyclic peptide production.92 Plasmids are engineered which 
code for the desired peptide sequence, flanked by two self-excising intein domains (the ‘split 
intein’). After translation, the desired peptide is spliced and cyclised head-to-tail; a process 
which can be performed in yeast, bacterial and human cells (Figure 19).93 To identify active 
PPI inhibitors, SICLOPPS is frequently combined with a Reverse Two-Hybrid System (RTHS) 
in genetically-engineered E. coli. The bacteria are dependent on the disruption of the target 
PPI for survival, so when effective cyclic peptide inhibitors are produced via SICLOPPS, the 
PPI is disrupted or inhibited, allowing the RTHS bacteria to survive and grow.94 The 
SICLOPPS/RTHS approach allows the identification of cyclic peptides by the desired 




Figure 19 A schematic overview of SICLOPPS approach to cyclic peptide production and screening. A library of 
SICLOPPS plasmids are produced, which code for the peptide of interest. Splicing of the desired sequence from 
the split-intein gives cyclic peptides. Combining SICLOPPS with a RTHS allows the identification of PPI inhibitors 
in an intracellular environment based on functional data.  
The methods of discovering biologically active cyclic peptides discussed in this section are 
extremely powerful; each method has distinct advantages and disadvantages, which are 
summarised in Table 3.  
Table 3 An overview of some library-based approaches of discovering therapeutic cyclic peptides. Adapted from 






Functional assay data 
 
Library size dependent on 
transformation of host 
 
Limited to natural amino acids 
 





commercial kits available  
 
High-affinity (nM) peptides 
can be identified 
Diversity limited by 
transformation efficiency of 
the host 
 
Screening with peptide linked 





In vitro; no limitation on 
library size due to 
transformation efficiency 
 
Multiple unnatural amino 
acids can be incorporated 
Screening with peptide linked 
to large mRNA strand; can 
affect binding affinity 
†SICLOPPS: Lower estimate (for hexamers) from Valeur et al.,94 upper estimate from Sohrabi et al.,85 Phage 
display: lower estimate from Sohrabi et al.,85 upper estimate from Passioura and Suga.89  
In the last two decades, several drug-discovery companies have been founded based on these 
technologies.41 One example is Bicycle Therapeutics, who employ phage display and the 
CLIPS cyclisation technology to discover therapeutic macrocyclic peptides, bicyclic peptides 
and peptide-drug conjugates (PDCs).96 Similarly, PeptiDream was founded by Hiroaki Suga 
to develop cyclic peptides using mRNA display techniques and the previously described 
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Flexizyme technology. Most recently, Curve Therapeutics was founded by Ali Tavassoli to 
develop cyclic peptide PPI inhibitors using SICLOPPS technique.85 There are five peptides in 
the clinic which were first synthesised and identified using display techniques,97 as well as 
three PDCs which will be discussed in Chapter 3.  
 
1.3.3 Cyclic peptides from structure-based design 
If significant structural information about the target is available (e.g. X-ray crystallography 
data) then peptides can be rationally designed with the assistance of in silico experiments. 
This approach is often adopted for the design of peptides to inhibit well-characterised PPIs, 
as the starting peptide sequence can often be derived from the protein-binding epitopes.15 
Computational experiments such as alanine scanning can determine key interactions and, 
along with molecular dynamics, this can guide the design of peptidomimetics.98 A key example 
of a peptide developed by structure-based design is ALRN-6924, an RCM stapled peptide PPI 
inhibitor targeting the HDM2/p53 PPI. ALRN-6924 is currently in Phase I/II clinical trials for 
patients with solid tumours or lymphoma (due for completion in 2020)99 and represents one of 
the very first stapled peptides to enter clinical trials.94  
 
1.4 Cyclic peptides on the market 
The presence of multiple cyclic peptides on the market demonstrates the success of 
macrocyclisation as a strategy for realising their therapeutic potential. Cyclic peptides account 
for 14 of the 60 marketed peptide drugs (Table 4), all of which are either natural products, or 











Table 4 An overview of selected marketed cyclic peptide drugs and their key features. Information from Choi and 
Joo,100 Lau and Dunn,2 and Baeriswyl and Heinis.101 NP = natural product, source given in brackets. IBS = irritable 
bowel syndrome. Some endogenous peptide hormones such as vasopressin and oxytocin have been excluded. 









1 Bacitracin Antibiotic 
C-terminus to 
side chain 
1948 NP (Bacteria) Topical 




3 Colistin Antibiotic 
C-terminus to 
side chain 
1959 NP (Bacteria) Topical, injection 




5 Cyclosporine A 
Immuno-
suppressant 
Head-to-tail 1983 NP (Fungus) 
Topical injection, 
oral 





















11 Lanreotide Anticancer Disulfide 2007 
Synthetic  
(NP analogue)  
Injection 


























Focusing on stapled peptides, bremelanotide is a cyclic analogue of α-melanocyte-stimulating 
hormone and is currently the only marketed stapled peptide, prescribed for the treatment of 
low sexual desire.102 Bremelanotide contains a one-component lactam bridge between a 
lysine and aspartic acid (Figure 20).103  
 
Figure 20 The structure of marketed peptide Bremelanotide, featuring a lactam bridge between a lysine and aspartic 
acid residue, highlighted in blue.  
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There are two RCM stapled peptides that have entered clinical trials, both developed by 
Aileron Therapeutics. ALRN-5281 is an agonist of growth hormone-releasing factor, 
developed to treat adult endocrine disorders. It was the first stapled peptide to be tested in the 
clinic, and a Phase I safety trial was completed in 2013, although no further clinical trials have 
been reported since.104 ALRN-6924, an HDM2/p53 PPI inhibitor was discussed previously 
(Section 1.3.3). These are both the first stapled peptides and the first peptides produced via 
structure-guided design to enter clinical trials.  
There are currently three chemotherapeutic peptide-drug conjugates in clinical trials, all of 
which contain bicyclic stapled peptides. These PDCs were developed by Bicycle Therapeutics 
and, for each, the peptide was identified by phage display and cyclised with CLIPS reagents.105 
A cytotoxin has been attached to each peptide via a cleavable linker; these PDCs will be 
discussed in more detail in Chapter 3.  
It is clear from the presence of over 60 marketed peptides that they have an important role in 
the therapeutic landscape, providing a wider repertoire of accessible targets and therefore 
allowing the treatment of a wider range of diseases. Stapling is an enabling technology for 
therapeutic peptides, addressing their short-comings and providing an opportunity to modulate 
their properties. As it has been outlined in this introduction, the functionalisation of two-
component stapled peptides provides a straightforward method of attaching moieties that can 













The development of stapled peptides as 
chemical tools to investigate protein-





2. Chapter 2 - The development of stapled peptides as chemical 
tools to investigate protein-protein interactions in human platelets 
2.1 Introduction  
2.1.1 Protein-protein interactions as drug targets 
Biological systems in the body are governed by a complex network of protein-protein 
interactions (PPIs), known collectively as the interactome.3 PPIs can be very important in 
disease states, thus providing a wealth of possibilities for the research of these diseases and 
the development of therapeutics. They can be divided into different structural classes, which 
include the interactions between two globular proteins or between a globular protein and a 
peptide (A and B respectively, Figure 21).  
 
Figure 21 A schematic diagram of two classes of PPIs: A) the interaction between two globular proteins (green and 
orange) and B) the interaction between a globular protein (green) and a peptide (orange). 
Compared to a deep, well-defined binding pocket, PPIs have vastly different compositions and 
topographies. They are typically large and shallow (surface area ~1,000-6,000 Å2), and 
binding usually depends on key interactions, named ‘hot spots’, which can be spread out over 
a large area.3 Historically, PPIs have been considered ‘undruggable’, meaning that for 
decades pharmaceutical research largely ignored a vast number of possible targets. Biologics, 
in particular antibodies, were amongst the first PPI inhibitors to be developed, although they 
are limited to extracellular PPIs.106,107 Improvements in structural biology and in silico methods 
have allowed the structure-based design of small-molecule PPI inhibitors, examples of which 
will be discussed in Section 2.1.2.1.108  
Peptides offer several advantages as PPI inhibitors; they are larger than small molecules and 
so can more easily span the interaction surface.109 Unlike biologics, they are capable of cell 
penetration and therefore can be considered for intracellular PPIs.110 Lastly, in some 
situations, peptide PPI inhibitors can be easily designed by mimicking one of the endogenous 
PPI binding partners. In particular, research has focused on the development of α-helical 
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peptides, as this is a key structural motif found in PPIs,111 for example in the Bcl-2 family of 
proteins.  
 
2.1.2 The Bcl-2 protein family 
Apoptosis, or programmed cell death, is vital in many biological processes, such as the 
maintenance of certain cell populations or as a defence mechanism after cells are damaged 
by disease.112 Inappropriate apoptosis events are central to many diseases, for example 
neurodegenerative diseases and cancer. In nucleated mammalian cells, there are two distinct 
pathways to apoptosis, the extrinsic and intrinsic, which eventually converge.112 Initiation of 
the extrinsic pathway involves the binding of ligands at cell-surface ‘death receptors’, whilst 
the intrinsic pathway depends on intracellular signalling due to cellular stresses such as DNA 
damage or oncogene activation.  
The Bcl-2 protein family are vital apoptosis-regulating proteins of the intrinsic pathway in 
nucleated mammalian cells.113 The Bcl-2 family includes pro-survival proteins Bcl-2, Bcl-xL, 
Bcl-w, Mcl-1 and A1. It also includes pro-apoptotic proteins Bax and Bak, and the BH3-only 
proteins Bad, Bmf, Bim, Bid, Puma and Noxa. The BH3-only proteins are so named because 
they only share the Bcl-2 homology (BH) domain 3, whereas Bcl-2, Bcl-xL, Bcl-w, Mcl-1 and 
A1 have multiple BH domains in common.114 The BH3 domain is an amphipathic α-helix 
approximately 26 amino acids long, and it is through this motif that the BH3-only proteins bind 
to other members of the Bcl-2 protein family (an example is shown in Figure 22 of Bcl-xL in 
complex with Bim).113  
 
Figure 22 An X-ray crystal structure of Bcl-xL in complex with Bim (residues 141-166). The α-helix of Bim is shown 




Under normal conditions, the pro-survival proteins sufficiently sequester Bak and Bax, 
promoting survival. When a cell is exposed to stress, the pro-apoptotic BH3-only proteins are 
induced; they can bind to and neutralise the pro-survival proteins or bind directly to pro-
apoptotic Bax and Bak,116 resulting in apoptosis via mitochondrial permeabilisation and 
subsequent cytochrome c release.117 Each BH3-only protein has a different affinity for the pro-
survival proteins, which is indicated in Figure 23. The exact nature of Bak and Bax activation 
by the BH3-only proteins is debated:113 it has been proposed that some of the BH3-only 
proteins (Bim, Bid and Puma) are so-called ‘activators’ and bind directly to Bak and Bax, 
leading to apoptosis.118 The other BH3-only proteins are ‘sensitisers’ which bind to complexes 
of pro-survival Bcl-2 proteins and cause the release of ‘activator’ BH3-only proteins, which are 
then free to bind to Bax and Bak. 
 
Figure 23 An overview of the Bcl-2 proteins and their role in the intrinsic pathway of apoptosis. The lines represent 
the specificities of the BH3-only proteins for the pro-survival proteins. Adapted from Happo et al.113 
Abnormal expression of Bcl-2 proteins is found in many different cancers, and as the PPIs 
between the BH3-only and Bcl-2 proteins (referred to as ‘BH3 PPIs’ from herein) play a key 




2.1.2.1 Small molecule BH3 PPI inhibitors 
Before significant structural information was obtained for the Bcl-2 proteins, biologics were 
considered as PPI inhibitors. Although antibodies lend themselves to successful inhibition of 
PPIs, the BH3 proteins are intracellular, and therefore cannot be accessed by these large 
biomolecules.120 An alternative approach was trialled, employing oligonucleotides to target 
Bcl-2 mRNA.121 Three such compounds entered clinical trials, one reaching phase III, 
however, it was not progressed further due to a lack of demonstrated therapeutic benefit.122 
Many small-molecule inhibitors of the BH3 PPIs have been developed,123 and those developed 
by Abbott Laboratories (now AbbVie) are amongst the first and most important to the field.122 
Research into small-molecule BH3 PPI inhibitors was initiated when the first X-ray crystal 
structures of Bcl-xL and Bcl-2 complexes were published, providing structural data on the 
nature of the PPI binding interfaces.124,125 A hydrophobic crevice was identified on the surface 
of Bcl-xL and Bcl-2 (A, Figure 24), where the α-helical BH3 domain of BH3-only proteins and 
peptides bind (B, Figure 24).  
 
Figure 24 X-ray crystal structures of Bcl-2 proteins. A) The 3D structure of Bcl-xL, showing the hydrophobic crevice 
on the front face which forms the PPI interface (PDB: 1MAZ). B) The structure of Bcl-xL bound to a Bim peptide 
(green, PDB: 1PQ1).  C) The structure of Bcl-2 bound to an analogue of ABT263 (PDB: 4MAN). The proteins are 
shown as a solvent-accessible surface with the following atom labelling: carbon, white; nitrogen, blue; oxygen, red; 
sulfur, yellow. Reprinted from Croce and Reed, copyright 2016, with permission from AACR. 
A key challenge of developing small-molecule BH3 PPI inhibitors with ‘drug-like’ properties 
was the large size of the PPI interface. A novel chemical fragment screening approach using 
solution NMR was employed to determine fragment binding to Bcl-2 proteins,126 and this 
discovery campaign  lead to the identification of ABT737, a potent antagonist of Bcl-2, Bcl-w 
and Bcl-xL, which represents the first example of a BH3 protein-mimicking drug.120,127 X-ray 
crystal structures confirmed that ABT737 bound in the same hydrophobic crevice on Bcl-2 as 
the native Bim peptide (C, Figure 24).  
Despite causing complete regression of tumours in animal models, ABT737 was not orally 
bioavailable, so ABT263 (Navitoclax) was developed as an orally-bioavailable analogue and 
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was progressed to phase I clinical trials; however, a mechanism-based side-effect of 
thrombocytopaenia was observed.128,129 As both ABT737 and ABT263 were non-selective Bcl-
2 inhibitors, ABT199 (Venetoclax) was developed by structure-based design as a selective 
Bcl-2 inhibitor to avoid this adverse side-effect and improve the oral availability. Venetoclax 
was approved by the US Food and Drug Administration (FDA) in 2016 for the treatment of 
chronic lymphocytic leukaemia and small lymphocytic lymphoma (Table 5).130,131 
Table 5 The structures of ABT737, ABT263 and ABT199 and their affinity for selected Bcl-2 proteins. Adapted from 
Vogler et al.120 and Souers et al.130 ND = no data.  
Compound Structure 
Ki (nM) 
Bcl-2 Bcl-xL Mcl-1 Bcl-w Bcl2-A1 
ABT737 
 
120 64 <20,000 24 <20,000 
ABT263 
 
<1 <0.5 550 <1 354 
ABT199 
 
< 0.01 48 ND 245 ND 
 
 
2.1.2.2 Stapled peptide BH3 PPI inhibitors  
As previously discussed, peptides can be better suited to targeting PPIs and have been 
employed as successful PPI inhibitors against Bcl-2 protein family members.18 An overview of 
stapled peptides of particular relevance to this thesis is given in Table 6. These peptides are 
predominantly based on RCM stapling, with one example of two-component stapling reported: 
a Bim BH3-only peptide which was stapled using the perfluoroaryl macrocyclisation approach 









Table 6 The sequences of selected stapled peptide PPI inhibitors of BH3-only proteins and comments on their 
biological activity and uses. Adapted from Walensky and Bird.25 * denotes a two-component stapled peptide. All 
other peptides are RCM stapled. Residues used for stapling shown in bold, X = non-canonical alkene-bearing 
amino acid, NL = norleucine. 
Protein Sequence Comments on biological activity Ref. 
Noxa 
QPSPAEAPAELEVECATQLRXFGDXLNFRQ 
Employed as a chemical tool to study 
conformation changes of Bak upon 
activation.  
133 
LEVESATQLRXFGDXLNFRQKL High-affinity Mcl-1 ligand (Kd 22 ± 12 nM).  134 
Bim 
IWIAQELRXIGDXFNAYYARR 
High-affinity Mcl-1 ligand (Kd 17 ± 8 nM). 135,134
,136  
IWIAQELRCIGDCFNAYYARR* 
Perfluoroaryl analogues displayed improved 
brain penetration compared to alkyl analogue 
in vivo.  
62,132  
EIWIAQELRXIGDXFNAYYA 
Selective chemical tool used to elucidate a 





High-affinity Bcl-xL ligand (Kd 12 ± 1.2 nM). 
Induces apoptosis in neuroblastoma.  
138 
QWAREIGAQLRXGADXLNAQY High-affinity Mcl-1 ligand (Kd 14 ± 5 nM). 134 
Bid 
DIIRNIARHLAXVGDXNLDRSI 
High-affinity Bax and Bcl-2 ligand  
(EC50 885 and 230 nM respectively). 
139 
FITC-EIIHNIARHLAXIGDXNLDHNIQ 
High-affinity Bak-binder (Kd 95 ± 15 nM). 
Chemical tool used to reveal that Bak and 
Bax are activated by direct BH3 interaction at 
different binding sites. 
140 
EDIIRNIARHLAXVGDXNLDRSI 
Selective chemical tool used to study 
conformation changes of Bak upon 
activation. 
133 
DIIRNIARHLAXVGDXNLDRSIRR High-affinity Mcl-1 ligand (Kd 50 ± 8 nM).  134 
EDIIRNIARHLAXVGDXNLDRSIW 
Inhibited the growth of human leukaemia 
xenografts in vivo.  
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Whilst none of these peptides have yet entered the clinic, some have served as invaluable 
chemical tools for the discovery of selective small-molecule Bcl-2 inhibitors.142 Walensky and 
co-workers found that a stapled peptide based on the sequence of the Mcl-1 BH3 α-helix 
bound with high affinity to the Mcl-1 protein (A, Figure 25). Using this, the group developed a 
screening platform for the identification of small-molecule Mcl-1 antagonists.143 Through this 
platform they identified and validified MIM1, a potent and selective small-molecule Mcl-1 
antagonist which was able to prevent Mcl-1-mediated suppression of the pro-apoptotic Bax 
protein (B, Figure 25). In an Mcl-1-dependent leukaemia cell line, MIM1 caused caspase 
activation and cell death.    
 
Figure 25 A) The structure of the Mcl-1 RCM stapled peptide, developed by Walensky and co-workers and used to 
identify Mcl-1 antagonists.143 B) The structure of MIM1, a selective Mcl-1 antagonist identified using the stapled 




2.1.3 Platelets and haemostasis 
When vascular injury occurs, a complex signalling pathway is initiated which ultimately results 
in the formation of a blood clot (or thrombus). This process is called haemostasis and it is 
dependent on the activity of sub-endothelial proteins such as collagen and von Willebrand 
factor (VWF), as well as platelets, small blood cells which play a critical role in several stages 
of haemostasis.144 Platelets circulate in a resting state (A, Figure 26) and to enact their primary 
role of thrombus formation in response to blood vessel damage they must become activated 
(B, Figure 26).145 Activation describes a series of phenotypic and morphological changes 
which occur in resting platelets upon exposure to certain stimuli. Platelet activation is known 
as primary haemostasis and it occurs simultaneously with coagulation events (known as 
secondary haemostasis); together the two systems form a thrombus (a blood clot).146  
 
Figure 26 Scanning electron micrographs of (A) a resting platelet and (B) activated platelets. Reprinted from The 
Lancet, Vol. 355, J. George, Platelets, 1531-1539, © 2020 with permission from Elsevier. 
Platelets aggregate at the site of blood vessel damage, where pro-thrombotic species (such 
as VWF, collagen and fibrinogen) have become exposed in the vascular wall and provide an 
adhesive surface through interactions with specific integrins expressed on the platelet 
membrane, namely GPIIb/IIIa, GPIb and GPVI (A, Figure 27).144 Platelets are subsequently 
activated, which leads to the formation of a thrombotic plug (B, Figure 27). The formation of 
the thrombotic plug occurs in several stages; the first stage is primary reversible adhesion 
wherein the platelets aggregate with each other and to the vascular wall. Following this, the 
initial plug grows and is stabilised. Blood vessel damage also initiates the coagulation 
cascade, causing coagulation events (secondary haemostasis). This results in the conversion 
of prothrombin to active thrombin, itself converting soluble fibrinogen into fibrin. Fibrin forms a 





Figure 27 A cartoon depicting thrombus formation. A: Blood vessel damage exposes pro-thrombotic species (e.g. 
VWF, collagen, fibrinogen) which bind to resting platelets via specific cell-surface receptors and cause platelet 
activation. B: Platelet activation and adhesion occur, forming a thrombus. C: The coagulation cascade results in 
the formation of insoluble fibrin, which stabilises the thrombus.  
Platelet formation occurs when megakaryocytes in the bone marrow undergo nuclear 
duplication and fragmentation; as fragments of cells, platelets are small and anuclear, a factor 
which has major implications when studying their intracellular pathways.147 Platelets circulate 
for 10 days on average, and about a third of platelet sequestration occurs in the spleen.  
 
2.1.4 Platelet activation  
There are a wide range of signalling molecules (platelet agonists) which cause platelet 
activation, including thromboxane A2 (TxA2), ADP and thrombin, which all bind to G-protein 
coupled receptors on the platelet surface (Figure 28).148 Additionally, collagen, thrombin and 





Figure 28 A cartoon depicting platelet activation. The binding of platelet agonists (e.g. VWF, collagen, thrombin) to 
receptors on the surface of the platelet induce activation, causing morphological changes, the presentation of 
adhesion molecules and granule release. Adapted from J. Ware,150 Gay and Felding-Habermann,149 and 
Nieswandt, Pleines and Bender.148 
The observed morphological change is believed to be due to the binding of thrombin to G-
protein coupled protease-activated receptors on the surface of the platelet. This causes a 
reduction in the intracellular cyclic AMP concentration and an increase in calcium, thus 
allowing the reorganisation of the platelet cytoskeleton and associated morphological 
changes.149 The composition of the platelet cell surface is also changed upon platelet 
activation. For example, P-selectin (CD62), a transmembrane protein stored in the α-granules 
of resting platelets, is translocated to the extracellular surface.151 Similarly, integrins such as 
GPIIb/IIIa which are also stored in α granules are released upon activation, increasing the cell-
surface expression of this adhesion receptor.152 Phosphatidylserine (PS), a phospholipid 
typically located on the inner leaflet of the platelet membrane bilayer, is also redistributed to 
the cell surface.153  
Activation also involves the release of granules from platelets; the species released in the 
granules have specific roles in platelet activation.151 There are three types of storage granules 
in platelets; dense, α and lysosomal and their contents also fit into three functional classes. 
Dense granules contain platelet agonists (e.g. ADP, calcium and TxA2), α granules contain 
adhesion molecules (e.g. P-selectin, fibrinogen and VWF) and lysosomal granules contain 
lysosomal enzymes (e.g. cathepsin).  
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The mechanisms involved in platelet granule secretion are not fully understood; however, it is 
widely believed that platelet shape change is a major effector. Many of the morphological and 
biochemical changes that happen during platelet activation are also observed during 
apoptosis of nucleated cells.153 These changes include PS exposure, cell shrinkage, and 
membrane blebbing.153,154 It has also been suggested that caspase activation, which plays a 
major role in apoptosis, may be involved in platelet activation.155 
 
2.1.5 The roles of platelets in disease states 
In addition to platelet activation as a result of wound formation, it can also occur as part of a 
wider systemic inflammatory response, with stimuli including cytokines, infective agents and 
shear stress.156 Predictably, severe platelet abnormalities such as thrombocytopenia (low 
platelet count) can result in various bleeding disorders.147 There are numerous anti-platelet 
therapeutics on the market, the most well-known of which is Aspirin.157 Aspirin is a widely used 
anti-inflammatory drug which prevents the biosynthesis of platelet agonist TxA2 through 
irreversible covalent inhibition of cyclo-oxygenase-1. As TxA2 is typically stored in α granules 
and released upon platelet activation, this ultimately decreases the amount of platelet 
activation, thus reducing inflammatory responses.152  
There are definite links between the functions of platelets and cancer metastasis, however, 
the exact nature of these are yet to be determined. In general, platelets can affect the 
development of a tumour in three ways; by complementing tumour adhesion, through shielding 
tumour cells from the immune system and by assisting in the selection of metastatic tumour 
cell phenotypes.149 It has therefore been noted that anti-platelet therapies which target the 
specific tumour-platelet interactions that enable the above-mentioned events would 
complement current anticancer therapies.149 Furthermore, the presence of platelet-leucocyte 
aggregates has been observed in various disease states, making them an interesting and 
underexplored target.149,158 
 
2.1.6 Bcl-2 proteins in platelets 
Certain members of the Bcl-2 proteins are known to be present in platelets; mRNA sequences 
encoding BH3-only proteins Bim, Bad, Bid, Bmf and Puma are known to be expressed in 
mouse platelets, along with Bax, Bak, Mcl-1, Bcl-2 and Bcl-xL.159 Additionally, protein 
expression in human platelets has been confirmed for Bax, Bak, Bcl-2 and Bcl-xL.160 It was 
found through studies of knockout mice that pro-survival Bcl-xL is vital for platelet survival: in 
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mice with a deletion of Bcl-xL the megakaryocytes platelet lifespan is reduced from 5 days to 
5 hours, resulting in thrombocytopenia which can be reversed through further deletion of pro-
apoptotic Bax and Bak.161 Conversely, it was shown that removing both the Mcl-1 and Bcl-2 
proteins in knockout mice did not adversely affect the production or survival of platelets.117  
Whilst small-molecule PPI inhibitor ABT737 caused complete regression of tumours in animal 
models, an associated thrombocytopenia was observed. The effects of ABT737 on platelets 
were examined, and it was found that the drug caused concentration-dependent PS exposure 
and induced higher levels of cytochrome c and caspase-3 activity, all of which are associated 
with activation of the intrinsic apoptotic pathway.160 Conversely, ABT737 had a modest effect 
on platelet activation-associated events, as measured by granule release and the increase in 
expression of the integrin GPIIb/IIIa on the platelet surface. The authors concluded that 
ABT737 causes rapid platelet apoptosis without activation.160 The same biological profile was 
true for ABT263, a related compound which also inhibits Bcl-2, Bcl-xL and Bcl-w.162,163 
However, ABT199, a selective Bcl-2 inhibitor, was found to cause tumour regression without 
thrombocytopenia.130,164 The different biological responses these small molecules provoke 
indicate that the BH3-only proteins have distinct and important roles in human platelets, which 
require further elucidation. 
 
2.1.6.1 Issues with studying PPIs in human platelets 
To fully understand the relationship between BH3-only protein-mediated apoptosis and 
activation in platelets it is necessary to elucidate the PPIs of the Bcl-2 protein family. However, 
the common methods for the study of PPIs include the use of transgenic animals, recombinant 
methods and small molecule inhibitors, all of which face significant issues when studying 
platelets.  
The use of transgenic animals is often costly and time-consuming, and there are key 
differences between species. For example, mice have smaller platelets and more platelet-rich 
plasma than humans.150 The study of BH3-only proteins in platelets is not possible using 
standard recombinant methods, as platelets are anuclear.165 Finally, the design of small 
molecule inhibitors for targeting large, shallow PPI sites is often challenging.13 Although there 
are numerous examples of successful PPI inhibitors, including ABT737, -263 and -199, this 
approach is not general, and each individual inhibitor often requires significant development. 
Additionally, highly selective chemical tools are necessary to unambiguously probe the roles 
of each BH3 protein. 
Stapled peptides present themselves as convenient chemical tools to study the BH3 PPIs in 
human platelets for several reasons. Firstly, significant structural information is available for 
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the BH3-only proteins, and the native sequences of the BH3 binding domains can provide the 
basis for peptide design. The stapled peptides listed in Table 6 (Section 2.1.2.2) provide 
numerous examples of this approach, and peptides developed in this way have the potential 
to be highly selective for their individual targets.13 Two-component peptide stapling allows the 
facile introduction of functionality; for example, cell-penetrating peptides (CPPs) to endow 
cellular permeability onto the peptides, and fluorescent tags to enable visualisation assays. 
Peptide stapling can also lock the peptide in a biologically relevant conformation, and 
significantly improve the proteolytic stability. It was for these reasons that stapled peptides 
were developed as novel chemical tools to study the BH3 PPIs in human platelets.77  
 
2.1.7 Previous work on stapled peptides in human platelets    
Previous work in the Spring group investigated whether stapled peptides could enter human 
platelets, and whether a stapled peptide based on the sequence of the Bim BH3 domain could 
elicit a biological response in human platelets. This work is published in Iegre et al.,77 and is 
reported in the thesis of Dr. Jessica Iegre.166 Unless otherwise stated all of the experiments 
reported in this section were performed by Dr. Jessica Iegre.  
To assess whether stapled peptides could enter human platelets, a model peptide was stapled 
with a variety of functionalised linkers using CuAAC stapling.a The platelet-penetration of these 
peptides was investigated by confocal microscopy and flow cytometry. A model peptide 
functionalised with a polyarginine CPP showed high levels of platelet uptake, localisation in 
the platelet cytosol and did not cause platelet activation. The individual roles of the BH3-only 
proteins in platelet apoptosis and activation are unknown, therefore, to investigate a 
biologically-relevant peptide sequence a stapled peptide based on the BH3 binding domain of 
Bim was synthesised and functionalised with a polyarginine R3 CPP (P19, Figure 29). P19 
was shown to be platelet permeable and to localise in the platelet cytosol using flow cytometry 
and confocal microscopy. The binding of P19 to Bcl-xL was assessed using a surface plasmon 
resonance assay, and it displayed comparable binding to the wild-type peptide P17 (P19 KDapp 
= 26 nM, P17 7.3 nM), and greater binding than a literature i,i+4 Bim RCM stapled peptide,139 
(Bim-SAHBa KDapp > 33 nM, B, Figure 29).  
 
a The peptides were synthesised by Dr. Yuteng Wu. Model peptide based on p53 sequence = TAMRA-Ahx-




Figure 29 The structures of stapled Bim peptides. A) The CuAAC stapled Bim peptide P19 reported by Iegre et 
al.77 and B) the Bim SAHBa peptide reported by Walensky and co-workers.139  
The effect of Bim peptide P19 on platelet apoptosis and action was measured and compared 
to ABT737, which does not activate platelets, but does causes PS exposure, a marker of 
apoptosis.160 PS exposure was assessed by measuring platelet-annexin V binding: P19 
caused 78 ± 1.3% annexin V binding after 3 hours, which is comparable to ABT737, and more 
potent than the literature Bim SAHBa peptide. P19 caused integrin GPIIb/IIIa activation (24.1 
± 2.4% positive platelets, measured by PAC-1 binding) and CD62P (53.7 ± 2.5%) and CD63 
(72.9 ± 5.3%) expression, which indicate α- and dense granule release, respectively. 
Conversely, treatment with ABT737 gave a negligible response for these activation markers, 
which is concurrent with literature reports.160  
This work revealed that functionalised stapled peptides can be platelet permeable and exert 
a biological effect. Mechanistic differences were revealed between the Bim stapled peptide 
P19 and ABT737, which is referred to as a ‘Bad mimetic’ as it has comparable selectivity to 
Bad, binding to pro-survival proteins Bcl-2, Bcl-xL and Bcl-w. Whilst both treatments caused 
similar levels of PS exposure, only P19 caused platelet activation, indicating that the Bim and 




2.2 Project aims and outline 
Following on from this promising work, it was proposed to synthesise stapled peptides 
corresponding to the remaining BH3-only proteins, incorporating a polyarginine CPP on the 
staple. The effect of these stapled peptides on events related to apoptosis and activation in 
human platelets would be investigated using flow cytometry. It was envisaged that these 
platelet-permeable chemical tools would enable more information to be gathered regarding 
the roles of the individual BH3-only family proteins, and that the information gained could 
provide the basis for the development of future therapeutics. The BH3-only family members 
are Bim, Bad, Bik, Bmf, Puma and Noxa - peptides corresponding to Bim, Bad and Bik were 
synthesised by Dr. Jessica Iegre,166 and the work reported in this thesis relates to the synthesis 
and preliminary biological testing of Bmf, Puma and Noxa stapled peptides.  
Initially, two-component CuAAC stapling at i,i+11 positions was employed for the Bmf, Puma 
and Noxa peptides (A, Figure 30), as it was believed that by spanning multiple turns of the 
helix, greater proteolytic stability might be imparted. However, it was found that these peptides 
could not be easily functionalised and therefore, the series was retired. A second series of 
peptides were synthesised with stapling at i,i+7 positions, using a linker which allowed facile 
functionalisation of the peptides (B, Figure 30).  
 
Figure 30 The general structures of the two series of CuAAC stapled peptides developed in this project. A) i,i+11 
peptides and B) i,i+7 peptides. Amino acids are represented by blue spheres. R = either OH or Ahx2-(D)Arg3.  
Overall, 12 peptides were synthesised, including three polyarginine functionalised stapled 
peptides based on the sequences of the Bmf, Puma and Noxa BH3-only proteins. For both 
series of unfunctionalised stapled peptides, the peptide secondary structures were analysed 
by circular dichroism spectroscopy (Figure 31). For the three functionalised stapled peptides, 
preliminary investigations into their effect on events associated with platelet apoptosis and 

























2.3 Results and discussion 
2.3.1 Development of i,i+11 BH3-only stapled peptides  
2.3.1.1 Stapled peptide design  
For the Bmf, Noxa and Puma peptides, stapling positions beyond i,i+4 were considered; it was 
decided that i,i+11 stapling positions may improve the proteolytic stability of the peptides, as 
the staple would span more turns of the α-helix (3 helical turns for i,i+11, 1 for i,i+4). The 
literature indicated that a bis-alkynyl carbazole linker would be suitable for i,i+11 stapling, as 
a model peptide synthesised by Dr. Yu Heng Lau with azido ornithine at i,i+11 positions 
exhibited 87% α-helicity when stapled with a carbazole staple (Figure 32).167  
 
Figure 32 The model peptide synthesised by Dr. Yu Heng Lau, with stapling between azido ornithine residues at  
i,i+11 positions with a bis-alkynyl carbazole linker.167 
The optimal positions within the native peptide sequences to place the azido ornithine residues 
were determined computationally.b For the Bcl-2 proteins there is comprehensive structural 
data allowing the rational design of stapled peptides. The stapled peptide sequences were 
derived from X-ray crystal structures of BH3-only protein complexes,c the analysis of which 
indicated suitable i,i+11 stapling positions where the staple was solvent-exposed and no 
clashes were predicted between the staple and intervening residues. The proposed peptide 
sequences for the i,i+11 stapled Bmf, Puma and Noxa peptides are shown in Table 7.   
Table 7 The sequences of the wild-type BH3 peptides P1-P3, and the i,i+11 BH3 peptides P4-P6. X = position of 
azido ornithine in the linear peptides. All peptides have a C-terminal amide.  
Peptide Peptide Sequence 
Bmf wild-type P1 Ac-IARKLQCIADQFHRL 
Puma wild-type P2 Ac-IGAQLRRMADDLNAQY 
Noxa wild-type P3 Ac-CATQLRRFGDKLNFR 
Bmf i,i+11 P4 Ac-IAXKLQCIADQFHXL 
Puma i,i+11 P5 Ac-IGXQLRRMADDLNXQY 
Noxa i,i+11 P6 Ac-CAXQLRRFGDKLNXR 
 
b Computational modelling performed by Dr Yaw Sing Tan (A*STAR Institute, Singapore). 
c PDB codes of the X-ray crystal structures of protein complexes are Bmf: 5TZQ, Puma: 5UUL and Noxa: 3MQP. 
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2.3.1.2 Peptide synthesis 
To synthesise the peptides listed in Table 7, Fmoc-protected azido ornithine 3 was required, 
and could be easily accessed from commercially available Nα-Fmoc-Nδ-Boc-L-ornithine, via 
deprotection and diazo transfer. The required diazo transfer reagent 1 was synthesised from 
sulfuryl chloride following the literature procedure (Scheme 5) in a moderate yield, with no 
purification required.168 Azido ornithine 3 was prepared according to the literature route;169 Boc 
deprotection of the commercially available starting material yielded the hydrochloride salt 2, 
and subsequent treatment of 2 with diazo transfer reagent 1 under the literature conditions 
gave 3 in a good yield (Scheme 5).169 Azido-ornithine 3 was used in subsequent solid-phase 
peptide synthesis (SPPS) without further purification.  
 
Scheme 5 The one-pot synthesis of diazo transfer reagent 1, and the synthetic route towards azido ornithine 3 via 
Boc deprotection of the commercially available starting material and subsequent diazo transfer. 
The wild-type (P1-P3) and linear azido (P4-P6) peptides were synthesised using automated 
microwave-assisted Fmoc-SPPS (Table 8). Low-loading Rink amide resin was used to prevent 
aggregation during peptide synthesis and give a C-terminal amide upon cleavage from the 
resin.d It was found that for the Noxa peptide P6 the N-terminal cysteine residue required 
manual coupling, as all attempts at synthesis of the full sequence on the automated peptide 
synthesiser were unsuccessful. The peptides were all capped at the N-terminus with an acetyl 
group, cleaved from the resin in a TFA cocktail containing 1,2-ethanedithiol (EDT)e to avoid 
potential side-reactions of methionine and cysteine residues,170 and purified by preparative 
HPLC prior to stapling. 
 
 
d A C-terminal amide is preferred over a carboxylic acid as it does not reduce the net positive charge of the peptide, 
a significant factor for cell permeability.98 Additionally, an amide moiety would be present at this position in the full 
protein sequences; this is also the reason for N-terminal acetyl capping.  
e Cleavage solution: TFA/TIPS/H2O/EDT (94:1:2.5:2.5). 
42 
 
Table 8 The sequences of the i,i+11 linear azido peptides P4-P6, wild-type peptides P1-P3, and their method of 
synthesis. All peptides have a C-terminal amide, X = azido ornithine.   
BH3 Protein Peptide Sequence Synthesis 
Bmf 
P1 Ac-IARKLQCIADQFHRL 











residue coupling, and 




2.3.1.3 Synthesis of carbazole linkers 6 and 7 
The carbazole linker 6 required for the i,i+11 stapling was synthesised according to the 
literature route (Scheme 6).167 Commercially available carbazole was brominated with N-
bromosuccinimide (NBS) to give 4 in a moderate yield, followed by a double-Sonogashira 
cross-coupling reaction to install the protected alkyne moieties, which proceeded in a good 
yield to give 5. The protected bis-alkynyl carbazole 5 could then be deprotected upon 
treatment with potassium carbonate to give the unfunctionalised linker 6 in a high yield after 
chromatographic purification. Alternatively, from intermediate 5, linker 7 could be synthesised 
via a one-pot alkyne deprotection and N-alkylation with 6-bromohexanoic acid under ultrasonic 
irradiation (Scheme 6). The carboxylic acid moiety in 7 provides a reactive handle for the 
attachment of the cell penetrating peptide.     
 
Scheme 6 The synthesis of staple linkers 6 and 7 from commercially available carbazole. 
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Previous studies indicated that the peptides would require functionalisation with a polyarginine 
CPP to promote platelet uptake (A, Figure 33).77 Therefore, a functionalised staple linker would 
be required bearing an R3 motif. It was decided for this series that two 6-aminohexanoic acid 
spacers would be introduced to increase the distance between the large staple and the binding 
residues of the peptide (B, Figure 33). It was also decided to use D- rather than L-arginine in 
the CPP, as the use of D-amino acids in CPPs can improve their proteolytic stability without 
negatively affecting their ability to translocate the cellular membranes.171  
 
Figure 33 A) The structure of the poly-L-arginine CPP used for the literature Bim stapled peptide,77 and B) the 
structure of the poly-D-arginine CPP proposed for these peptides, incorporating two 6-aminohexanoic acid spacers 
between the benzene linker and the polyarginine peptide.   
It was proposed that the synthesis of the CPP-functionalised linker could be achieved by SPPS 
of the CPP P7, then performing an amide coupling with the deprotected N-terminus of the 
resin-bound P7 and linker 7 (Scheme 7). The resulting functionalised alkyne staple could be 
cleaved from the resin under standard cleavage conditionsf  and purified by preparatory HPLC 
to give the functionalised linker, 8. This linker could then be used in peptide stapling reactions 
with the linear azido peptides P4-P6.  
 
Scheme 7 The proposed synthesis of 8, the polyarginine functionalised carbazole linker. The polyarginine CPP P7 
would be synthesised by SPPS, and the N-terminus of the peptide capped with linker 7. The linker-peptide 
conjugate could then be cleaved from the resin to give 8.  
 
f TFA/H2O/TIPS/CH2Cl2 (95:2.5:2.5:2.5). 
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P7 was synthesised by automated SPPS as previously described, and the coupling of P7 and 
7 proceeded smoothly. It was found, however, that the carbazole moiety was not compatible 
with the resin cleavage conditions, and upon addition of the cleavage cocktail to resin-bound 
8 the reaction mixture turned black and no desired product could be detected by LCMS. This 
was also observed under alternative cleavage conditions consisting of 0.1 N HCl in 
hexafluoroisopropanol (HFIP), and treating carbazole linker 7 with either TFA or HCl resulted 
in a black mixture, which, when analysed by 1H NMR showed no peaks correlating to the 
carbazole.g Consequently, a different stapling architecture was required for the synthesis of 
stapled polyarginine functionalised peptides, as a solution-phase synthesis of the proposed 8 
would be time consuming. It was decided that the unfunctionalised stapled peptides would be 
synthesised using P4-P6 and linker 6, and the α-helicity of these peptides would be analysed 
by circular dichroism (CD) spectroscopy. This data would guide the decision of whether to 
develop a functionalisable i,i+11 linker, or whether to focus on alternative staple lengths.  
 
2.3.1.4 Stapling with unfunctionalised linker 6 
The linear azido i,i+11 peptides P4-P6 were cyclised with linker 6 using standard two-
component CuAAC stapling conditions, as reported in the literature (Table 9).44  
Table 9 The sequences of azido peptides P4-P5, and the conversion of the CuAAC stapling reactions of these 
peptides and linker 6 under the conditions shown.  X = azido ornithine. Amino acids are shown as blue spheres. % 
Conversion determined by LCMS analysis of the reaction mixtures after 18 h.  
 
Linear peptide Sequence Stapled peptide Conversion (%) 
P4 Ac-IAXKLQCIADQFHXL P4-6 >99 
P5 Ac-IGXQLRRMADDLNXQY P5-6 88 
P6 Ac-CAXQLRRFGDKLNXR P6-6 >99 
During the preparatory HPLC purification of the Noxa stapled peptide P6-6, it was observed 
that the peak corresponding to the desired stapled peptide on the HPLC chromatograph was 
extremely broad. A similarly broad peak was observed in the analytical HPLC trace of the 
purified peptide (Appendix 6.2); it is possible that the cause of this broad peak is complexation 
of the peptide and copper catalyst.44 As a purity could not be determined for peptide P6-6 it 
 
g Reactions and analysis performed by Dr. Jessica Iegre, University of Cambridge.166 
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could not be used in further peptide characterisation or biological assays with confidence, and 
was excluded from subsequent analysis.  
 
2.3.2 Circular dichroism spectroscopy for studying peptide secondary 
structures 
Circular dichroism (CD) is a spectrographic technique which allows the study of protein and 
peptide secondary structures in solution.172 In CD spectroscopy, the differential absorption of 
circularly-polarised light is measured, and common structural features such as α-helices and 
β-sheets can be identified by differences in these absorptions in the far-UV;173 for example, α-
helices have a characteristic minimum at 222 nm (Figure 34).172 Although CD spectroscopy is 
not definitive for the study of peptide secondary structures, it is practically straightforward and 
gives a good estimation.   
In the native BH3-only proteins, the BH3 domain has an α-helical structure.113 However, taken 
out of the stabilising environment of the protein tertiary structure, linear peptides often display 
random coil structures in solution. It was anticipated that stapling linear BH3 sequences will 
result in macrocyclic peptides which display a comparable or higher α-helicity than the wild-
type sequences. This has been illustrated in the literature for BH3-only stapled peptides 
(Figure 34),18 although it has also been reported that an increase in binding affinity is not 
necessarily related to an increase in α-helicity.174  
 
Figure 34 The CD spectra for the wild-type Bim peptide (Bim BH3, brown) displaying a random coil structure, and 




h Further permissions related to the material excerpted should be directed to the ACS. 
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2.3.2.1 Analysis of i,i+11 BH3-only stapled peptides by CD spectroscopy  
The secondary structures of the i,i+11 BH3 stapled peptides were analysed by CD 
spectroscopy and compared to the linear sequences. Pure samples of the Bmf and Puma 
peptides were measured in MeCN/H2O (1:1) at 100 µM. The measured ellipticity (millidegrees) 
was normalised against the measured ellipticity at 207 nm and plotted, and the percentage of 
α-helical content was calculated for each peptide.175,176 For the Bmf series, the stapled peptide 
P4-6 displayed a significantly lower α-helical content (8%) than the wild-type peptide P1 (32%, 
A, Figure 35). A decrease in helical content upon stapling was also observed for the Puma 
peptides: the wild-type peptide P2 displayed a higher α-helical content than the stapled 
peptide P5-6 (34% vs. 24% respectively, B, Figure 35). This shows that the i,i+11 stapling 
actively disrupted the adoption of an α-helical secondary structure for these sequences.i  
    
Figure 35 CD spectra for (A) Bmf peptides P1 and P4-6, and (B) Puma peptides P2 and P5-6. All ellipticities (mdeg) 
have been normalised to the ellipticity at 207 nm. The % α-helicity is given in brackets after the peptide number in 
the legend.  
The CD data, along with the challenges faced during the attempted functionalisation of 
carbazole linker 7, lead to the termination of the i,i+11 series of BH3-only stapled peptides. 
Instead, i,i+7 stapling was investigated, as this would still span multiple turns of an α-helix (two 
turns compared to one turn for i,i+4 stapling), and therefore, may improve the proteolytic 
stability of the peptides, however it does not require the problematic carbazole linker.  
 
2.3.3 Development of i,i+7 BH3-only stapled peptides   
2.3.3.1 Stapled peptide design 
Based on literature reports, whilst the optimal linker for inducing α-helicity with i,i+11 stapling 
is the carbazole scaffold (A, Figure 36), the optimal linker for i,i+7 two-component CuAAC is 
 
i Low α-helicities were also observed for i,i+11 CuAAC stapled Bad, Bid and Bim peptides, which were synthesised 
and analysed using CD spectroscopy by Dr. Jessica Iegre.166 
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based on a 3,5-diethynylbenzoic acid scaffold (B, Figure 36).167,23 The same benzene scaffold 
was used for the literature i,i+4 stapled Bim peptides.77,166 Unlike the carbazole linker E, the 
3,5-diethynylbenzoic acid staple is compatible with TFA-mediated resin cleavage and can 
therefore be functionalised via a similar route as was proposed in Scheme 7. 
 
Figure 36 The structures of the optimal stapling linkers for different CuAAC stapling positions. The carbazole linker 
(A) is optimal for i,i+11 stapling and the benzene linker (B) is i,i+4 and i,i+7 stapling.167 
The i,i+7 series of azido peptides were designed computationally following the same principles 
as was described for the i,i+11 peptides (Section 2.3.1.1).j   
 
2.3.3.2 Peptide synthesis 
Azido ornithine 3 was prepared as described previously (Section 2.3.1.2), and the linear azido 
peptides were synthesised via automated Fmoc-SPPS.  
Table 10 The sequences of the azido i,i+7 peptides P8-P10. All peptides have a C-terminal amide. X = azido ornithine. 
BH3-only protein Peptide Sequence 
Bmf P8 Ac-IARKLQXIADQFHXL 
Puma P9 Ac-IGAXLRRMADXLNAQY 
Noxa P10 Ac-CATQLRXFGDKLNXR 
 
2.3.3.3 Synthesis of benzene linker 10 
Benzene linker 10 was prepared according to the literature synthesis (Scheme 8).23 From 
commercially available methyl 3,5-dibromobenzoate, a double-Sonogashira cross-coupling 
reaction introduced the protected alkyne moieties to give 9 in an excellent yield after 
chromatographic purification. The final step, a base-mediated one-pot deprotection and ester 
hydrolysis gave the desired linker 10 in a good yield after recrystallisation.  
 




Scheme 8 The synthesis of 10 from commercially available methyl 3,5-dibromobenzoate. 
 
2.3.3.4 Stapling with unfunctionalised linker 10 
Two-component CuAAC stapling reactions were performed with the i,i+7 azido peptides P8-
P10 and the unfunctionalised linker 10 under the literature conditions.77 The stapling 
proceeded smoothly for the Bmf and Puma peptides P8 and P9, to give the unfunctionalised 
i,i+7 stapled peptides P8-10 and P9-10 respectively (Table 11).  
Table 11 The sequences of azido peptides P8-P10 and their conversions in peptide stapling reactions under the 
conditions shown. X = azido ornithine. Amino acids are shown as blue spheres. % Conversion determined by 
LCMS analysis.  
 
Linear peptide Sequence Stapled peptide Conversion (%) 
P8 Ac-IARKLQXIADQFHXL P8-10 >99 
P9 Ac-IGAXLRRMADXLNAQY P9-10 88 
P10 Ac-CATQLRXFGDKLNXR P10-10 - 
However the stapling reaction of the Noxa peptide P10 gave a complex mixture, and analysis 
of the reaction mixture by analytical HPLC showed a broad peak in the region around 6.8 
minutes (A, Figure 37). This phenomenon was also observed during the purification of i,i+11 
Noxa stapled peptide P6-6, and one possible explanation was the coordination of the peptide 
sequence to the copper species present in the stapling reaction mixture.44 This was somewhat 
confirmed when copper-chelator EDTA was added to the P10-10 stapling reaction mixture; 
subsequent HPLC analysis showed that broad peak disappeared (B, Figure 37). This suggests 
that stapled peptide P10-10, unlike the other peptides investigated, was able to coordinate to 





Figure 37 The analytical HPLC traces of the P10-10 stapling reaction mixture, in the absence (A) and presence (B) 
of copper-chelator EDTA. The disappearance of the broad peak at ~7 minutes after addition of EDTA suggests 
that the peptide is chelating to copper species present in the reaction mixture.  
It was suspected that the N-terminal cysteine residue of the Noxa peptide P10 was causing a 
significant contribution to the coordination of the peptide to copper. The same cysteine residue 
was believed to be the reason for issues experienced during the SPPS of this peptide, as it 
was not amenable to microwave-assisted coupling on the automated peptide synthesiser and 
required manual coupling. Therefore, a mutant peptide P11 was designed, replacing the N-
terminal cysteine residue with isoleucine (P11 sequence: Ac-IATQLRXFGDKLNXR, where X 
= azido ornithine). This mutation was suggested as isoleucine is present instead of cysteine 
at the same position in other BH3-only peptides.134,135 The mutated peptide was modelled and 
compared to the X-ray crystal structure of the original Bim peptide in complex with a Bcl-2 
protein, which suggested that the isoleucine would fit well in the binding pocket.k 
CuAAC stapling was performed with P11 and linker 10 and gave a significantly improved 
reaction profile, yielding the desired stapled peptide after preparatory HPLC purification 
(Scheme 9). Analysis of the reaction mixture by analytical HPLC did not indicate any 
complexing of the peptide to the copper catalyst species.  
 






Scheme 9 The synthesis of P11-10 by CuAAC stapling with linear peptide P11 and linker 10 under the literature 
conditions.44  
 
2.3.3.5 Synthesis of polyarginine-functionalised linker 11 
The polyarginine CPP P7 was synthesised by standard SPPS (Scheme 10). The N-terminal 
amine of the peptide chain was coupled to 10 then cleaved from the resin under standard 
cleavage conditions and purified by preparative HPLC to give the functionalised linker 11.  
 
Scheme 10 The synthesis of functionalised linker 11. CPP P7 was synthesised via standard SPPS and capped 
with linker 10. The peptide was cleaved from the resin and purified by HPLC to yield 11. 
 
2.3.3.6 Stapling with functionalised linker 11 
CuAAC stapling was performed with linear peptides P8, P9 and P11 and functionalised linker 
11 under the literature conditions.44 For each reaction, the reaction time was extended until 
complete conversion to the desired stapled peptide was achieved, with analysis of the reaction 
mixtures performed by analytical HPLC and LCMS (Table 12). These stapling reactions 
proceeded to completion within 3 hours, and P8-11, P9-11 and P11-11 were obtained after 




Table 12 The sequences of azido peptides P8, P9 and P11 and the reaction times required for complete conversion 
to DP in peptide stapling reactions with 11 under the conditions shown. X = azido ornithine. Amino acids are shown 






Reaction time (h) Conversion 
(%) 
P8 Ac-IARKLQXIADQFHXL P8-11 1 >99 
P9 Ac-IGAXLRRMADXLNAQY P9-11 1 >99 
P11 Ac-IATQLRXFGDKLNXR P11-11 3 >99 
 
2.3.4 Analysis of i,i+7 BH3-only stapled peptides by CD spectroscopy 
CD spectroscopy of the peptides was performed as previously described for the i,i+11 
peptides (Section 2.3.2). The wild-type peptides P1-P3 were compared to their 
unfunctionalised stapled analogues (P8-10, P9-10 and P11-10), to avoid any interference from 
the polyarginine CPP. From the CD data it is apparent that the i,i+7 stapling is successful in 
inducing helicity, as for all of the peptides the stapled analogues displayed higher percentage 
helicities than the wild-type peptides. For the Bmf peptides (A, Figure 38), the stapled peptide 
P8-10 displayed a higher helicity (40%) than the wild-type peptide P1 (32%). For the Puma 
peptides (B, Figure 38), the stapled peptide P9-10 displayed the highest percentage α-helicity 
of all the peptides analysed (44%), an improvement over the wild-type peptide P2 (34%). The 
greatest improvement in helicity upon stapling was observed for the Noxa peptides (33% for 
P11-10 vs. 21% for P3, C, Figure 38). It is hoped that this increase in helicity upon stapling 
will translate into a reduced entropic penalty upon binding of the BH3-only peptides to pro-
survival Bcl-2 proteins compared to the linear sequences, although this requires experimental 
confirmation. Furthermore, the presence of the staple should lead to an increase in proteolytic 




Figure 38 CD spectra and % α-helicities for selected i,i+7 peptides: A) Bmf peptide P8-10, B) Puma peptide P9-10 
and C) Noxa peptide P11-10 with the wild-type peptides P1-P3 for comparison. All ellipticities have been normalised 
to a single wavelength (207 nm) and % α-helicity is given in brackets after the peptide number in the legend. 
 
2.3.5 Preliminary biological evaluation of i,i+7 BH3-only stapled peptides 
The bioactivity of the functionalised BH3-only peptides P8-11, P9-11 and P11-11 were 
assessed in human platelets alongside ABT737,160 initially looking at events associated with 
platelet apoptosis and activation.  
PS exposure, which is indicative of platelet apoptosis,177 and activation,178 can be quantified 
in human platelets by measuring the specific binding of a fluorescently-labelled recombinant 
protein, annexin V, to PS. The percentage of positive platelets corresponds to annexin V-
binding and consequently to PS exposure.112 In a preliminary assay, human platelets were 
incubated with P8-11, P9-11 and P11-11, and the binding to annexin V was measured over 3 
hours (A, Figure 39). Whilst the control compounds (DMSO and ABT737) displayed the 
anticipated biological response,160 only the result for P8-11 after 3 hours (21.9% annexin V 
binding) was significantly different to the vehicle, DMSO. The other time points for P8-11, and 
the data for P9-11 and P11-11 do not show any significant difference from DMSO, indicating 
that these peptides do not cause PS exposure in human platelets.  
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Figure 39 The preliminary data for platelet PS exposure and activation marker binding after treatment with P8-11, 
P9-11 and P11-11. A) The percentage positive platelets after incubation with peptides (10 µM), after 1, 2 and 3 h. 
B) The percentage positive platelets for PAC1 (white bar), CD62P (grey bar) and anti-CD63 (black bar) binding 
after incubation with peptides (10 µM) for 1 h. Each data point was replicated at least twice on two separate days. 
DMSO (1%) and ABT737 (10 µM) were included as controls. Data represent the mean ± standard deviation. 
Statistical significance compared to DMSO: **** P < 0.0001, ** P between 0.005 and 0.01, * P between 0.01 and 
0.05, ns = non-significant.    
Events associated with platelet activation, such as increased expression of integrins and the 
secretion of both α- and dense granules, can be measured by flow cytometry with fluorogenic 
antibodies that bind specifically to certain receptors.152 Standard platelet activation markers 
include:  
• PAC-1, an antibody that specifically binds to the active form of integrin GPIIb/IIIa. 
• CD62P that binds to P-selectin, an α-granule membrane protein.179  
• An anti-CD63 antibody that specifically binds to CD63, a marker found in dense  
granules that becomes externalised on the platelet surface during activation.160,151  
In a preliminary assay, washed platelet suspensions were incubated with P8-11, P9-11 and 
P11-11 for 1 hour and the percentage of platelets that bound to each of these antibodies was 
measured by flow cytometry (B, Figure 39). Treatment with ABT737 resulted in very low levels 
of activation marker binding, which is in-keeping with literature reports.160 Only the results for 
CD62P and anti-CD63 binding after treatment with P11-11 were significant (28 and 4.8% 
respectively), meaning that this peptide caused α- and dense granule release, events 
associated with platelet activation. For the other combinations of peptide treatment and 
activation marker, non-significant binding was observed, although, there is a large error 
associated with several of these results, therefore it is imperative that the data are replicated.  
These combined results from the preliminary assays were somewhat unexpected. Bmf and 
Bad have the same specificities for Bcl-2 proteins in nucleated cells, therefore Bmf peptide 
P8-11 could be expected to display a similar level of PS exposure as ‘Bad-mimetic’ ABT737 
(ABT737 gives >80% annexin V-binding after 3 hours). Similarly, in nucleated cells Puma and 
Bim have the same specificity for the pro-survival proteins,113 and an analogous i,i+7 
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polyarginine-functionalised Bim peptide displayed >60% annexin-V binding after 3 hours and 
>30% positive platelets for all three activation markers after 1 hour,l whereas treatment with 
Puma peptide P9-11 was no different to the vehicle for both annexin V and activation marker 
binding. Finally, to date there are no literature reports of Noxa expression in human platelets, 
however peptide P11-11, gave significant levels of CD62P and anti-CD63 binding.  
These assays will be repeated to improve the reliability of the data and allow confident 
conclusions to be drawn as to the effect of peptide treatment on annexin V and activation 
marker binding. If the observations discussed above are found to be valid, then further 
biological investigations are required to confirm that the observed phenotypic changes are a 








The aim of this project was to develop chemical tools with which the roles of the BH3-only 
proteins in human platelets could be further elucidated. To this end, nine novel CuAAC stapled 
peptides were synthesised, based on the sequences of the α-helical BH3 domains of the Bmf, 
Puma and Noxa BH3-only proteins (Figure 40). Two different positions for CuAAC stapling, 
i,i+7 and 11, were investigated for synthetic tractability and the ability to induce α-helicity in 
the resulting stapled peptides. CD spectroscopy confirmed that the i,i+7 stapling architecture 
was successful in inducing α-helicity in the peptides, and this stapling methodology was used 
to rapidly synthesise polyarginine-functionalised stapled peptides P8-11, P9-11 and P11-11. 
 
Figure 40 The BH3-only stapled peptides synthesised in this project. All peptides are C-terminal amides. X = 
Orn(N3), Ahx = 6-aminohexanoic acid. Amino acids are represented by blue spheres.  
In preliminary assays measuring the effect of the peptides on platelet activation and apoptosis, 
Bmf peptide P8-11 caused a low level of PS exposure, and Noxa peptide P11-11 induced 
dense- and α granule release. No significant activity was observed for the remaining peptides, 
indicating a heterogeneous phenotypic response to the different BH3-only stapled peptides. 
Further investigations are ongoing to confirm these preliminary results and to validate the 
mode of action of the peptides. It is anticipated that these chemical tools will enable further 
information to be gathered regarding the individual roles of the Bmf, Puma and Noxa BH3-
only proteins in human platelets, and consequently may provide the basis for the development 
of novel therapeutics.  
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2.5 Future work  
First, the data regarding the effect of P8-11, P9-11 and P11-11 on PS exposure and activation 
marker-binding in platelets will be replicated. The binding of the peptides to different pro-
survival proteins (e.g. Bcl-xL for Bmf and Puma peptides P8-11 and P9-11, and Mcl-1 for the 
Noxa peptide P11-11) can be measured by surface plasmon resonance.77 X-ray 
crystallography will be used to confirm that the stapled peptides are binding at the PPI 
interface of the pro-survival proteins for peptides with high binding affinities.m Additionally, the 
platelet uptake of fluorescently-labelled peptides will be measured, and the cellular localisation 
confirmed with confocal microscopy.77 If it is identified that the peptides do not bind to any of 
the pro-survival proteins, or are unable to enter human platelets then alterations to the peptide 
sequences, staple architectures or CPP will be investigated.  
To further probe the role of the Bcl-2 protein family in apoptosis of human platelets, assays 
measuring events that are closely related to mitochondrial apoptosis will be performed, and 
compared to ABT737, which has already been widely studied in the literature. Examples of 
assays that can be performed include measuring cytochrome c release,160 caspase 
activity,180,153 and mitochondrial membrane depermeabilisation.156 To confirm whether the i,i+7 
stapling does improve the proteolytic stability of the stapled peptides, the serum stability will 
be measured and compared to the wild-type sequences.77 
Finally, the development of the selective Bcl-2 inhibitor ABT199 illustrates that selective Bcl-2 
inhibitors that do not cause platelet apoptosis have potential as anti-cancer agents. Therefore, 
any stapled peptide which binds with high affinity to a pro-survival protein but has no effect on 
platelet apoptosis will be investigated as a new-modality anti-cancer therapeutic. Furthermore, 
to target the peptide to a specific cell-type, a homing peptide could be appended in place of, 
or in addition to the cell-penetrating tag on the staple. 
  
 









The development of cleavable stapled 





3. Chapter 3 - The development of cleavable stapled peptide-drug 
conjugates to target Pseudomonas aeruginosa 
3.1 Introduction 
3.1.1 Antimicrobial resistance  
Antimicrobial resistance (AMR) describes the way in which bacteria (and other pathogens) 
modify their phenotype in order to evade the activity of antimicrobial drugs. As early as 1945, 
Sir Alexander Fleming warned in his Nobel Prize lecture: “It is not difficult to make microbes 
resistant to penicillin in the laboratory by exposing them to concentrations not sufficient to kill 
them, and the same thing has occasionally happened in the body.”181 As highlighted by 
Fleming, a pressing factor in AMR development is the over- and misuse of antimicrobials, 
which select for advantageous mutations. AMR can be passed from one resistant organism to 
another, leading to resistant populations of infecting pathogens. 
Today, AMR is a very real and alarming threat to global health, garnering significant attention 
from global organisations. In 2016 the UK government, in collaboration with the Wellcome 
Trust, commissioned a report on AMR. The report estimated that by 2050 the number of global 
AMR-related deaths could be as high as 10 million per year, significantly outnumbering the 
predicted deaths due to cancer.182 In 2019, the Interagency Coordination Group (IACG) on 
AMR produced a report for the Secretary-General of the United Nations.183 The IACG stated 
that if effective action is not taken now, the economic cost of AMR could be comparable to 
that of the 2008 global financial crisis.  
Preventing the progression of AMR requires a multi-faceted approach. The Pew Charitable 
Trusts put together a working group of leading scientists and experts to produce a ‘Scientific 
Roadmap for Antibiotic Discovery’.184 Recommendations include increasing public awareness, 
using existing drugs sparingly and enriching the current antibiotic discovery pipeline. However, 
the rapid onset of AMR makes the development of new antimicrobials challenging. It is not 
surprising therefore that the pharmaceutical industry is divesting from antimicrobials in favour 
of therapeutic areas with more commercial return, for example oncology.185 Current antibiotic 
pipelines are heavily focused on prophylactics, leaving a need for antibiotics to treat 
infections.186 The Pew Charitable Trusts report specifically points towards the need for non-
traditional and multi-targeted therapies. This is echoed by the key messages and 
recommendations of the IACG 2019 report, which include the need for the development of 




3.1.2 Pseudomonas aeruginosa  
Pseudomonas aeruginosa is an opportunistic pathogen that presents a major threat to 
immunocompromised individuals such as patients with AIDS, cystic fibrosis (CF), burns 
victims and new-born babies.187 It is also responsible for around 10% of nosocomial bacterial 
infections.188 As an ESKAPE pathogen,n P. aeruginosa demonstrates high levels of resistance 
to standard antibiotics and, consequently, the World Health Organisation (WHO) have 
identified the development of novel antibiotics to treat this pathogen as a critical priority.189 
Current treatment for P. aeruginosa infections are antibiotics including aminoglycosides (e.g. 
tobramycin), fluoroquinolones (e.g. ciprofloxacin), polymyxins (e.g. colistin), cephalosporins 
(e.g. ceftazidime), carbapenems (e.g. meropenem) and penicillin/β-lactamase inhibitor 
combinations (e.g. piperacillin-tazobactam).190 The extensive use of these drugs exposes the 
bacteria to intense selection pressures, resulting in the rapid emergence of multi-drug 
resistance (MDR). As the prevalence of MDR P. aeruginosa infections increases, determining 
the appropriate medication requires the analysis of patient isolates for drug susceptibility, 
which increases the treatment time and cost.191  
Developing effective treatments for P. aeruginosa infections is extremely challenging due to 
the intrinsic resistance mechanisms displayed by this pathogen; the formation of biofilms and 
the nature of the Gram-negative bacterial envelope are two contributing features. 
 
3.1.2.1 Biofilms  
A biofilm consists of bacteria embedded in an extracellular matrix composed of lipids, DNA, 
polysaccharides, and proteins. Biofilm composition has a large impact on cell-to-cell 
interactions and the overall bacterial virulence.191 Biofilms are intrinsically resistant to 
antibiotics and host clearance mechanisms, such as phagocytes.192 It is therefore beneficial 
for bacteria to form biofilms as they protect the bacteria from antibiotics, bacteriophages and 
other competing organisms. P. aeruginosa readily forms biofilms on the surface of medical 
implants, often necessitating intensive courses of antibiotics and additional surgeries.193 
Additionally, chronic P. aeruginosa infections are common in CF patients, as the mucus plugs 
formed in the lungs provide an ideal environment for colonisation and biofilm formation.194 
Such infections represent a major cause of mortality in the CF patient population.188,195 
 
n ESKAPE = Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter 
baumannii, Pseudomonas aeruginosa, and Enterobacter spp. Together these pathogens are the leading cause of 
nosocomial infections globally.347 
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One cause of the AMR displayed by bacterial biofilms is the delayed penetration of drugs 
through the biofilm matrix. However, it has been suggested that, for P. aeruginosa infections, 
this is not the primary protective mechanism.196 Instead, it has been shown that a more 
probable explanation is that bacteria in biofilms have reduced rates of metabolism and growth. 
As most antibiotics are more effective against rapidly-growing cells, bacteria living within 
biofilms are less susceptible.192 A final, more putative mechanism involves the growth of 
‘persister’ cells within the biofilm.197 This theory states that some cells within the biofilm 
develop a specific MDR phenotype. Treatment with antibiotics kills most of the non-persister 
cells in the biofilm, leaving a population of MDR, persister bacteria.198  
 
3.1.2.2 Gram-negative bacterial membranes 
Unlike mammalian cells, most bacteria have an outer layer that determines the shape of the 
cell and protects the cellular contents from damage.199 This is the bacterial cell wall, which is 
comprised of peptidoglycan, a mesh-like structure made up of polysaccharide strands 
crosslinked with short peptides.200 Bacteria are characterised according to the composition of 
their cell wall using the Gram staining test. Gram-positive bacteria are named as such because 
they have a thick cell wall which absorbs and retains a crystal violet dye. Conversely, Gram-
negative bacteria have a thin cell wall protected by an outer membrane, therefore, they only 
absorb a small amount of dye and are decolourised after washing.187  
The Gram-negative cell envelope consists of the outer membrane, a periplasmic space 
containing a thin peptidoglycan cell wall and the inner membrane (Figure 41).201 Gram-positive 
bacteria, by comparison, have just an inner membrane, but a much more extensive 
peptidoglycan layer, hence why they retain the crystal violet dye during the Gram staining test. 
The outer membrane in Gram-negative bacteria has a distinct composition compared to the 
inner membrane; it is asymmetric, with the inner leaflet comprised of phospholipids and the 
outer leaflet made up of lipopolysaccharide, a glycolipid containing lipid A which is unique to 
Gram-negative bacteria (Figure 41). The outward-facing phosphate groups of the 
lipopolysacharide give the outer membrane a negatively charged exterior.201 The outer 
membrane contains surface proteins involved in a variety of roles such as transport; multi-
component proteins such as porins span the outer membrane allowing the passage of specific 




Figure 41 A simplified diagram showing the Gram-negative bacterial envelope, consisting of the outer membrane, 
a thin peptidoglycan layer and the inner membrane. The outer membrane contains lipopolysaccharide, lipid A, 
porins and surface proteins.    
The integrity of the cell envelope is vital for bacterial survival; the cell wall provides structural 
rigidity to the bacteria and prevents it from swelling. The outer membrane is also necessary 
as a selective barrier, allowing the transport of essential nutrients and the exclusion of 
potentially toxic chemicals; it is generally permeable to small ions and small hydrophilic 
molecules and impermeable to larger hydrophobic and amphipathic molecules. The unique 
properties of the bacterial outer membrane allow the selective targeting of Gram-negative 
bacteria over Gram-positive bacteria and mammalian cells.202  
The outer membrane of P. aeruginosa exhibits a particularly low permeability to drugs. 
Furthermore, it contains a battery of efflux pumps with wide substrate scopes that are capable 
of removing xenobiotic drugs that do manage to bypass this membrane and gain entry to the 
cell.203 Consequently, common antibiotics such as penicillins, cephalosporins, tetracyclines, 
quinolones and chloramphenicol are often ineffective against this species.187  
 
3.1.3 Antibiotics  
Antibiotics are chemicals that either kill or prevent the growth of microbes. The word antibiotic 
can be literally translated to ‘anti-life’, however the term is generally used today to mean either 
antibacterial or antifungal agents.204 The broader term antimicrobials extends this definition to 
include antiviral and antiparasitic agents; this report focusses on the bacterium P. aeruginosa 
and so the two terms will be used interchangeably. 
Humankind has been benefitting from the use of antimicrobial agents for thousands of years: 
there are documented examples of mouldy bread, honey and herbs being used to treat 
infections in ancient Egypt, China and Rome.187 In the early 20th century, Paul Ehrlich noticed 
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whilst developing dyes for bacterial stains that some compounds had an antibacterial effect. 
This led to his laboratory searching for the ‘magic bullet’ – a drug which would have the desired 
therapeutic effect without affecting human cells. Their screening efforts resulted in 
arsphenamine, the first synthetic antimicrobial agent that was used to treat syphilis.205 The 
next era of antimicrobial discovery involves the well-known story of penicillin G discovery by 
Sir Alexander Fleming. The translation of his original observation into a clinically relevant 
medicine undoubtedly saved many lives and sparked a campaign of antimicrobial discovery 
and development that resulted in many of the key drugs still in use today.206 In 2019, WHO 
published the 21st Essential Medicines List, which documents the drugs that are necessary to 
meet the needs of a healthcare system, and includes over 40 antimicrobials.84 Antimicrobial 
agents can be fully synthetic, semi-synthetic, natural products or novel modalities; some of 
the major classes of antibiotics are listed in Table 13.  
Table 13 An overview of the major classes of antibiotics, with key examples, sources and targets. Adapted from 
Brown and Wright.207  
Class Example Target Source 
Sulfonamides Sulfanilamide Folate synthesis Synthetic 
Fluoroquinolones Ciprofloxacin DNA topoisomerases Synthetic 
β-Lactams Ceftazidime Cell wall synthesis Natural product 
Oxazolidinones Linezolid Protein synthesis Synthetic 
Aminoglycosides Neomycin Protein synthesis Natural product 
Glycopeptides Vancomycin Cell wall synthesis Natural product 
Polymyxins Polymyxin B Bacterial cell membrane Natural product 
Cyclic lipopeptides Daptomycin Bacterial cell membrane Natural product 
Tetracyclines Tetracycline Protein synthesis Natural product 
These classes of antibiotics have been reviewed extensively elsewhere, but particular 
attention will be afforded here to the fluoroquinolones and β-lactams as they are of particular 
relevance to this chapter.187,204,208  
 
3.1.3.1 Quinolones and fluoroquinolones  
The quinolones are a class of broad spectrum, fully synthetic antibiotics which are amongst 
the most prescribed antibiotics globally.209 They act by inhibiting two DNA topoisomerases, 
DNA gyrase and topoisomerase IV. DNA gyrase is responsible for actively introducing 
negative supercoils into DNA and DNA topoisomerase IV relaxes positive supercoils; both are 
essential for bacterial survival.204 The first generation of quinolones were introduced in 1962, 
and two decades later a second generation, the fluoroquinolones, were developed with 
improved pharmacokinetic and pharmacodynamic properties.187 Ciprofloxacin, levofloxacin 
and moxifloxacin are fluoroquinolone antibiotics included in the WHO Essential Medicines List 




Figure 42 The structures of fluoroquinolone antibiotics ciprofloxacin, levofloxacin, and moxifloxacin. 
Resistance to fluoroquinolones is increasing, in part due to their widespread usage.210 Bacteria 
are capable of modifying drug targets so that the drug becomes ineffective and the target is 
functional.204 In P. aeruginosa, DNA gyrase mutations are often the first step in the 
development of resistance.211 Other mechanisms involve the over-expression of efflux pumps, 
which reduces the intracellular concentration of the drug: a lowered concentration at the target 
not only reduces the antibacterial effect but also can favour mutations in the target leading to 
resistance.212,213 As many efflux pumps have a broad substrate scope, their over-expression 
can increase resistance not just against the treating antibiotic, but other classes as well.  
 
3.1.3.2 β-Lactams  
The β-lactams are a class of antibiotics which contain a β-lactam ring motif and include 
penicillins, cephalosporins, monobactams and carbapenems. They represent the most 
commonly consumed antibiotics globally.214 Penicillin G and cephalosporin C represent the 
first molecules in each of these classes of β-lactams (Figure 43).187 
  
Figure 43 The structure of β-lactam antibiotics penicillin G and cephalosporin C.  
β-Lactam antibiotics target the transpeptidase enzymes which contain a catalytic serine 
residue and facilitate cross-linking within the peptidoglycan portion of the bacterial cell wall. 
The integrity of the cell wall is vital for survival; inhibiting the cross-linking reactions within the 
peptidoglycan weakens the cell wall and causes bacteria to rupture. In the transpeptidase 
mechanism, a (D)Ala-(D)Ala moiety at the end of one peptide chain binds to the enzyme, and 
a catalytic serine residue facilitates the formation of an amide bond between this peptide chain 




Figure 44 A simplified mechanism of transpeptidase-catalysed peptidoglycan cross-linking. The catalytic serine 
residue of the transpeptidase enzyme is highlighted in red, the (D)Ala-(D)Ala moiety is shown in black, and the 
cross-linking peptide chain is highlighted in blue.  
It is thought that penicillin works by binding to the transpeptidase enzyme as it has a similar 
structure to the terminal (D)Ala-(D)Ala dipeptide (A, Figure 45).187 The normal transpeptidase 
mechanism is initiated with penicillin as the substrate, however due to the structure of the β-
lactam, a covalent intermediate is formed which blocks the active site (B, Figure 45).  
 
Figure 45 A) A comparison of the structure of the (D)Ala-(D)Ala dipeptide and a general penicillin scaffold, B) the 
mechanism by which a β-lactam antibiotic blocks the active site of transpeptidase enzymes. R = variable group.  
Since the mass production of penicillin G was enabled by the combined research efforts of 
Fleming, Corey and Chain, this class of antibiotics has benefitted millions of patients.206 The 
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second class of β-lactam antibiotics to be discovered were the cephalosporins, which are 
structurally related to penicillins but display higher resistance to acid degradation and β-
lactamase (BL) activity (two major drawbacks with the earlier penicillin drugs).187  
Bacterial resistance towards β-lactam antibiotics is well understood, and is mainly due to the 
production of BL enzymes.215 BLs are structurally similar to transpeptidases and can sequester 
β-lactam antibiotics by hydrolysing the 4-membered ring, rendering the drug inactive. For most 
BL enzymes, this problem can be overcome through the co-administration of BL inhibitors, for 
example clavulanic acid.187 Additional resistance mechanisms are similar to those discussed 
for the fluoroquinolones; porins and efflux pumps also play a major role in β-lactam resistance, 
particularly in P. aeruginosa, by maintaining a low intracellular concentration of the drug.204 
The final key mechanism by which resistance emerges is the mutation of the drug target, in 
this case certain transpeptidases.187  
 
3.1.3.3 Problems with current antibiotics 
Many antibiotics suffer from low bioavailability, requiring high and regular dosing to maintain 
a sufficient concentration of the drug at the site of infection.216 This can lead to several 
problems, one of the most threatening of which is the development of resistance mechanisms. 
However, another major issue is the systemic toxicity that is inherent for some classes of 
antibiotics. Key examples include the polymyxin family of antibiotics, which are last-resort 
drugs for P. aeruginosa infections however their clinical use has been limited for years due to 
associated nephro- and neuro-toxicity.217 Additionally, the FDA recently updated the guidance 
for ciprofloxacin to include warnings about adverse effects associated with low blood sugar 
and mental health.218 Whilst broad-spectrum antibiotics are valuable as they allow treatment 
without the need for time-consuming and costly diagnosis, their use can result in significant 
side-effects.219 Conversely, narrow-spectrum antibiotics (or ‘precision antibiotics’) allow the 
selective targeting of certain strains whilst sparing other bacterial communities in the body, 
but precise and reliable diagnostic tests are required to determine a suitable drug.220 Many 
antibacterial targets are conserved amongst different species, so antibiotic treatments 
frequently risk harming non-infecting, non-pathogenic bacteria, which can result in gastro-
intestinal side effects.216 Whilst trivial for most, this can be dangerous for patients with 
additional health conditions.  
Within the current arsenal of antibiotics, there is a chronic lack of new chemical structures and 
bacterial targets. Current treatments are heavily reliant on a few structural classes of drugs 
and a small reserve of targets. WHO surveillance of AMR has highlighted that pathogenic 
bacteria are showing increasing levels of resistance towards last-resort antibiotics such as 
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carbapenems, and, since 2000, only six new classes of antibiotics have been brought to 
market.221 Promisingly, several of these drugs have novel mechanisms of action, however, 
they only target Gram-positive bacteria,222 and four out of the six ESKAPE pathogens are 
Gram-negative, leaving a niche that remains to be filled.223 More efforts are required to develop 
effective drugs capable of overcoming the challenges posed by Gram-negative bacteria, such 
as the low permeability of the outer membrane and formation of drug-resistance biofilms.216  
The current lack of new antibiotics is the result of a more general issue, the poor rate of 
antibiotic discovery. After the initial rush of the so-called ‘Golden-era’ of antibiotic discovery, 
very few new classes of antibiotics were brought to market between the 1960s and 2000s.224 
During this time, new drugs were typically structurally-similar members of existing classes, 
which do little to solve the emerging resistance crisis.225 It is clear that there are too few 
antibacterial agents in development to address the challenge of MDR.226  
Various organisations and government entities are united in calling for more investment in 
antibiotic discovery. Aside from traditional small molecule drugs, recommendations have been 
made for the investigation of non-traditional and alternative therapies, focussing on different 
bacterial targets and more unusual molecular architectures. The 2015 WHO Global Action 
Plan on AMR calls for investment in the development of new medicines,226 which is echoed 
by The Pew Charitable Trusts’ Scientific Roadmap for Antibiotic Discovery, which identifies 
the need for research into ‘non-traditional therapeutic approaches’ including ‘non-small 
molecule approaches’.184 The UK Government Review on AMR goes one step further, 
specifically naming antimicrobial peptides (AMPs), phage therapy and antibodies as promising 
alternative therapies requiring investment and research.185   
 
3.1.4 Alternative antimicrobial strategies  
AMR has forced researchers to consider novel approaches to combat bacterial infections. 
These approaches can be broadly split into two categories: the re-purposing of existing 
antimicrobials and the development of novel therapeutic agents. Existing drugs can be 
repurposed as prodrugs and hybrid antimicrobials. Novel therapies include new targets such 
as quorum sensing inhibitors, efflux pump inhibitors and membrane-disrupting peptides.208,227 





A prodrug is an inactive chemical which is converted into an active drug once inside the body, 
either via a chemical or enzymatic transformation.228 Prodrugs can have improved aqueous 
solubility and reduced side effects compared to the active drug and therefore represent an 
attractive method for re-purposing existing antibiotics.229 In particular, producing a prodrug that 
has masked polarity and charged functional groups can improve bacterial cellular penetration.  
Fluoroquinolone ciprofloxacin suffers from poor aqueous solubility and low intestinal 
permeability. As a result, ciprofloxacin prodrugs have been investigated via modifications of 
the carboxylic acid moiety, for example a triethylene glycol-ciprofloxacin prodrug (Figure 46), 
which showed a 400-fold improvement in aqueous solubility and a comparable minimum 
inhibitory concentration (MIC) to ciprofloxacin in the presence of esterase enzymes.230  
 
Figure 46 The structure of a ciprofloxacin-PEG prodrug, with the PEG ester group highlighted in blue.230 Esterases 
catalyse the release of free ciprofloxacin.  
Whilst the previous example used human esterases to release the active therapeutic, a more 
refined approach is to use bacterial enzymes so that the active drug is only revealed in the 
presence of bacteria. To this end, cephalosporin moieties have been used as release 
mechanisms. In this instance the β-lactam ring of the cephalosporin is selectively cleaved by 
BLs and the intermediate 6-membered ring can undergo a 1,4-elimination, resulting in the 
release of the cargo at the 3’-methylene position (Scheme 11). The cephalosporin ring system 
is favoured over other β-lactam scaffolds as it has obvious handles for synthetic derivatisation 
and it exhibits superior stability compared to penicillin scaffolds.187 
 
Scheme 11 The BL hydrolysis of the β-lactam ring in a cephalosporin. This is followed by 1,4-elimination and 
subsequent release of a leaving group, R1. R is a variable group on the cephalosporin.  
The cephalosporin group was first used as a prodrug moiety in antibody-directed enzyme 
therapy for cancer treatment in the 1990s.231 In this therapy, treatment with a prodrug of the 
desired cytotoxin is followed by an antibody targeting a specific tumour cell type, with BL 
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enzymes covalently attached to it. Consequently, the cytotoxin prodrug is only converted to 
the active drug at the desired site of action. For this approach, an enzyme was required which 
had satisfied the following criteria: to be highly substrate specific, to have the ability to catalyse 
a scission reaction, and to be highly orthogonal to enzyme activity in the body so that the drug 
would not be released elsewhere. These requirements are satisfied in the cephalosporin 
group. The BL-mediated release of many drugs was investigated including for taxol and 
doxorubicin.232–234  
More recently a cephalosporin prodrug of ciprofloxacin was reported, masking the carboxylic 
acid that is necessary for antibiotic activity, but contributed to the poor solubility and 
permeability of this drug (A, Figure 47).235 In the presence of BL-producing bacterial strains 
the prodrug had a two-fold lower MIC value than ciprofloxacin, whereas in BL-negative strains 
the prodrug was 10-fold less active.  
 
Figure 47 The structure of two prodrugs featuring a cephalosporin release mechanism. A) A cephalosporin-
ciprofloxacin prodrug,235 and B) A cephalosporin-peptide prodrug developed by Desgranges et al.236 
Desgranges et al. applied a similar prodrug strategy to a peptide with antimicrobial activity, 
which exhibited an intimate relationship between its overall positive charge and antimicrobial 
activity (B, Figure 47).236 Modifying the N-terminus of the peptide with a cephalosporin moiety 
would reduce this overall charge and the authors hypothesised that the resulting prodrug 
would have a lower activity. The cephalosporin group ensures that the ‘free’ peptide is only 
released in the presence of BL producing bacteria, allowing selective release. When tested 
against BL-positive strains of Escherichia coli and Staphylococcus aureus the prodrug was 
not as active as the parent peptide, however the prodrug was about two-fold more active in 
BL-positive E. coli than a BL-negative strain. The authors hypothesised that this approach 
may be more effective with a shorter peptide with a lower overall positive charge, as there 




3.1.4.2 Drug-drug conjugates 
Combination treatments are frequently used in the clinic, the most common being the co-
administration of a β-lactam antibiotic with a BL inhibitor. Amoxicillin/clavulanic acid is one 
such combination which features on the WHO List of Essential Medicines.84 
Certain drug combinations are considered to be synergistic if their overall inhibitory effects are 
greater than the sum of their individual inhibitory effects, which allows lower doses of each 
component, thus reducing side-effects and off-target toxicity.237 The probability of a bacterium 
developing resistance towards two drugs at the same time is low, therefore combination 
therapies can slow down the rate at which resistance emerges.238 However, synergistic effects 
observed in vitro often do not translate in vivo, particularly for Gram-negative bacteria.239 A 
possible cause for this is the different pharmacokinetic properties of the individual drugs, 
however, covalently linking the drugs can solve this problem by forcing them to adopt the same 
pharmacokinetic profile.238  Additionally, the properties of one of the drugs can improve those 
of the other, for example by increasing its cellular penetration and reducing efflux.240 There is 
precedent for the production of conjugated, hybrid antimicrobial agents in nature, an example 
being the thiomarinols.241   
Antibiotic conjugates where both parts exert an antimicrobial function of their own are 
sometimes referred to as ‘hybrid’ drugs.238 The construction of these hybrids is one of the 
strategies deployed to expand the use of fluoroquinolone antibiotics in the face of widespread 
AMR. Conjugates of ciprofloxacin account for a large proportion of the literature on hybrid 
antibiotics for several reasons.242 Firstly, fluoroquinolones typically have good cell penetration 
and are stable to a wide range of chemical transformations, which in part accounts for their 
success in the clinic to date.243 There is also a wealth of literature available on the structure-
activity-relationships of different fluoroquinolone analogues that can guide conjugate design. 
Finally, many fluoroquinolones are themselves dual-targeting, inhibiting both DNA 
topoisomerase IV and II (DNA gyrase).244 This means that if the chemical modification 
necessary for conjugation reduces the affinity of the fluoroquinolone scaffold for one of these 
enzymes, it may still retain activity towards the other.  
A conjugate of the fluoroquinolone moxifloxacin and the aminoglycoside tobramycin clearly 
illustrates the advantages of covalent conjugation (A, Figure 48).240 The hybrid antibiotic 
displayed improved outer membrane permeability and reduced efflux in P. aeruginosa 
compared to the individual components. Under conditions designed to subject the bacteria to 
selective pressure, the MIC values for tobramycin and moxifloxacin increased by 512- and 16-
fold respectively, whereas the MIC for the hybrid conjugate only increased by 2-fold, indicating 
that it delays the development of resistance.  
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Hybrid antimicrobials have been tested in the clinic, for example TD-1792, a conjugate of the 
glycopeptide vancomycin and the cephalosporin ceftazidime, both targeting different aspects 
of cell wall biosynthesis, developed by Theravance Biopharma (B, Figure 48). TD-1792 
displays synergistic activity against MDR Gram-positive bacterial strains that cannot be 
achieved with a combination of the individual drugs.245 TD-1792 completed Phase II clinical 
trials for the treatment of Gram-positive skin infections in 2007, but no clinical trials have been 
listed since.246  
 
Figure 48 The structures of two hybrid antimicrobials. A) A drug-drug conjugate consisting of moxifloxacin (blue) 
and tobramycin (red).240 B) TD-1792, consisting of vancomycin (blue) and ceftazidime (red).245 
Drug-drug conjugates are not the only class of hybrid drug that have been reported. In 
addition, conjugates consisting of antibiotics attached to chemicals which either promote their 
uptake, target the drug to the bacteria or sensitise the bacteria to the drug have been 
investigated.  
 
3.1.4.3 Siderophore-drug conjugates 
Chemicals that promote the uptake of compounds into bacterial cells are found in nature and 
can be exploited to facilitate the absorption of cytotoxic synthetic compounds: siderophores 
are one such example. Iron is essential for bacteria, however, Fe(III) has an extremely low 
aqueous solubility and therefore is not bioavailable to most microorganisms.247 Consequently 
bacteria have developed strategies for iron uptake, one of which is the production of iron-
71 
 
binding siderophores. Typical siderophore structural motifs include catecholates, 
carboxylates, phenolates and hydroxamates.248 Natural siderophore-antibiotic conjugates 
exist, called sideromycins. Albomycin is one example, comprising a hydroxamate iron-binding 
motif attached to a thioribosyl pyrimidine antibiotic moiety (Figure 49). Once inside the 
bacteria, the peptide linker is cleaved, releasing the antibiotic.249  
 
Figure 49 The structure of albomycin, a natural antibiotic (red)-siderophore (blue) conjugate. 
Inspired by this natural siderophore-antibiotic conjugate, synthetic conjugates have been 
synthesised with many different combinations of siderophore and antibiotic.238 The Nolan 
group have contributed widely to this field, developing ciprofloxacin- and β-lactam-siderophore 
conjugates. Their initial work focused on developing β-lactam-siderophore conjugates that 
were selectively taken up by IroN, a siderophore receptor associated with increased 
virulence.250 Conjugates of penicillins ampicillin and amoxicillin were synthesised, 
incorporating a derivative of natural siderophore enterobactin, a cachecolate that is common 
in Gram-positive bacteria and displays one of the highest affinities for iron (Figure 50).251 It 
was found that the β-lactam-siderophore conjugates displayed a 100-fold increase in 




Figure 50 The structure of an antibiotic-siderophore conjugate comprised of a β-lactam (red) and enterobactin 
analogue (blue).250 
More recently, the Nolan group conjugated ciprofloxacin to a siderophore to improve cellular 
uptake (Figure 51).252 The conjugate acts as an inactive prodrug, and is selectively taken up 
by bacteria which express the uptake machinery for enterobactin. The free drug is released 
intracellularly after hydrolysis of the siderophore. The conjugate shows comparable activity to 
free ciprofloxacin, however the highlight of this work lies in the mechanism of release. Studies 
found that hydrolysis of the enterobactin moiety is mediated by IroD, a cytoplasmic hydrolase 
which is expressed in pathogenic strains of E. coli. This demonstrates, therefore, that 
siderophore-antibiotic ‘prodrugs’ could be designed which are selectively taken up and 
hydrolysed only in pathogenic bacteria.  
 




3.1.4.4 Cell-penetrating peptide-drug conjugates 
Another approach to improving the accumulation of antibiotics inside bacteria is the 
attachment of cell-penetrating peptides (CPPs). Some CPPs are able to translocate bacterial 
membranes with no bacteriostatic or bactericidal activity, others display toxicity towards the 
bacteria, and many CPPs sit between these two extremes in activity. The exact role of the 
CPP in a CPP-drug conjugate varies depending on the example and the target bacteria. 
Deshayes et al. published a drug-CPP conjugate consisting of the aminoglycoside tobramycin 
conjugated to the protein-derived CPP penetratin,253 which has no antimicrobial activity and 
therefore serves only to improve the cellular uptake of the drug in this instance. The conjugate 
displayed improved antibacterial activity and significantly increased inner membrane 
permeability compared to the individual components and higher antibacterial activity against 
so-called ‘persister cells’ compared to tobramycin alone (Figure 52).  
 
Figure 52 The structure of a penetratin (blue spheres)-tobramycin (red) conjugate.253  
Riahifard et al. developed a conjugate comprised of cyclic [R4W4K] peptide and 
fluoroquinolone levofloxacin Q (Figure 53).254 The cyclic CPP [R4W4K] displays antibacterial 
activity, and when conjugated to levofloxacin Q, the resulting CPP-drug conjugate displayed 
a significant improvement in antibacterial activity against methicillin-resistant S. aureus 
(MRSA) and Klebsiella pneumoniae, where the parent drug had been inactive.  
 
Figure 53 The structure of a cyclic PDC consisting of c[R4W4K] (blue spheres) and levofloxacin Q (green).254 
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More recently, a polyarginine CPP was attached to vancomycin in an effort to restore 
antibacterial activity against vancomycin-resistant bacterial strains.255 The lead candidate 
which displayed a significantly improved antibacterial activity compared to vancomycin alone, 
and was active against several vancomycin-resistant strains (Figure 54). An in vivo study of 
S. aureus-infected mice showed that the conjugate reduced the number of colony-forming 
units whilst maintaining a stable body weight.  
 
Figure 54 The structure of a vancomycin (red)-polyarginine (blue) conjugate.255 
 
3.1.4.5 Selective release strategies  
Selective release strategies allow a biologically active chemical to be released or revealed 
under specific environmental conditions. These strategies are usually paired with approaches 
that have already been discussed, such as prodrugs, peptide-drug conjugates (PDCs), and 
siderophore-drug conjugates. In the context of antimicrobial therapeutics, the use of a 
selective release moiety which is sensitive to the presence of the infecting microbe yields an 
‘infection-activated’ system.216 These systems can have advantages including improved 
antimicrobial activity, fewer side effects and the reduced emergence of drug-resistance 
mechanisms. As BLs are produced by resistant bacteria, the BL-sensitive cephalosporin 
moiety can be employed as an infection-activated system. A possible application of such a 
release mechanism is in drug delivery via enzyme-sensitive polymeric vesicles. To this end, 
Li et al. synthesised enzyme-sensitive polymeric vesicles encapsulating vancomycin.256 The 
polymers incorporated a cephalosporin moiety, and BL hydrolysis of this group revealed a 
self-immolative linker. Subsequent immolation caused degradation of the polymeric vesicle, 
releasing the encapsulated drug (Figure 55). The authors observed that the BL-sensitive 
vesicles enabled selective delivery of antimicrobial agents to BL-producing bacterial strains: 
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vesicles containing vancomycin were able to inhibit the growth of MRSA whilst pro-biotic 
strains such as Enterococcus faecalis were unaffected.  
 
Figure 55 An overview of the release mechanism of BL-sensitive polymeric vesicles. The cephalosporin moiety is 
shown in red, the self-immolative linker in blue and a fragment of the polymer back-bone in black.256 
Inspired by the intracellular release of an antibiotic component from natural sideromycins such 
as albomycin, Miller et al. combined the approaches of siderophore conjugation and selective 
release through incorporating a cephalosporin linker between a siderophore and an 
oxazolidinone antibiotic (Figure 56).257 The siderophore allowed intracellular delivery of the 
conjugate, which was cleaved by BL hydrolysis of the cephalosporin linker, releasing the free 
oxazolidinone warhead. Whilst oxazolidinones are typically active against Gram-positive 
bacteria, the conjugate was active against Gram-negative bacteria, illustrating that this 
strategy allows the repurposing and retargeting of existing antibiotics. Additionally, the studies 
showed that the BL cleavage was necessary for activity, as the non-cleavable analogues 




Figure 56 The structure of a cleavable siderophore-oxazolidinone conjugate reported by Miller et al.257 The 
siderophore is shown in blue, the cephalosporin in black and the oxazolidinone in red.  
CPP-drug conjugates have already been discussed as a strategy to improve the bacterial 
penetration of a drug. However, infections due to mycobacteria pose an additional challenge, 
as the bacteria are able to reside in intracellular compartments of the host organism’s cells, 
meaning that a drug must cross both the eukaryotic and bacterial membranes to reach its 
intended target. Kelley and co-workers incorporated a cephalosporin release mechanism in 
an unusual drug delivery strategy for targeting mycobacteria.258 Methotrexate is a 
dihydrofolate reductase inhibitor which could be used to treat infections of Mycobacterium 
tuberculosis, however, it is unable to penetrate the cell wall of the mycobacteria. Additionally, 
the drug must penetrate the eukaryotic cell and enter the phagosomes in which the 
mycobacteria are residing. To overcome this issue, Kelley and co-workers conjugated 
methotrexate to a cationic, lipophilic peptide (called the ‘delivery peptide’); this PDC was 
capable of entering the mycobacteria, and was in turn appended via a cephalosporin moiety 
to an anionic peptide which promotes phagocytosis. The resulting conjugate was able to enter 
eukaryotic cells via phagocytosis and, when in the vicinity of the infecting mycobacteria, the 
cephalosporin linker was hydrolysed releasing the delivery PDC, which could enter the 




Figure 57 The structure of a methotrexate-peptide conjugate developed by Kelley and co-workers. Methotrexate 
and the cationic delivery peptide are shown in blue, the cephalosporin linker in red and the anionic peptide in green. 
Adapted from Pereira et al.258  
Another example of a cleavable PDC targeting intracellular pathogens was published by 
Brezden et al.259 Aminoglycosides are ineffective against bacteria that can reside in 
macrophages, such as Mycobacteria, Salmonella and Brucella spp., as they are unable to 
penetrate eukaryotic cell membranes. Brezden et al. conjugated aminoglycoside kanamycin 
to a CPP, P14LRR (Figure 58). P14LRR improved the cellular penetration of kanamycin and 
exerted an antimicrobial effect itself via membrane disruption. The authors synthesised and 
tested both a hydrocarbon non-cleavable and a disulfide cleavable analogue. The cleavable 
disulfide analogue could be reduced once the construct was inside the eukaryotic cell, 
releasing the peptide and drug as separate species. The intracellular antimicrobial activity of 
the conjugates was assessed, and it was found that the peptide and drug on their own were 
incapable of clearing an intracellular population of various Mycobacteria, Salmonella and 
Brucella strains from a macrophage cell line. The non-cleavable conjugate showed similar 
activity to a combination of the drug and peptide, however, the cleavable conjugate showed a 
significantly improved activity against all of the bacteria. In M. tuberculosis, 93% of the 




Figure 58 The structure of the cleavable and non-cleavable PDCs developed by Brezden et al.260 The drug, 
kanamycin, is shown in red, the linker in black and the CPP, P14LRR, in blue. Adapted from Brezden et al.260,261  
 
3.1.5 Antimicrobial peptides 
Antimicrobial peptides (AMPs) are an emerging class of antimicrobial compounds with great 
potential as new antibacterial therapeutics. AMPs are also referred to as host defence 
peptides as they modulate a wide range of biological functions in the host organism, including 
the innate immune system.262,263 The literature defines AMPs as a subset of CPPs as they are 
cationic and amphipathic, allowing them to interact with cell membranes. Unlike most CPPs, 
however, AMPs cause significant membrane disruption and by this mechanism exert 
bactericidal and bacteriostatic effects. As very few drugs interact with lipid membranes as their 
target, AMPs represent an interesting and unique class of antimicrobial agents.187 Another 
attractive feature of AMPs is that the cellular membranes of pathogens (e.g. bacteria, yeast, 
fungi) vary from the host’s cellular membranes, enabling selective targeting of the infectious 
species.264 For these reasons, AMPs are receiving increased interest as potential 
therapeutics.265  
Indeed, the data repository of AMPs (DRAMP) database lists over 3,800 AMPs, whilst 
increasing numbers of novel AMPs are published every year.266,267 Moreover, in 2018 there 
were 70 AMPs in clinical trials, thus, representing an expanding and exciting new field of 
antibiotic discovery.268 A 2016 review by the Wellcome Trust listed AMPs in the top 10 




3.1.5.1 Mechanisms of action 
AMPs can have various bacterial targets including efflux pumps,269 specific outer membrane 
proteins,270 and intracellular targets,271 however, the most common mechanism of action by 
far is membrane disruption. Significant bacterial membrane disruption leads to increased flow 
of water and ions and destroys the transmembrane electrochemical gradient, causing cell 
swelling and osmolysis and resulting in cell death.272 AMPs often show selectivity for Gram-
negative bacteria as the thick cell wall of Gram-positive bacteria represents a significant barrier 
to the bacterial cell membrane.187     
AMPs can have different secondary structures, including β-turns and random coils (or 
‘extended peptides’) but by far the most predominant structural motif is the α-helix.266,273 AMPs 
typically have an overall cationic charge and are amphipathic, and it is these distinct 
biophysical properties that enable their interaction with bacterial membranes.274 As both the 
outer leaflet of the Gram-negative outer membrane and the outer surface of the cell wall in 
Gram-positive bacteria are negatively charged, interactions with AMPs are guided by 
electrostatic interactions. Secondly, AMPs must be water-soluble and able to penetrate 
hydrophobic lipid membranes, which requires them to adopt a conformation that enables both; 
for most AMPs this is an amphipathic α-helix. The α-helicity and amphipathicity enables the 
formation of oligomers, wherein each AMP is arranged with the hydrophobic face pointing 
inwards and the hydrophilic face solvent-exposed.272  
These properties have led to the proposal of two main mechanisms by which membrane 
disruption occurs: the barrel-stave and carpet model. The barrel-stave mechanism involves 
the association of AMPs (either as monomers or oligomers) with the bacterial membrane, then 
the formation of pore-like structures where the hydrophobic faces of the peptides face 
outwards (A, Figure 59).275 These structures are then able to penetrate the membrane (B, 
Figure 59). The toroidal-pore mechanism is related and involves the same steps in a different 
order: the same pore-like structures form within the membrane, rather than prior to insertion.276 
 
 
Figure 59 A cartoon representing the barrel-stave model of membrane disruption. A: Peptides associate with the 
membrane either as monomers or oligomers. B: Additional peptides associate and insert into the membrane. The 
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peptides are shown as red and blue cylinders or lines and the membrane lipids as grey spheres. Reprinted with 
permission from Brogden.272 (Copyright Springer Nature 1969). 
The carpet model involves AMP monomers or oligomers interacting with the phospholipids on 
the outer membrane and covering it in a carpet-like manner (A, Figure 60).277 Once a particular 
threshold AMP concentration is reached, the natural curvature of the membrane is significantly 
disrupted, causing disintegration (B, Figure 60).  
 
Figure 60 A cartoon representing the carpel model of membrane disruption. A: Peptides associate with the 
membrane as monomers or oligomers. B: Once a threshold concentration has been achieved transient pores are 
formed. The peptides are shown as red and blue cylinders or lines and the membrane lipids as grey spheres. 
Reprinted with permission from Brogden.272 (Copyright Springer Nature 1969). 
AMPs can interact with other antibiotics, with numerous synergistic combinations featuring 
AMPs now reported in the literature. Although as yet unproven, it is largely accepted that the 
mechanism by which this synergy arises is via AMP-mediated membrane disruption allowing 
the other antibiotic increased access to its target.278 By using antibiotics in synergy with AMPs, 
lower doses of these toxic chemicals can be administered. Additionally, the synergistic action 
can allow a broad spectrum of activity for the drug, which enables the treatment of a wider 
range of bacterial infections and decreases the chances of resistance developing.223 
If not synergistic, drugs can have an additive effect, and act as permeabilisers or sensitisers 
for other antibiotics. Typically, this involves one compound targeting intrinsic or acquired 
antibiotic resistance mechanisms, thus improving the permeability of a second drug, or re-
sensitising the bacteria to this drug. AMPs can act in this way by targeting the outer membrane, 
which is a major cause of drug resistance in Gram-negative bacteria.278  
 
3.1.5.2 Bacterial resistance to antimicrobial peptides  
Bacteria have developed resistance mechanisms to AMPs, although the underrepresentation 
of AMPs on the market often means that these resistance mechanisms are overlooked when 
discussing the potential for AMPs as novel therapeutics. A fundamental resistance mechanism 
is the production of enzymes such as proteases, predominantly associated with the outer 
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membrane. Other AMP-sequestering proteins are produced which bind to AMPs and render 
them inactive, for example Staphylokinase produced by S. aureus.279  
Other mechanisms of resistance involve modifications to the outer surface of the bacteria. For 
example, some Gram-negative bacteria can reduce the overall negative charge of their outer 
membrane, thus reducing the electrostatic attraction of cationic AMPs.280 Gram-positive 
bacteria can modify the composition of their cell wall to achieve the same effect. Additionally, 
some pathogenic strains, including P. aeruginosa, can produce an anionic polysaccharide 
capsule that surrounds the cell. It is believed that this capsule is capable of sequestering AMPs 
before they are able to reach the outer membrane.279  
As previously discussed, biofilm formation reduces the activity of antibiotics; this is also the 
case for AMPs. This is in part due to the reduced penetration of AMPs through the extracellular 
matrix and partly due to the presence of extracellular polysaccharides which can bind to and 
sequester AMPs.279 A final key feature of AMP resistance in bacteria is efflux: there are many 
efflux pumps in bacteria for which AMPs are substrates, for example the resistance-
nodulation-cell division family transporters present in many Gram-negative bacteria. 
Additionally, many strains of bacteria that produce and secrete AMPs as part of their own 
defences have AMP-specific efflux pumps which can contribute to the efflux of non-
endogenous AMPs.279  
 
3.1.5.3 Macrocyclic antimicrobial peptides 
As previously discussed in Chapter 1, macrocyclic peptides have a number of advantages 
over their linear counterparts, including increased serum stability and reduced conformational 
flexibility. In the context of therapeutic AMPs, performing macrocyclisation for these reasons 
is also relevant. A therapeutic AMP must survive both eukaryotic and prokaryotic proteases 
before reaching its target. Additionally, as many AMPs must adopt an α-helical, amphipathic 
structure to exert their antibacterial activity, conformational rigidity may improve the activity. 
The α-helicity of AMPs is dependent on their environment, in particular the pH and salt 
concentration.281 In CF patients, who are at risk from opportunistic pathogens like P. 
aeruginosa, often chronic infections occur in the pulmonary mucus. This is an environment 
with a high salt concentration that renders many AMPs ineffective,282 however, 
conformationally locking AMPs can improve their salt-stability.281 Finally, AMPs suffer from 
poor bioavailability which can limit their use to topical applications. Macrocyclisation provides 
an opportunity to add functionality or modify the properties of the peptide to improve 
bioavailability.283     
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There are many examples of both natural and synthetic macrocyclic AMPs in the literature, 
that use a variety of macrocyclisation chemistries.202,283–285 This thesis is concerned with 
macrocyclisation by peptide stapling, and so particular attention will be afforded to stapled 
antimicrobial peptides (STAMPs) here. 
 
3.1.5.4 Stapled antimicrobial peptides 
Reports of STAMPs are dominated by one technique, ring-closing metathesis (RCM). 
Literature examples of stapled AMPs include linear AMPs isolated from natural sources which 
have been stapled to improve their properties, de novo designed stapled AMPs, and AMPs 
featuring more than one staple (‘stitched peptides’).283 Examples of these three types of 
stapled AMPs will be discussed in this section.  
Luong et al. investigated the effect of introducing a hydrocarbon staple to polybia-MP1, a linear 
AMP isolated from wasp venom, alongside specific amino acid substitutions which increased 
the overall positive charge.286 One of the analogues, MP1S-Q12K, displayed significantly 
improved MIC values against Gram-positive bacterial strains over the wild-type sequence 
(Figure 61), and, unlike the wild-type peptide, MP1S-Q12K displayed no activity towards 
Gram-negative strains. The stapled peptide was more helical than the wild-type sequence, 
and significantly more stable in a trypsin digestion assay: over 97% of unmodified MP1S-Q12K 
was present after incubation for 60 minutes compared to only 15% for the wild-type peptide.   
 
Figure 61 The structure of an all-hydrocarbon stapled analogue of polybia-MP1, MP1S-Q12K, reported by Luong 
et al.286 The amino acid residues are represented by blue spheres, the unnatural amino acids by green spheres 
and X = alkenyl unnatural amino acids.   
Dinh et al. investigated the de novo design of short, amphipathic all-hydrocarbon STAMPs.287 
Starting from a heptapeptide scaffold, they placed the all-hydrocarbon bridge between i,i+4 
positions and inserted amino acid residues in the remaining places to maximise the 
amphipathicity; lysine residues on the hydrophilic face and alanine and tryptophan on the 
hydrophobic face, an example is given in Figure 62. All of the STAMPs displayed an increased 
α-helical content compared to the unstapled analogues, however, it is interesting to note that 
the most helical peptide did not give the highest level of growth inhibition when tested against 
a panel of different Gram-positive and -negative strains, and the two peptides which displayed 
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the most potent activity against S. aureus and E. coli also displayed the highest levels of 
haemolysis.  
 
Figure 62 A: The linear sequence of an all-hydrocarbon STAMP designed by Dinh et al.287 B: A helical wheel 
representation of the STAMP. The hydrophobic amino acid residues are represented by blue spheres, the 
hydrophilic residues by orange spheres and the unnatural amino acids by green spheres. X = the unnatural amino 
acids, the oct-4-enyl linker is represented by a green line. 
Chapuis et al. investigated the effect of introducing two hydrocarbon staples into AMPs 
lasioglossin and melectin, both isolated from bee venom, to investigate how the double staple 
architecture affected the peptides’ pharmacological properties.288 Alkenyl amino acids were 
introduced into the hydrophobic portion of the peptide so that the number of cationic residues 
remained constant. A series of lasioglossin and melectin analogues were synthesised with 
either one or two hydrocarbon staples of different lengths and positions, and it was found that 
the introduction of two staples into the peptides gave mixed results. For example, one doubly-
stapled analogue of lasioglossin, LL-IIIs-4, showed significantly reduced activity compared to 
the wild-type peptide (Figure 63). However, the double staple conferred a high level of α-
helicity and proteolytical stability; LL-IIIs-4 showed minimal degradation in a trypsin digestion 
assay.  
 
Figure 63 The structure of a ‘stitched’ peptide, LL-IIIs-4 reported by Chapuis et al.288 The hydrophobic amino acid 
residues are represented by blue spheres, the hydrophilic residues by orange spheres and the unnatural amino 
acids by green spheres. X = alkenyl unnatural amino acids.   
These examples show the complicated relationship between α-helicity, conformational 
flexibility, amphipathicity, antibacterial activity and haemolysis. Whilst there are many 
examples of all-hydrocarbon stapled AMPs with improved proteolytic stability and α-helicity, 
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these peptides can also display higher levels of haemolysis and lowered antibacterial 
activity.283 To address this potential minefield when designing new stapled AMPs, Walensky 
and co-workers undertook a systematic screening approach to determine design guidelines, 
using all-hydrocarbon stapled analogues of AMP magainin II as a model system.289 A key 
finding was that the staple must be incorporated into pre-existing regions of hydrophobicity to 
avoid undesirable haemolysis. Taking their findings from magainin II, an algorithm for stapled 
AMP design was constructed; using this algorithm the authors were able to rapidly design 
stapled AMPs with high levels of antibacterial activity and negligible haemolysis without the 
need for a systematic library screen for each different AMP. Following on from this work, 
Walensky and co-workers have filed a patent for all-hydrocarbon stapled AMPs based on the 
sequence of magainin II.40   
Whilst the overwhelming majority of literature STAMPs make use of RCM stapling, there are 
examples where other macrocyclisation techniques have been employed. One example is a 
bicyclic peptide developed by the Reymond group.290 The addition of a 3,5-
bis(chloromethyl)toluoyl group at the N-terminus of the peptide allowed alkylation with two 
cysteine residues to give a thioether linkage (Figure 64). The linear ‘tail’ of the peptide was 
found to be unstable in serum, however the enantiomeric peptide containing all D-amino acids 
was significantly more stable and gave comparable MIC values to polymyxin B against MDR 
strains of Acinetobacter baumannii. The bicyclic peptide also inhibited biofilm formation of P. 
aeruginosa, E. coli and A. baumannii.  
 
Figure 64 The structure of the bicyclic, thioether bridged peptide developed by the Reymond group.290 The amino 
acids are represented by blue spheres, and the letters represent the D enantiomers of the amino acids. The 
cyclisation linker is highlighted in red.  
The Pentelute group investigated various macrocyclic AMPs which were conjugated to an 
antibody targeting E. coli, creating an antibody-antibiotic conjugate.291 Analogues of the AMP 
cathelicidin were stapled with a perfluoroalkyl linker via an SNAr reaction (Figure 65). The 
stapled peptides all displayed improved serum stability compared to their linear counterparts, 




Figure 65 The structure of one of the perfluoroalkyl stapled peptides developed by Pentelute et al. for use in a 
peptide-antibody conjugate.291 
 
3.1.6 Peptide-drug conjugates 
PDCs contain a covalently-linked peptide and pharmaceutical drug, natural product or toxin. 
Antimicrobial PDCs belong to the class of ‘hybrid drugs’, which were discussed in Section 
3.1.4. The role of the peptide in a PDC can be either:   
1. To act as a targeting agent  
2. To provide an alternative and additional mechanism of action  
3. To improve cellular uptake of the drug 
Examples of PDCs where the peptide is assuming each of these roles will be discussed in this 
section except for the last. The appendage of CPPs to drugs to improve their cellular uptake 
was discussed in Section 3.1.4.4 and in Chapter 2, and will not be discussed further here.  
 
3.1.6.1 Homing peptide-drug conjugates 
To date, the most advanced PDCs are all in the field of cancer therapies, which typically 
consist of drugs conjugated to homing peptides, which specifically bind to cell-surface 
receptors that are overexpressed on cancer cells.292 Lutathera® is currently the only marketed 
PDC, consisting of octreotate (a disulfide-bridged peptide which mimics the pharmacological 
effect of somatostatin) covalently linked to a chelated radionuclide lutetium-177 (Figure 66).293 
It was approved by the FDA in 2018 for the treatment of gastroenteropancreatic 
neuroendocrine tumours. Somatostatin receptors are overexpressed in most neuroendocrine 
tumours, allowing selective binding and internalization of Lutathera®. Once internalised, the 




Figure 66 The structure of marketed PDC Lutathera®. The targeting peptide, octreotate, is shown in blue and the 
drug, radionuclide 177Lu, in red. 
There are currently three chemotherapeutic PDCs in clinical trials, which have all been 
developed by Bicycle Therapeutics. They all consist of a bicyclic peptide, a cleavable linker, 
and a cytotoxic drug. The bicyclic peptides, BT1718, BT5528 and BT8009, were discovered 
using phage display and CLIPS cyclisation, then further optimised through the introduction of 
unnatural amino acids to improve binding and replace metabolically-labile residues.105 BT1718 
was developed for the treatment of lung cancer, and the peptide component binds with high 
affinity to membrane type-1 matrix metalloprotease which is over-expressed in triple-negative 
breast cancer and non-small cell lung cancer. Its cytotoxic payload is tubulin-binder 
mertansine, which is attached to the targeting bicyclic peptide via a disulfide cleavable linker 
(Figure 67). BT1718 is currently in Phase I/IIa clinical trials due for completion in 2022.294,295 
 
Figure 67 The structure of BT1718, a PDC consisting of cytotoxin mertansine (red) linked to a bicyclic peptide (blue 
spheres) via a disulfide cleavable linker (green). 1NAl = 1-naphthyl-L-alanine, tBuGly = L-tert-leucine.  
BT5528 targets Ephrin receptor A2, which is overexpressed in many cancers including ovarian 
and pancreatic. It is comprised of monomethyl auristatin E, a cytotoxin which prevents the 
polymerisation of tubulin, bound to a bicyclic peptide through a cathepsin-cleavable linker 
(Figure 68).105 BT5528 entered Phase I/II clinical trials in 2019.296 Another PDC, BT8009 has 
the same drug-cleavable linker structure as BT5528 but differs in the peptide moiety, instead 
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incorporating a peptide which targets Nectin-4, a cell adhesion molecule overexpressed in 
lung and bladder cancer (Figure 68).297  
 
Figure 68 The structures of BT5528 and BT8009, two PDCs consisting of bicyclic peptides (blue spheres) linked 
to cytotoxin monomethyl auristatin E (red) via a cathepsin cleavable linker (green). 1NAl = 1-naphthyl-L-alanine, 
HyP = 4-hydroxyproline, hArg = homoarginine.  
 
3.1.6.2 AMP-drug conjugates 
Aside from targeting a specific cell-type, another role for a peptide in a PDC is to provide an 
additional and alternative mechanism of action. When incorporated into a PDC, a membrane-
disrupting AMP exerts an antimicrobial effect in its own right, but also increases the uptake 
and the traditional drug component of the PDC.298 Whilst there are no AMP-containing PDCs 
in the clinic, many have been reported in the literature.276,299,300 An illustrative example is a 
chloramphenicol PDC reported by Chen et al.301 Chloramphenicol has a high antimicrobial 
activity, however, it suffers from nonspecific distribution and severe side effects in vivo. UBI29-
41 is a cationic AMP that had previously been used for imaging and diagnosis of bacterial 
infections. The conjugation of chloramphenicol and UBI29-41 lowered the cytotoxicity of the drug 




Figure 69 The structure of a PDC developed by Chen et al.301 Chloramphenicol is shown in red, the linker in black 
and AMP UBI29-41 as blue spheres. 
Ptaszyńska et al. investigated conjugates of levofloxacin and ciprofloxacin with AMPs based 
on a fragment of human lactoferrin, which distorts the bacterial outer membrane.302 One of the 
PDCs investigated featured a human lactoferrin-derived peptide, HLopt2, conjugated to 
ciprofloxacin via a disulfide linker (Figure 70). The resulting PDC displayed the highest 
antimicrobial activity out of all the PDCs screened against S. aureus, E. coli and P. aeruginosa. 
Further studies confirmed that the disulfide was reduced intracellularly, releasing the peptide 
and a ciprofloxacin-cysteine species; the authors hypothesised that this contributed to the 
elevated antimicrobial activity.  
 
Figure 70 The structure of a disulfide-linked ciprofloxacin-HLopt2 conjugate reported by Ptaszyńska et al.302 
Ciprofloxacin is highlighted in red and the peptide HLopt2 is represented by blue spheres. 
PDCs have been reported which incorporate STAMPs. In 2017, a patent application was filed 
by the Walensky research group describing RCM stapled analogues of the AMP magainin II. 
The patent mentions conjugation of the peptides to ‘appropriate antimicrobial agents’ and 
discusses the conjugation of the STAMPs to carrier proteins to enable their cellular 
permeability, although no structural information about the conjugates is given.271,303  
It is clear from the examples discussed in this section that inventive combinations of alternative 
antimicrobial strategies are being explored, for example cleavable STAMP-drug 
conjugates,260,302 and infection-controlled release of antibiotics from siderophores,257 
prodrugs,235 and polymeric vesicles.256 Simultaneously, whilst peptide stapling is improving 
the therapeutic potential of AMPs, the benefits of two-component peptide stapling, particularly 
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with respect to the development of functionalised peptides, is yet to be fully realised for AMPs. 
This section describes the development of an innovative antimicrobial PDC which draws 
inspiration from these fields and aims to yield a therapeutic which is advantageous over each 




3.2 Project overview and aims  
The primary aim of this project was to develop a novel PDC comprised of a STAMP, a selective 
release moiety, and an antibiotic drug. Based on literature reports of other alternative 
antimicrobial strategies (vide supra), it was hypothesised that the PDC would have several 
unique features that would be advantageous over current antimicrobial therapies: 
• As the STAMP and small molecule antibiotic would have different mechanisms of action, 
this would be a dual-targeting conjugate; the many advantages of such ‘hybrid antibiotics’ 
were discussed in the introduction (Sections 3.1.4 and 3.1.5).  
• It was envisioned that the AMP would be selective for P. aeruginosa, allowing the 
conjugate to be targeted to this species of bacteria. This could reduce the side effects 
associated with some broad-spectrum small-molecule antibiotics.  
• An enzyme-cleavable moiety between the AMP and the drug would enable selective 
release of the free drug. This would avoid issues of the conjugation position negatively 
affecting the antibiotic activity of the drug. By incorporating a moiety that could be 
selectively cleaved by pathogenic bacteria, reduced off-target toxicity could be achieved. 
The work described in this section can be divided into two sections. The first part details the 
selection of a suitable stapled peptide. This was done by identifying AMPs from the literature 
and screening stapled analogues for antimicrobial activity. For the peptide screen 24 peptides 
were synthesised, and from this library one STAMP (AMP2-17, Figure 71) was selected that 
gave good antimicrobial activity and selectivity for P. aeruginosa over S. aureus.  
 
Figure 71 The structure of AMP2-17, the two-component STAMP chosen from the peptide screen performed in 
Section 3.3.2 and PDC1. 
The second section describes the selection of each component, and the overall design of 
PDC1 (Figure 71). The synthesis of the first-generation linkers required for PDC1 is detailed 
in Section 3.3.6, and in Section 3.3.7 the second-generation linkers are discussed, including 




3.3 Results and discussion 
3.3.1 Synthesis of unfunctionalised STAMPs 
3.3.1.1 Peptide selection and design 
There are two possible approaches to the development of a novel STAMP: de novo design or 
by applying a stapling strategy to a literature AMP. It was decided that the second approach 
would be more efficient for this project as the aim was to develop novel a PDC rather than a 
novel AMP. Additionally, it would be revealing to apply a novel stapling strategy to AMPs, as 
any stapling methodologies outside of RCM have been underexplored in the literature. First, 
a panel of literature AMPs (both linear and RCM stapled) with the desired properties were 
identified. The criteria used to select these peptides included good antimicrobial activity 
towards P. aeruginosa, little or no haemolysis and sequences long enough to accommodate 
a stapling linker. Once suitable peptides had been identified, stapled analogues would be 
designed and synthesised. The resulting panel of stapled AMPs would then be screened to 
determine their minimum inhibitory concentration (MIC) against P. aeruginosa; the stapled 
peptide(s) displaying the best MIC values would then be taken on to constitute the peptide 
fragment of the full cleavable PDC.  
To this end, a panel of 8 AMPs were selected from the literature, which were derived from a 
wide range of sources, including bacteria (AMP3),304 humans (AMP6 and AMP7),305,306 and 
several from animal sources (Table 14). AMP1 and AMP2 were originally derived from AMPs 
isolated from the Korean frog, Rana rugosa.307,308,309 Additionally, AMP4 originated from a 
peptide found in porcine myeloid cells and AMP5 is derived from Anoplin, an AMP isolated 
from the solitary wasp Anoplius samariensis.310,311 The AMPs chosen spanned a range of 
different lengths (from 10-20 amino acids) and compositions, some with free N-termini and 
some with lipidated N-termini. It was envisioned that this structural diversity would increase 









Table 14 The peptides selected for the initial screen, their literature sequences and the novel sequences 
determined for cys-DVH stapling. All peptides are C-terminal amides, and all are N-terminal amines unless 









































With respect to their antimicrobial activity, a direct comparison of the chosen AMPs could not 
be performed due to the use of different assays and bacterial strains by each group. Broadly, 
AMP1a is an analogue of gaegurin-4, which has an intermediate MIC value (100 μg/mL) for 
P. aeruginosa; this peptide was chosen to investigate whether stapling could improve the MIC 
value to afford a more potent peptide. AMP2a was highly active towards all Gram-negative 
and Gram-positive strains tested and AMP3a rapidly killed P. aeruginosa (NCTC 6750 strain) 
following treatment. AMP4a displayed good lethal concentrations against a wide range of P. 
aeruginosa strains including MDR strains, and comparable time-kill kinetics to polymyxin B for 
P. aeruginosa (LCCI strain). AMP5a showed some selectivity for P. aeruginosa (PAO1 strain) 
over other Gram-negative and -positive strains and a 6-fold selectivity for P. aeruginosa over 
E. coli. Both AMP6a and -7a displayed promising in vivo properties: AMP6a was shown to be 
highly effective in vivo, reducing lung injury and bacterial load in P. aeruginosa infected mice, 
and AMP7a displayed a good MIC against P. aeruginosa (ATCC 27853 strain) and even better 
MIC values against some clinical isolates. In a mouse model of sepsis, AMP7a gave reduced 
mortality and improved survival rates. With respect to cytotoxicity, AMP2a, AMP4a and 
AMP6a gave undetectable haemolysis under the respective assay conditions and AMP3a and 
-7a only gave minimal haemolysis at the minimum lethal concentration (MLC). No data 
regarding haemolysis was reported in the literature for AMP1a or AMP5a.  
To make stapled analogues of these AMPs, cysteine-divinylheterocycle (Cys-DVH) stapling 
was chosen, due to the advantages discussed in Chapter 1.67 DVH stapling is highly 
chemoselectivity towards cysteine residues, and the native cysteine amino acids are cheaper 
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and give more efficient SPPS compared to the preparation of sequences containing unnatural 
amino acids, such as the azido amino acids used for CuAAC stapling. Additionally, the DVH 
stapling linkers offer the same opportunities for functionalisation as the bis-alkynyl linkers 
required for CuAAC stapling. For Cys-DVH stapling, the AMPs needed to contain two cysteine 
residues, and it was decided to place the cysteine residues at i,i+7 positions in the peptide 
sequences, as it is widely accepted that stapling between these positions can improve the α-
helicity.15,42 It was desirable for the STAMPs to have reasonable levels of α-helicity, as for 
many AMPs increased α-helicity can lead to greater antimicrobial activity.283 Consequently, a 
key requirement for the selected AMPs was that cysteine residues could be inserted at i,i+7 
positions in the peptide sequence without disrupting the predicted α-helicity, amphipathicity or 
overall cationic charge, all of which are important for antimicrobial activity.  
The optimal staple position was guided by in silico experimentation performed by Dr. Yaw Sing 
Tan (A* Institute, Singapore). Briefly, structures of AMP1-7 were modelled, assuming they 
formed a perfect α-helix, and the staple was placed so that the overall cationic charge and 
amphipathicity (both of which are linked to antimicrobial activity) were preserved.98,312 
Additionally, any potentially unstable residues such as methionine were replaced by the staple 
where possible. Molecular dynamics simulations were performed on the linear and stapled 
versions of AMP1 and -2 to predict the ability of the staple to maintain peptide helicity. After 
the selection of suitable peptides from the literature and the in silico-guided design of cysteine 
analogues, seven linear cysteine-containing AMPs, AMP1-AMP7, were selected for stapling 
(Table 14). 
 
3.3.1.2 Synthesis of linear peptides 
AMP1-AMP7 were synthesised using microwave-assisted Fmoc-SPPS. Low-loading Rink 
amide MBHA resin was used as the C-terminal amide was desired, and low-loading resin 
would assist in the prevention of on-resin aggregation. All of the peptides were cleaved from 
the resin without acetyl capping, leaving an N-terminal amine, except AMP1 and -3 which 
were capped with an acetyl group, and AMP5 which was capped with octanoyl chloride in 
keeping with the literature sequences for these peptides.304,307,311 For the cleavage of the 
peptides from the resin, often EDT is added to the cleavage cocktail for thiol-containing 
peptides to prevent unwanted oxidation and alkylation.313 Trial reactions were performed using 
both standard cleavage conditions (TFA/TIPS/H2O/CH2Cl2 (92.5:2.5:2.5:2.5), 40 °C, 45 min) 
and EDT conditions (TFA/TIPS/H2O/EDT (94:1:2.5:2.5), 40 °C, 45 min). It was found that for 
AMP1-AMP7, the purity of the crude peptide was the same regardless of the cleavage cocktail 
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used so for practical simplicity the standard cleavage conditions were used. The crude 
peptides were purified by preparative reverse phase HPLC prior to peptide stapling.  
 
3.3.1.3 Synthesis of DVH linkers 14 and 17 
Both DVT and DVPs have been used in peptide stapling methodologies.67,69 Trial stapling 
reactions were performed to ascertain whether a DVT or DVP linker would give the best 
stapling reaction with AMP1-AMP7. The key factors were the solubility of the linker and the 
stapled peptide product and the reaction profile. For these trial reactions, simple DVT and 
DVP linkers were synthesised. The DVT linker was synthesised according to the literature 
synthetic route shown below (Scheme 12).67 Briefly, an SNAr reaction between sarcosine ethyl 
ester and 2,4,6-trichloro-1,3,5-triazine gave 12 in an excellent yield. A bis-Suzuki-Miyaura 
cross-coupling with potassium vinyl trifluoroborate gave the ester 13 in a moderate yield, and 
a final step of basic ester hydrolysis generated the desired linker 14 in a 56% yield after 
trituration.  
 
Scheme 12 The synthesis of peptide stapling linker 14 from commercially available 2,4,6-trichloro-1,3,5-triazine. 
A simple phenyl-propyl DVP linker 17 was synthesised following the same synthetic route as 
the DVT linker. From commercially available starting material 2,4,6-trichlopyrimidine, the initial 
SNAr reaction with 3-phenylpropan-1-amine gave the incorrect regioisomer 16 as a by-product, 
resulting in a moderate yield of 15 (Scheme 13). The isomers were chromatographically 
separable.  
 
Scheme 13 The synthesis of desired product 15 and unwanted regioisomer 16 via an SNAr reaction of 2,4,6-
trichlopyrimidine and 3-phenylpropan-1-amine. 
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Next, the bis-Suzuki-Miyaura cross-coupling gave the desired product 17 in a 70% yield 
(Scheme 14). 
 
Scheme 14 The synthesis of 17 from 15 via a bis-Suzuki-Miyaura cross-coupling.  
 
3.3.1.4 Test stapling reactions and optimisation  
With the linear peptides AMP1-AMP7 and simple linkers 14 and 17 in hand, test stapling 
reactions were performed with AMP4 as a model peptide, using the literature conditions for 
Cys-DVT stapling (Scheme 15).67 Analytical HPLC and LCMS were used to monitor the 
reaction mixtures and compare the performance of the DVH linkers.  
 
Scheme 15 The trial peptide stapling reactions performed with peptides AMP4 and linkers 14 and 17 under the 
literature conditions for Cys-DVT stapling.67 
For the stapling reaction with DVT 14, the analytical HPLC traces of the reaction mixture at 0 
hours showed a complex reaction profile and after 18 hours only the mass corresponding to 
the starting material was observed when analysed by LCMS. When an additional 0.5 
equivalents of linker 14 was added and the reaction left for 18 hours, still no product was 
observed. Conversely, with DVP 17 after 36 hours a species with the correct mass for the 
stapled peptide was observed by LCMS analysis. However, the reaction mixture went cloudy 
on addition of the linker (as a stock solution in DMSO), indicating that either the linker or 
stapled peptide were insoluble in the reaction solvent system. Based on the preliminary results 
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from these trial reactions, the DVT linker was discontinued and subsequent optimisation 
focused on the DVP linker.  
Alternative reaction conditions were trialled with AMP2 and linker 17 which included a much 
higher proportion of organic solvent, and pH 6 buffer rather than pH 8 (Scheme 16). Under 
these conditions, with the peptide and linker concentrations as before, it appeared that the 
solubility issues had been solved as the reaction proceeded cleanly to the desired product 
with full conversion after 2 hours. However, when this reaction was attempted on a larger 
scale,o it was found that the addition of the linker as a stock solution in DMSO still resulted in 
limited solubility. 
 
Scheme 16 The conditions trialled for the stapling of peptide AMP2 with linker 17. 
As a result, the effect of both the reaction solvent system and the linker stock solution 
composition was investigated using AMP2 and 17 (Table 15). Different solvent combinations 
were trialled, and the transparency of the reaction mixture (as determined by eye) after the 
addition of the linker was monitored.  
Table 15 The result of investigations into different combinations of solvent systems and stock solutions of linker 17 
for the stapling of peptide AMP2 under the conditions shown.  
 
Entry Solvent system 
Solution of 
linker 17† 
Outcome on addition of 
linker to reaction mixture†† 
1 40% MeCN/NaPi (pH 8, 50 mM) DMF/MeCN (1:1) Cloudy 
2 3:1 MES (pH 6, 50 mM)/DMF DMF Cloudy 
3 3:1 DMF/MES (pH 6, 50 mM) DMF/MeCN (1:1) Clear 
4 3:1 NaPi (pH 6, 50 mM)/DMF DMF/MeCN (1:1) Cloudy 
†All stock solutions of linker 17 = [50 mg/mL] 
††Outcome measured by judging transparency of reaction mixture by eye  
 
o ‘Larger scale’ = 0.034 mmol cf. 0.00068 mmol scale for the previously described trial reactions 
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It was found that a solvent system of 3:1 DMF/MES (pH 6, 50 mM), with the linker added as a 
DMF/MeCN stock solution (entry 3, Table 15) gave a clear reaction mixture. These conditions 
were taken forwards for subsequent peptide stapling using DVP linker 17 and will be referred 
to as the ‘standard conditions’ from hereon.  
 
3.3.1.5 Synthesis of unfunctionalised STAMPs 
Using the optimised conditions, stapling reactions were performed with AMP1-AMP7 (Table 
16). The stapling reactions all proceeded smoothly under the standard conditions to give the 
desired stapled peptides. 
Table 16 The sequences of AMP1-AMP7, and the conversion of the stapling reactions of these peptides and linker 
17 under the conditions shown. Amino acids are shown as blue spheres. % Conversion determined by LCMS 
analysis of the reaction mixtures after 18 h. 
 
Peptide Sequence Stapled peptide Conversion (%) 
AMP1 Ac-TLKQFCKGVGKWCVK  AMP1-17 96 
AMP2 FCKWAFKWCKK AMP2-17 >99 
AMP3 Ac-WCLKKFRGCF AMP3-17 >99 
AMP4 RFRRLCKKWRKRCKKI AMP4-17 97 
AMP5 C8-GCLKFIKKCL AMP5-17 >99 
AMP6 KWVQNYCKHLGRKCHTLKT AMP6-17 >99 
AMP7 NLFRKLCHRLFRRCFGYTLR AMP7-17 96 
 
3.3.1.6 Synthesis of capped ‘control peptides’ 
Control peptides were required to compare to the STAMPs in biological testing, to analyse the 
impact of cyclisation on antimicrobial activity. In the literature, cysteine-stapled peptides are 
often compared to their linear counterparts, however to ensure that no disulfide bonds form 
during the storage or testing of the peptides, capped control peptides were synthesised using 
a mono-vinyl pyrimidine ‘capping reagent’.314 The capping reagent 18 was synthesised via a 
Suzuki-Miyaura cross-coupling between commercially available 2-amino-4-chloropyrimidine 
and potassium vinyl trifluoroborate under literature conditions (Scheme 17).315 The reaction 
proceeded cleanly in a high conversion, however a significant amount of mass was lost during 




Scheme 17 The synthesis of 18 via a Suzuki-Miyaura cross-coupling reaction. 
The linear cysteine-containing peptide AMP1-AMP7 were reacted with 18 to give the desired 
capped peptides. Due to the superior solubility of 18 and the resulting capped peptides 
compared to linker 17 and the stapled peptides, alternative coupling conditions with a lower 
proportion of organic solvent could be used, allowing direct injection of the reaction mixtures 
for HPLC purification (Table 17). Under these conditions, the stapling reactions all proceeded 
in full conversion to give the desired products, which were purified by preparatory HPLC.  
Table 17 The sequences of AMP1-AMP7, and the conversion of the capping reactions of these peptides and 
capping reagent 18 under the conditions shown. Amino acids are shown as blue spheres. % Conversion 
determined by LCMS analysis of the reaction mixtures after 18 h. 
 
Peptide Sequence Capped peptide Conversion (%) 
AMP1 Ac-TLKQFCKGVGKWCVK  AMP1-18 >99 
AMP2 FCKWAFKWCKK AMP2-18 98 
AMP3 Ac-WCLKKFRGCF AMP3-18 98 
AMP4 RFRRLCKKWRKRCKKI AMP4-18 >99 
AMP5 C8-GCLKFIKKCL AMP5-18 97 
AMP6 KWVQNYCKHLGRKCHTLKT AMP6-18 >99 
AMP7 NLFRKLCHRLFRRCFGYTLR AMP7-18 >99 
 
3.3.1.7 Summary of peptide synthesis  
In total, 21 peptides were synthesised for the initial biological screen: seven linear cysteine-
containing AMPs, seven unfunctionalised STAMPs and seven capped AMPs as control 




Figure 72 The general structures of AMPX-17 and AMPX-18, where X = 1-7. For peptide sequences see Table 16 
and Table 17.   
 
3.3.2 Biological testing of unfunctionalised STAMPs 
A rapid and facile assessment of antibacterial activity was desired, so that a suitable peptide 
could be identified for incorporation into the cleavable PDC. To this end the linear peptides 
AMP1-AMP7, stapled peptides and capped peptides were screened to assess their 
antimicrobial activity in a broth dilution minimum inhibitory concentration (MIC) assay, which 
compares the growth of bacteria both in the presence and absence of antimicrobial agents 
after incubation for 24 hours.316 The turbidity of a bacterial suspension increases when the 
bacterial growth occurs, and changes in the optical density (OD) of the growth medium can 
be used to assess growth inhibition. If complete inhibition of growth has been achieved the 
growth media will be clear; if the bacteria are unaffected then the media will have become 
cloudy during the incubation period. The difference in turbidity of the media can be analysed 
via measuring the OD at 600 nm (OD600).  
For AMP1-17 to AMP7-17, it was hoped that there would be no significant loss of inhibitory 
activity upon cyclisation. At this stage of the project it was unknown what the specific role of 
the peptide would be in the conjugate, and therefore whether a high level of antibacterial 
activity would be necessary. The peptide itself could act as a bactericidal agent, requiring a 
high level of antimicrobial activity. Alternatively, the peptide could be acting as a sensitiser 
and/or targeting moiety for ciprofloxacin, meaning that a lower level of antibacterial activity 




3.3.2.1 Inhibition of growth: Initial screen at 256 μg/mL  
An initial screen to determine the antimicrobial activity of the peptides was performed with all 
the peptides at a concentration of 256 µg/mL.p For peptides that inhibited growth at 256 μg/mL, 
serial dilution assays were performed to determine a more precise MIC value. The following 
strains were used in the MIC assay: P. aeruginosa PAO1 (wild-type reference strain),317 YM64 
(PAO1 derivative strain lacking the four major outer membrane efflux pumps),318 and S. aureus 
25923 (a commonly used Gram-positive laboratory reference strain). Strain YM64 was 
included to assess whether the peptides were actively effluxed from the bacteria; if this were 
the case a lower MIC would be expected for YM64 than PAO1. S. aureus was included to see 
if the peptides displayed activity towards a Gram-positive species, or whether they displayed 
selective activity against Gram-negative bacteria only.  
As a positive control, colistin (polymyxin E) was selected. The polymyxin family of macrocyclic 
AMPs were discovered in the 1940s and display potent and specific activity towards Gram-
negative bacteria.217 Colistin was used clinically for several decades but was ultimately 
withdrawn due to nephrotoxicity and neurological side effects, however it is still a last resort 
drug for the treatment of P. aeruginosa infections.188 The mechanism of action for the 
polymyxins is not fully understood, but it is believed to involve binding of the cationic peptide 
to the negatively charged lipid A portion of the lipopolysaccharide on the external cell wall of 
Gram-negative bacteria.319 Colistin was chosen as a positive control as it is cheap, 
commercially available and inhibits growth through disruption of the membrane, the 
anticipated mechanism of action for the STAMPs. In addition to this, as colistin has been 
thoroughly researched, literature values for the MIC against various bacterial strains are 
available.320  
The growth-inhibiting activity of the stapled peptides, capped peptides, linear cysteine-
containing peptides, and linkers 14 and 17 were assessed at 256 μg/mL, and this initial 
screen identified two STAMPs (AMP2-17 and AMP4-17) that inhibited the growth of PAO1 
and AMP6-17 that showed partial growth inhibition (Table 19). These STAMPs selectively 
inhibited both PAO1 and YM64 and there was no effect on the growth of S. aureus: the full 
data for these peptides is shown in Table 18. For all of the other peptides, no inhibition of 




p According to the European Committee on Antimicrobial Susceptibility Testing (EUCAST), bacteria are deemed 
‘resistant’ to a compound if no antimicrobial activity is observed at 256 µg/mL.374 
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Table 18 The results from the initial screen of antimicrobial activity at 256 µg/mL against P. aeruginosa strains 
PAO1 and YM64 and S. aureus for AMP2-17, AMP4-17, AMP6-17 and related analogues. All other peptides 
displayed no antimicrobial activity at 256 µg/mL. ‘Inhibition’ refers to growth media with a comparable OD600 to the 
control wells containing just broth. ‘No inhibition’ refers to growth media which has a comparable OD600 to the 
control wells containing bacterial suspension. ‘Partial inhibition’ refers to a well which has an OD600 between these 
two extremes.  
Peptide 
Bacterial strain 
PAO1 YM64 S. aureus 
AMP2a No inhibition Inhibition No inhibition 
AMP2 No inhibition No inhibition No inhibition 
AMP2-18 No inhibition No inhibition No inhibition 
AMP2-17 Inhibition No inhibition No inhibition 
AMP4a Inhibition Inhibition No inhibition 
AMP4 No inhibition No inhibition No inhibition 
AMP4-18 Inhibition Inhibition No inhibition 
AMP4-17 Inhibition No inhibition No inhibition 
AMP6a Inhibition Inhibition No inhibition 
AMP6 No inhibition No inhibition No inhibition 
AMP6-18 No inhibition No inhibition No inhibition 
AMP6-17 Inhibition Inhibition No inhibition 
17 No inhibition No inhibition No inhibition 
18 Partial inhibition Partial inhibition Partial inhibition 
 
The stapling reagent 17 displayed no antimicrobial activity, however capping reagent 18 
displayed partial inhibition of all of the strains tested against. As the same moiety was not 
going to be present in the final cleavable PDC, it was decided that this result was not relevant.  
 
3.3.2.2 Inhibition of growth: Serial dilution MIC assay 
The peptides that displayed inhibition of growth at 256 µg/mL were analysed further in a serial 
dilution MIC assay to determine approximate MIC values. For this, the literature sequences 
were desired as additional control peptides, and so AMP2a, -4a and -6a were synthesised by 
SPPS and purified by preparative HPLC (for sequences see Table 14).  
The serial dilution assay follows the same set up as previously described, however each 
compound is serially diluted by two-fold along each well of a row on a 96-well plate, allowing 
growth inhibition to be assayed at concentrations between 256 and 0.5 µg/mL. The results 
from this assay are given in Table 19. Data for AMP2, -4 and -6 from the initial screen at 256 






Table 19 The results from the serial dilution MIC assay for peptides that were identified in the previous screen. The 
inhibition of peptides at concentrations between 256-0.5 µg/mL were tested against bacterial strains PAO1, YM64 
and S. aureus for AMP2-17, AMP4-17, AMP6-17 and related analogues. ND = no data. 
Peptide 
Bacterial strain 
PAO1 YM64 S. aureus 
AMP2 
 
AMP2-17 64  64 ND 
AMP2-18 >256* >256* >256* 
AMP2a >256 >256 >256 
AMP2 >256* >256* >256* 
AMP4 
 
AMP4-17 64 64 ND 
AMP4-18 ND ND ND 
AMP4a 32 64 >256 
AMP4 >256* >256* >256* 
AMP6 
 
AMP6-17 >256 >256 >256* 
AMP6-18 >256* >256* >256* 
AMP6a >256 >256 >256 
AMP6 >256* >256* >256* 
Colistin (polymyxin E)  8 8 >256 
*Results from 256 µg/mL screen described previously. All other results from serial dilution MIC assay. 
 
The results from the serial dilution MIC assay showed that AMP6-17 (or related analogues) 
did not exhibit any antimicrobial activity. This means that the inhibition of growth observed in 
the screen at 256 µg/mL was not a reliable result and this peptide was subsequently excluded 
from further investigations. The literature peptide AMP6a failed to display any antimicrobial 
activity under these assay conditions (cf. 24-48 µg/mL in the literature), however this disparity 
could be due to differences in the assay set up and the bacterial strains used.306,321  
Whilst AMP4-17 did not have the same high level of antimicrobial activity reported in the 
literature for AMP4a (MIC 2-4 μg/mL),310 promisingly these peptides show not dissimilar 
activity under the assay conditions used for the initial screen (AMP4a 32 µg/mL, AMP4-17 64 
µg/mL). Pleasingly, the peptides displayed similar MIC values for P. aeruginosa strains PAO1 
and YM64, indicating that efflux was not an issue for these antimicrobials (AMP4-17 64 µg/mL 
for PAO1 and YM64). Additionally, no inhibition of growth was observed for S. aureus, 
indicating that the peptides were selectively active against Gram-negative P. aeruginosa 
strains over the Gram-positive S. aureus.  
For AMP2, out of all the analogues tested, the stapled analogue AMP2-17 had the highest 
antimicrobial activity (AMP2-17 64 µg/mL, all other peptides >256 µg/mL). This could be 
because the staple is holding the peptide in a more α-helical conformation, thus improving its 
ability to interact with the bacterial membranes. Interestingly, AMP2a did not show any 
inhibition of growth against PA, (cf. 12.5 μg/mL reported in the literature) however again this 
could be due to differences between the bacterial strains used and the conditions of the 
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assay.309 As was the case for AMP4-17, no inhibition of growth was observed for S. aureus 
and AMP2-17 had the same MIC value (64 μg/mL) for PAO1 and YM64.  
Both AMP2-17 and AMP4-17 showed very reasonable MIC values against P. aeruginosa, 
however, it was decided that, in order to simplify the development of the proof-of-concept 
PDC, only one peptide sequence would be used. AMP2-17 was chosen as it showed 
antimicrobial activity when stapled but not linear, therefore some aspect of the peptide stapling 
was conferring antimicrobial activity onto the peptide sequence; additional biological testing 
would be required to fully elucidate this phenomenon. Additionally, AMP2-17 was shorter than 
AMP4-17, resulting in a faster and more efficient SPPS. If the PDC constructed using AMP2-
17 was promising, then the construction of a PDC using AMP4-17 could be performed to 
showcase the modular design.  
 
3.3.2.3 Effect of STAMPs on biofilm formation  
The aim of this project was to develop an antimicrobial PDC to treat P. aeruginosa infections, 
therefore for the STAMPs, MIC values for growth-inhibition were used to determine which to 
incorporate into the PDC design. However, as previously discussed, biofilm formation can 
contribute greatly to the antibiotic resistance and virulence of P. aeruginosa. Antimicrobial 
agents can prevent biofilm formation and disrupt pre-formed biofilms, however, they can also 
cause bacterial stress that may induce biofilm formation.322 The effect of the unfunctionalised, 
active STAMPs on the formation of P. aeruginosa biofilms was assessed using a standard 
crystal violet staining assay. In this assay, bacteria are incubated with sub-inhibitory 
concentrations of an antimicrobial agent, then the amount of biofilm present is quantified by 
crystal violet staining and recording the optical density at 595 nm (OD595).323 Preliminary 
investigations were made with AMP2-17 and AMP4-17 looking at the effect of sub-inhibitory 
concentrations of peptide on the formation of P. aeruginosa biofilms over 24 hours using 
polymyxin E as a positive control (Figure 73). This assay gave interesting initial results, 
however these data need repeating for further validation, and therefore did not influence the 
overall PDC design. Near-inhibitory concentrations of AMP2-17 caused an increase in biofilm 
formation compared to untreated PAO1 bacteria, indicating a bacterial stress response, 
whereas near-inhibitory concentrations of AMP2a showed a significant reduction in biofilm 
formation. AMP4-17 and the linear analogue AMP4a displayed similar effects on biofilm 
formation, with near-inhibitory concentrations leading to less crystal violet straining than 




Figure 73 Preliminary results from a crystal violet staining assay to assess the effect of subinhibitory concentrations 
of growth-inhibiting peptides on the biofilm formation of PAO1. Plotted is the OD595 of the growth media after 
treatment with peptides at the concentration given in brackets. PME = polymyxin E, the positive control. Data is 
shown as the mean of two repeats ± standard deviation.  
At this stage of the project, the assays described in this section were deemed appropriate for 
the preparation of the complete PDC construct. Further testing would be required to 
investigate the mechanism of action of the STAMPs, however it was decided to perform more 
in-depth biological investigations once the full, cleavable PDC had been synthesised and the 
unfunctionalised STAMP and PDC could be analysed together.  
 
3.3.4 Circular dichroism spectroscopy of AMPs 
To determine the effect of stapling on the secondary structure of the peptides, AMP2-17 and 
AMP2a were analysed using circular dichroism (CD) spectroscopy. Whilst there is no 
information in the literature regarding the secondary structure of peptide AMP2a, there is for 
the gaegurin-5 peptideq from which AMP2a is derived.324 Gaegurin-5 displayed a random coil 
in aqueous buffer, and it was only in the presence of either 2,2,2-trifluoroethanol (TFE), a 
known helix-stabiliser,325 or a bacterial membrane-mimicking environment such as sodium 
dodecyl sulfate (SDS) or dodecylphosphocholine (DPC) micelles that helicity was observed.326 
This conformational disparity between aqueous and membrane-mimicking environments has 
been widely observed for membrane-disrupting peptides, and supports the proposed carpet 
and barrel-stave mechanisms of action.277 
Samples of AMP2-17, AMP2 and AMP2a in MeCN/H2O (1:1) were analysed by CD 
spectroscopy (A, Figure 74). As expected, the literature sequence AMP2a displayed a low α-
 
q GGN5 sequence = FLGALFKVASKVLPSVKCAITKKC.324 
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helical content (11%), and pleasingly the stapled peptide, whilst still displaying a relatively low 
percentage helicity, had a much higher percentage helicity (AMP2-17, 26%). This indicates 
that the staple is able to fix the peptide in a more α-helical conformation. To investigate how 
the helical content of the parent peptide sequence varied in different environments, CD 
spectroscopy was performed with AMP2a in aqueous buffer, and in the presence of TFE and 
SDS (B, Figure 74). In keeping with the literature reports for the gaegurin-5, it was found that 
AMP2a displayed a random coil structure in NaPi buffer (8% α-helicity), and the α-helical 
content was significantly improved in the presence of SDS (18%) and TFE (36%).324  
 
Figure 74 CD spectra for AMPs A) The CD spectra of AMP2-17 and AMP2a in MeCN/H2O (1:1). B) The CD spectra 
of AMP2a in different solutions: TFE = 50% aq. TFE solution, SDS = 30 mM SDS solution and NaPi = 10 mM, pH 
7.4 NaPi buffer. The % helicity is given in brackets in the legend.  
 
3.3.5 Design of peptide-drug conjugate 
The cleavable PDC described in this thesis is composed of a STAMP, a cleavable linker and 
an antimicrobial drug (A, Figure 75). For a proof-of-concept PDC, each component must be 
carefully and rationally selected to maximise the probability of success, whilst validating the 
proposed biological mechanism of action. The selection of the stapled peptide component was 
described in the previous section (B, Figure 75). For the construction of the full PDC, the linear 
peptide sequence validated in AMP2-17 was used. However, a different staple was required 
to enable incorporation of the cleavable linker and drug instead of the 3-phenylpropan-1-amino 




Figure 75 A: A cartoon depicting a PDC comprising a stapled peptide (blue helix), a cleavable linker (green 
rectangle) and an antimicrobial drug (yellow star). B: The structure of AMP2-17, which forms the basis of the stapled 
peptide component. The 3-phenylpropan-1amino moiety is highlighted in blue.   
Ciprofloxacin was chosen as the drug, as it is widely used in the clinic to treat P. aeruginosa 
infections (A, Scheme 18).327 Additionally it is very cheap, stable to a wide range of chemical 
transformations and contains suitable synthetic handles for the attachment of other groups.328 
For these reasons, it has been widely used in conjugate and pro-drug strategies, thus 
providing precedence for its application in a cleavable PDC.242 A cephalosporin scaffold was 
chosen as the cleavable moiety, as it has been used successfully in various prodrug and 
selective release strategies.56,57,77–79 This is primarily due to their relative stability (compared 
to penicillins) and selective and efficient β-lactam hydrolysis and elimination when exposed to 
β-lactamase (BL) enzymes (B, Scheme 18).  
 
Scheme 18 A) Ciprofloxacin, B) the BL hydrolysis of the β-lactam ring in a cephalosporin. This is followed by 1,4-
elimination and subsequent release of a leaving group, R2. R1 is a variable group on the cephalosporin. 
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With the individual components confirmed, the attachment strategy was considered. As a 
proof-of-concept PDC, a simple synthetic route was desired so that the final construct could 
be rapidly synthesised and tested. Starting with the cleavable linker, the chosen cephalosporin 
moiety contains two chemical handles for attachment: the amine at position C-7 and the 
methylene at position C-10 (R1 and R2 respectively, B, Scheme 18). Amides formed at position 
7 are stable to BL hydrolysis, making this a suitable attachment point for the stapled peptide. 
The group attached to position 10 is ultimately eliminated after BL hydrolysis, hence it was 
decided that the drug, ciprofloxacin, would be connected at this position (R2, B, Scheme 18). 
Ciprofloxacin can be conjugated either via the carboxylic acid (e.g. A, Figure 76)235 or 
piperazine amine (e.g. B, Figure 76)252 and examples of both exist in the literature. The 
carboxylic acid is necessary for antibacterial activity, therefore conjugation at this position 
would mask the activity of ciprofloxacin until cleavage of the cephalosporin, resulting in a pro-
drug effect.329,212 Conversely, conjugation via the piperazine amine could have a less marked 
effect on the activity. As it was unknown whether masking the effect of ciprofloxacin would be 
necessary, it was decided that both attachment points would be investigated. 
 
Figure 76 The structures of two literature ciprofloxacin conjugates. A: A cleavable ciprofloxacin prodrug with 
conjugation via the carboxylic acid,235 and B: A ciprofloxacin-siderophore conjugate, where ciprofloxacin is attached 
via the amine.252 Ciprofloxacin is highlighted in blue. 
The synthetic route was designed using the cheapest and most widely available starting 
material, 7-aminocephalosporanic acid (7-ACA). Possible chemical conjugation strategies for 
the connection of the three components are shown in Figure 77. For the attachment of the 
DVP to the cephalosporin, two robust linkage strategies are CuAAC (A, Figure 77) or amide 
coupling (B, Figure 77). These strategies were considered as CuAAC is known to be highly 
chemoselective and modular, whereas amide coupling is often high yielding and practically 
simple. For both approaches, the building blocks are widely available and easily accessible. 
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Amide coupling would require the introduction of a carboxylic acid moiety onto the DVP staple, 
although no modification would be needed on the cephalosporin. A CuAAC strategy would 
require modification of both the DVP staple and cephalosporin to introduce the azide and 
alkyne moieties. For the conjugation of the cephalosporin to the ciprofloxacin, attachment via 
the piperazine amine would necessitate carbamate formation at position C-10 of the 
cephalosporin (C, Figure 77). Attachment via the carboxylic acid would require displacement 
of the acetate group in 7-ACA with the ciprofloxacin carboxylate (D, Figure 77); literature 
routes existed for these transformations.   
 
Figure 77 An overview of possible connections between the three different portions of the cleavage linkers (non-
exhaustive). The DVP and cephalosporin could be attached via A) CuAAC B) or amidation. Ciprofloxacin could be 
attached at position 10 of the cephalosporin via C) carbamate formation with the piperazine amine or D) via 
displacement with the carboxylic acid. 
The attachment strategies highlighted in Figure 77 represent just a few possibilities from a 
vast number of potential approaches. It was noted that the nature of the linkage between the 
components of the PDC may affect the biological activity, for example their length, 
conformational flexibility, and lipophilicity. However, with no information in the literature 
available to guide the design, the main design consideration for the initial proof-of-concept 
PDC was synthetic tractability. Optimisation of the linkages to maximise the antimicrobial 
activity could be performed at a later stage.   
 
3.3.6 Synthesis of first-generation linkers 
The design of the first-generation linkers 19 and 20 are shown in Figure 78. CuAAC was 
chosen for the attachment of the DVP to the cephalosporin as this reaction proceeds under 
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mild conditions, is highly chemoselective and modular. In this manner, the modular CuAAC 
strategy would enable rapid and efficient synthesis of multiple compounds using the key DVP 
fragment, including biological controls. It was envisioned that 4-azidobenzoic acid would be 
used to introduce an azide moiety to the cephalosporin as it was cheap and commercially 
available. Ciprofloxacin could then be attached via the piperazine nitrogen in 19, and via the 
carboxylic acid in 20. 
 
Figure 78 The structure of generation 1 cleavable linkers 19 and 20. 
Focus was next placed on determining the synthetic strategy. Retrosynthetic analysis of both 
19 and 20 involved disconnection of the 1,4-triazole via a CuAAC, giving common alkyne 21 
and the azides 22 and 23 (Scheme 19).  
 
Scheme 19 The retrosynthetic analysis of proposed linkers 19 and 20. 
Synthesis of 21 followed a literature procedure (Scheme 20).68 From commercially available 
2-amino-4,6-dichloropyrimidine, the vinyl groups could be introduced to give 24, via a Suzuki-
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Miyaura cross-coupling as was described for the synthesis of 17. Subsequent alkylation of the 
amine in 24 would install the alkyne moiety to give the desired staple, 21.  
 
Scheme 20 The retrosynthetic analysis of 21 to a commercially available starting material. 
For 22, disconnection of the carbamate gives ciprofloxacin and an activated carbonate at 
position 10 on the cephalosporin ring; the choice of 4-nitrophenyl carbonate will be discussed 
in Section 3.3.6.2 (25, Scheme 21). Formation of this activated carbonate would require an 
alcohol at this position, 26, which could be generated via deacetylation of 27. The final step 
involved an amide coupling between commercially available starting materials 4-azidobenzoic 
acid and 7-ACA.   
 
Scheme 21 The retrosynthetic analysis of 22 to commercially available starting materials. 
For 23, disconnection at the ester gives ciprofloxacin and 27, the same intermediate as found 
in the retrosynthetic analysis for 22 (Scheme 22). The literature synthesis of similar conjugates 
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as 23 involves displacement of the C10 acetate group on the cephalosporin by N-Boc 
protected ciprofloxacin.235  
 
Scheme 22 The retrosynthetic analysis of 23 to 27 and ciprofloxacin. 
 
3.3.6.1 Synthesis of 21 
Following the above proposed protocols, investigations towards the synthesis of the PDC 
commenced. Firstly, DVP 21 was synthesised according to the literature procedure (Scheme 
23).68 Commercially available 2-amino-4,6-dichloropyrimidine was subjected to Suzuki-
Miyaura cross-coupling conditions to install the two vinyl groups. This proceeded in a 
moderate yield to give 24; despite complete conversion, substantial mass was lost during 
chromatographic purification due to significant product streaking. Subsequent alkylation with 
6-iodo-1-hexyne gave 21 in a low yield, albeit with enough material to pursue the remaining 
synthesis.   
 
Scheme 23 The synthesis of 21 via Suzuki-Miyaura cross-coupling and alkylation via the literature route.68 
 
3.3.6.2 Synthesis of 19: Route 1 
The first step in the synthesis of linker 19 was the deacetylation of commercially available 7-
ACA to give 28. Literature approaches to this transformation included hydrolysis with 
tetrabutylammonium hydroxide (TBAOH)236 or sodium hydroxide.330 Both of these conditions 
were trialled; it was found that using sodium hydroxide gave a higher isolated yield (40% 
compared to 29% with TBAOH), and there were issues with the isolation of the product using 
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TBAOH (Scheme 24). Sodium hydroxide-mediated hydrolysis still gave a low-moderate yield, 
and the resulting product was extremely difficult to analyse due to poor solubility. 
 
Scheme 24 The base hydrolysis of 7-ACA to give 28 using either a) NaOH,330 or b) TBAOH.236 
The next step in the synthesis involved amide bond formation with the amine at position 7 of 
28. 4-Azidobenzoic acid was converted into acid chloride 29 under the conditions shown in a 
quantitative yield (Scheme 25). Coupling of 29 and 28 using conditions reported by 
Desgranges et al.236 gave the desired product 26, as confirmed by LCMS and 1H NMR analysis 
of the reaction mixture. However, chromatographic isolation of the desired product was not 
possible due to the co-elution of a significant side-product, which itself could not be isolated 
or characterised (Scheme 25). The crude reaction mixture was used to trial the formation of 
the activated carbonate. Several activated carbonates of cephalosporins have been reported 
in the literature, including 1,2,2,2-tetrachloroethyl and 4-nitrophenyl:236,257 the 4-nitrophenyl 
carbonate was initially chosen as the reagents required were more widely available. Crude 26 
was treated with 4-nitrophenyl chloroformate, however a complex mixture was formed and 
after chromatographic purification no product was isolated (Scheme 25). 
 




Given the problems with this route, including consistent low yields, problems with isolating 28 
and lack of success in the formation of 25, an alternative route was sought. It was decided 
that protecting the carboxylic acid of 7-ACA could improve the solubility of the intermediates 
to circumvent the significant handling issues faced in route 1.  
 
3.3.6.3 Synthesis of 19: Route 2 
Route 1 had followed the synthesis reported by Desgranges et al., involving basic hydrolysis 
of 7-ACA followed by acylation with 29 (Scheme 26).236 Route 2 was based on the synthesis 
of BL cleavable siderophore-ciprofloxacin conjugates reported by Liu et al. (Scheme 26).257 
This synthetic route involved protection of the 7-ACA carboxylic acid in the first step, forming 
a much more soluble intermediate for the following steps. A step in route 2 was a selective 
lipase-catalysed deacetylation at the 10 position on the cephalosporin ring; this reaction was 
developed by the Miller group specifically for the generation of cephalosporin analogues.331 
 
Scheme 26 An overview of the two possible synthetic routes to 19 investigated. 
 
3.3.6.3.1 Ester protection and amide coupling 
Route 2 commenced with the protection of 7-ACA as a tert-butyl ester, which proceeded 
smoothly and in a high yield under the literature conditions to give 30 (Scheme 27).332 The 
desired product, whilst requiring no purification, was extremely hygroscopic, hence 30 was 
immediately subjected to the subsequent amide coupling in order to maximise the yield. 
114 
 
Acylation of 30 with 29 under amidation conditions reported by Miller et al. gave 31 in a 52% 
yield after purification by FCC.257  
 
Scheme 27 The synthesis of 31 under the literature conditions.257  
 
3.3.6.4 Investigations toward the synthesis of 23  
With 31 in-hand, a key transformation in the synthesis of isomeric linker 23 was investigated. 
The displacement of the C-10 acetate group on 31 with N-Boc-ciprofloxacin, 32, is achieved 
in the literature by treatment with trimethylsilyl iodide (TMSI) to form an intermediate iodo 
species, 33.235 N-Boc-ciprofloxacin was synthesised from commercially available ciprofloxacin 
in a high yield via treatment with Boc anhydride and formation of the sodium salt 32 (Scheme 
28).333  
 
Scheme 28 The synthesis of 32 from commercially available ciprofloxacin under the literature conditions.333 
The displacement reaction was attempted with 32 and 31 (Scheme 29). Unfortunately, under 
the literature conditions only 32 was recovered from the reaction mixture and there was no 




Scheme 29 The attempted synthesis of 34 under the conditions reported by Evans et al.235 
Alternative conditions were investigated for this reaction (Table 20). Using sodium iodide 
instead of TMSI to activate the acetate group towards displacement gave a complex mixture, 
as did the use of BF3.OEt2 (entries 2 and 3 respectively, Table 20).  
Table 20 The conditions trialled for the reaction of 31 with 32. 
 
Entry Conditions Outcome 
1 TMSI in CH2Cl2 then 32 and cat. DMF in 1,4-dioxane 
No desired product isolated, 
32 recovered 
2 NaI in CH2Cl2, then 32 
Complex mixture, no desired 
product isolated 
3 BF3·OEt2 in CH2Cl2, then 32 
Complex mixture, no desired 
product isolated 
It is possible that 34 could be synthesised via a displacement reaction with an alternative alkyl 
halide intermediate to 33, for example alkyl bromide 35, which can be accessed via allylic 
bromination of commercially available 7-aminodesacetoxycephalosporanic acid (7-ADCA). A 
trial reaction was performed with 7-ADCA and N-bromo succinimide (NBS) under irradiation 
by visible light (Scheme 30).334 Although the mass of 35 was observed by LCMS analysis, the 




Scheme 30 The attempted allylic bromination of 7-ADCA to give 35. 
Due to the challenges encountered in the synthesis of first-generation linkers, 19 and 20, in 
addition to newly published information that indicated the proposed linker design was not 
optimal, it was decided to abandon the proposed strategy. This information, and the 
subsequent changes made are discussed in the following section.  
 
3.3.7 Synthesis of second-generation linkers  
In 2019, Evans et al. published a series of ciprofloxacin prodrugs that utilised the 
cephalosporin moiety for selective unmasking of the active drug.235 During the development 
of these prodrugs, the authors investigated the effect of different groups at the cephalosporin 
C7 amide on the rate of BL-mediated hydrolysis using whole-cell NMR assays (Table 21). A 
range of analogues were synthesised and the MIC values were assessed against a clinically 
relevant E. coli strain, CTF073, both with and without the expression of an extended spectrum 
BL, CTX-M-1. Using the drug cephalothin for comparison (entry 1, Table 21), the authors found 
that direct attachment of aromatic groups to the C7 amide was not tolerated and a low 
percentage of hydrolysis was observed (entries 2-5, Table 21), whereas aliphatic substituents 
led to more substantial hydrolysis, particularly for shorter alkyl chains (entries 6-8, Table 21). 
An additional in vitro assay, using recombinant BL AmpC, indicated that the low levels of 
hydrolysis observed in the whole-cell assay for the longer chain analogues was due to poor 
cellular penetration. Based on the data gathered from all the analogues tested, the authors 
chose to incorporate a simple acetyl amide at the C7 position (entry 8, Table 21) in the 






Table 21 Selected examples of prodrugs synthesised and tested by Evans et al., including MIC values and % 
hydrolysis.235 BL = CTX-M-1.  
 
Entry R1 
MIC (μM in CFT073) % hydrolysis in 
CFT073 + BLa + BL - BL 
1 
 
25 >400 68 
2 
 
>400 >400 3 
3 
 
>400 >400 3 
4 
 
>400 >400 0 
5 
 
>400 >400 4 
6  100 >400 7 
7  200 >400 25 
8  400 >400 67 
aHydrolysis of 100 µM of compound after 1 h, as measured by a whole cell NMR assay.  
This information provided useful insights that could be applied to the first-generation linkers 
19. This linker contains a quaternary carbon at the C7 amide position (Figure 79), however 
the data reported by Evans et al. suggest that this would not be optimal for hydrolysis (see 0-
4% hydrolysis for entries 2-5 respectively, Table 21). Although the assays reported in the 
paper were performed in E. coli and not P. aeruginosa, the BLs CTX-M-1 and AmpC used in 
the reported assays are present in clinical isolates of P. aeruginosa.335–337 
 
Figure 79 The structure of first-generation linker 19 and second-generation linker 36. The change in linker design 
is highlighted in red.  
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To make the necessary design alterations whilst retaining the synthetic strategy used in route 
2, the azide moiety could be changed from 4-azidobenzoic acid to 2-azidoacetic acid. This 
substitution would replace the quaternary carbon with a two-carbon aliphatic chain, however 
2-azidoacetic acid was deemed too expensive to use, considering the low yields associated 
with the previously described synthetic route. Instead, a simpler strategy would be to directly 
couple the cephalosporin to the DVP via an aliphatic linker, removing the CuAAC step. From 
the study by Evans et al., alkyl chains of intermediate length gave reasonable levels of 
hydrolysis, therefore a 3-carbon linker would be placed between the DVT and 
cephalosporin.235 Additionally, it was decided to focus on the carbamate-linked ciprofloxacin 
design given the challenges faced with the synthesis of the carboxylic acid-linked design 
(Section 3.3.6.4).   
 
3.3.7.1 Retrosynthetic analysis of second-generation linkers  
The retrosynthetic analysis of second-generation linker 36 followed the same procedures as 
the synthesis of the first-generation linker 19, in a different order (Scheme 31). With the tert-
butyl ester protecting group in place throughout the synthesis, the carbamate 37 could be 
synthesised via displacement of an activated carbonate 38 with ciprofloxacin. The activated 
carbonate could be synthesised from the alcohol 39, which in turn could be derived from the 
deacetylation of 40. Finally, disconnection of the amide bond at the C-7 position would give 




Scheme 31 The retrosynthetic analysis of linker 36 to 41 and previously described intermediate 30. 
Retrosynthetic analysis of 41 followed the same literature route as 17, with an additional final 
step of ester hydrolysis (Scheme 32).338 Suzuki-Miyaura cross-coupling would install the two 
vinyl groups, and an SNAr reaction between commercially available 2,4,6-trichloropyrimidine 
and ethyl 4-aminobutanoate would introduce the aliphatic linker and ester moiety.  
 
Scheme 32 The retrosynthetic analysis of 41 to commercially available starting materials. 
 
3.3.7.2 Synthesis of 41 
41 was synthesised using a route analogous to 17 (Scheme 33) under literature conditions.69 
An SNAr reaction was performed with commercially available 2,4,6-trichloropyrimidine and 
ethyl 4-aminobutyrate to give 43 in a 31% yield after chromatographic purification, due to poor 
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regioselectivity. Suzuki-Miyaura cross-coupling installed the two divinyl groups to give 42 in a 
quantitative yield, and hydrolysis of the ethyl ester gave the desired DVP staple 41 in a 
reasonable 60% yield, in a sufficient purity that further purification was not required.  
 
Scheme 33 The synthesis of 41 from commercially available starting materials, according to the literature route.69 
 
3.3.7.3 Amide coupling of 30 and 41 
Next, conditions for the amide coupling of 30 and 41 were investigated (Table 22). Standard 
amide coupling reagents such as HATU, EDC·HCl and propylphosphonic anhydride solution 
(T3P, 50% in DMF) were trialled. Additionally, DMT-MM and DCC were trialled as there is 
literature precedence of these reagents being employed for amide coupling reactions 
performed on cephalosporin systems.339,340 
Table 22 The results of different reaction conditions for the amide coupling reaction of 30 and 41 to give 40. 
 
Entry Conditions Outcome 
1 DMT-MM in MeOH No reaction 
2 HATU, DIPEA in DMF 47% isolated yield of 40 
3 T3P, NEt3 in DMF 39% conversion to 40 by LCMS 
4 EDC·HCl in CH2Cl2 Complex mixture 
5 DCC in THF 9% conversion to 40 by LCMS 
Despite literature precedence for their success in amide couplings of cephalosporins, DMT-
MM gave no reaction (entry 1, Table 22) and DCC gave poor conversion (entry 5, Table 22). 
EDC·HCl (entry 4, Table 22) gave a complex mixture. Both HATU (entry 2, Table 22) and T3P 
(entry 3, Table 22) resulted in higher conversion by LCMS analysis of the crude reaction 
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mixtures, however there were side products present in the reaction with T3P that were 
challenging to remove by FCC. Coupling with HATU gave a cleaner reaction and 47% isolated 
yield of 40. For these reasons, these conditions were selected. 
 
3.3.7.4 Lipase deacetylation 
In the literature, the base-mediated hydrolysis of a cephalosporin C-10 acetate group has 
been shown to form the undesired alkene-isomer or lactone, either as the only product or as 
a major side-product.331 In the synthesis of 28, the use of NaOH or TBAOH to effect this 
transformation was low-yielding (Section 3.3.6.2). Hydrolysis by lipase enzymes is a milder 
and more efficient alternative, and for this reason Patterson and Miller investigated different 
lipases and reaction conditions for the selective hydrolysis of cephalosporin C-10 acetate 
groups.331 They found that the acrylic resin-bound Candida antarctica lipase B (CAL B) gave 
a high yielding and clean deacetylation. 40 was subjected to the literature conditions, and the 
hydrolysis was found to be high-yielding, giving 39 as the only product, which was advanced 
without purification (Scheme 34).  
 
Scheme 34 The synthesis of 39 via lipase deacetylation of 40 under the literature conditions.331 
Upon reaction scale-up, several observations were made with respect to how the reaction set-
up affected the final yield of 39. Firstly, the order of solvent addition was important, as 40 was 
soluble in THF but not hexane. Therefore, the addition of THF dissolved the starting material, 
and subsequent addition of hexane to this solution created a fine suspension. If the order was 
reversed, and hexane added first, 40 remained stuck to the bottom of the reaction vessel and 
was then partially degraded during the reaction to unknown species. Secondly, to reduce the 
amount of starting material that degraded during the reaction, it was necessary to reduce the 
reaction times to 3 days from over 10 days. Consequently, performing the small-scale reaction 




3.3.7.5 Carbamate synthesis via the activated carbonate 
The next stage in the synthesis involved the formation of an activated carbonate using alcohol 
39. The conditions previously described for this transformation from the synthesis of the 
generation 1 linkers were trialled, using 4-nitrophenyl chloroformate, however no desired 
product was formed and starting material was returned (Scheme 35).  
 
Scheme 35 The attempted formation of 38 under the conditions shown. No reaction occurred. 
Alternative conditions were trialled using bis(4-nitrophenyl)carbonate and DIPEA in DMF 
(Scheme 36), and under these conditions the starting material was consumed and the desired 
product 38 was observed by LCMS analysis of the reaction mixture.315 As two equivalents of 
bis(4-nitrophenyl)carbonate were required for full conversion, the reaction was difficult to 
monitor and purify due the presence of highly UV-active by-products containing the 4-
nitrophenol moiety. Therefore, after a mild basic work-up, crude 38 was taken on crude to the 
next step in the synthesis.  
 
Scheme 36 The successful formation of 38 under the conditions shown.315 
The synthesis of carbamate 37 required the displacement of the 4-nitrophenol moiety of 38 
with the piperazine amine of ciprofloxacin. Various conditions were trialled to achieve this 
transformation: initially, HOAt and DIPEA in a pyridine/DMF solvent system were attempted,r 
however after 48 h no reaction was observed upon LCMS analysis of the reaction mixture 
(entry 1, Table 23). To ensure that the free carboxylic acid of ciprofloxacin was not hindering 
the reaction, these conditions were repeated using ethyl ester-protected ciprofloxacin. For this, 
44 was synthesised by treatment of ciprofloxacin with sulfuric acid in ethanol, according to the 
 
r Jiraborrirak Charoenpattarapreeda, University of Cambridge, unpublished work. 
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literature procedure.341 The desired product, 44, was isolated in a 67% yield without the need 
for purification.  
 
Scheme 37 The esterification of ciprofloxacin to give 44 under the literature conditions.341 
44 was trialled under the displacement conditions with 38 however no desired product was 
formed (entry 2, Table 23). Under the reaction conditions, ciprofloxacin (as either the free acid 
or ethyl ester) was insoluble and remained as a suspension in the reaction mixture, which 
could explain the lack of desired reactivity. Alternative conditions were trialled wherein 
ciprofloxacin was heated in aqueous base, to form a dispersed suspension, prior to the 
addition of the carbonate (entry 3, Table 23).342 Under these conditions, consumption of 38 
and the formation of the desired product, 37, were observed by LCMS analysis of the reaction 
mixture.  
Table 23 The conditions trialled for the formation of carbamate 37 from 38.  
 
Entry Conditions Outcome (LCMS) 
1 
HOAt, DIPEA, ciprofloxacin 
Pyridine/DMF (1:6), rt, 48 h 
No reaction 
2 
HOAt, DIPEA, 44 
Pyridine/DMF (1:6), rt, 48 h 
No reaction 
3 
Ciprofloxacin, NaHCO3, H2O, 40 °C 
then 38 in 1,4-dioxane, rt, 2 h 
SM consumed, DP formed 
as part of mixture 
Overall, the synthesis of carbamate 37 from alcohol 39 proceeded via formation of the mixed 
carbonate 38, which was added as a crude mixture to a suspension of ciprofloxacin in aqueous 
base, yielding the desired carbamate, 37 (Scheme 38). This transformation was extremely low 
yielding, giving only a 4% yield of 37 from 39. The low yield was in part due to mass loss in 
the final purification step of reverse-phase FCC. Additionally, this reaction was only performed 
once on a small scale, and it was anticipated that on a larger scale, and with some optimisation 




Scheme 38 The synthesis of carbamate 37 from alcohol 39 via the mixed carbonate 38. 
 
3.3.7.6 Peptide stapling and ester deprotection 
Looking forward, the final synthetic steps towards the complete PDC require deprotection of 
the tert-butyl ester protecting group of 37 and peptide stapling with AMP2. The literature 
conditions for the ester deprotection involve treatment with TFA in CH2Cl2.235,257 However, poor 
stability of the DVP motif under acidic conditions has been observed,s therefore, it was decided 
that the best strategy would be to perform the peptide stapling prior to the ester deprotection, 
thus removing the potentially unstable vinyl groups. A trial peptide stapling reaction was 
performed with 37 and AMP2 under the standard conditions (Scheme 39), and the mass of 
the desired stapled peptide, AMP2-37, was observed by LCMS analysis of the crude reaction 
mixture. Investigations are ongoing with respect to a larger scale peptide stapling reaction and 
subsequent ester deprotection.  
 




Scheme 39 The trial peptide stapling of AMP2 with linker 37 under the standard conditions, and the proposed ester 
deprotection of the resulting stapled peptide AMP2-17.  
 
3.3.8 Synthesis of control linkers 
To provide further insights into the mechanism of action of the proposed PDC, control stapled 
peptides were required. For the initial biological testing, a non-cleavable analogue of PDC1 
was desired to highlight the effect of BL hydrolysis on the activity of the PDC. Additionally, a 
control compound containing the stapled peptide and cephalosporin motif was desired to 
confirm that the cephalosporin gave no additional toxicity, and therefore attribute any change 
in antimicrobial activity to the presence of ciprofloxacin in the conjugate. Control peptides 
AMP2-45 and AMP2-46 were designed, which required linkers 45 and 46 respectively (Figure 
80). The simplest route to 45 was a direct amide coupling between 41, an intermediate in the 
synthesis of 37, and ciprofloxacin. To synthesise AMP2-46, 46 was required for the peptide 




Figure 80 The structures of the control peptides, AMP2-45 and AMP2-46, and the linkers required for the peptide 
stapling, 45 and 46 respectively.  
 
3.3.8.1 Synthesis of control linker 45 
An amide coupling was performed with 41 and 44 with T3P to give 47 (Scheme 40). It was 
found that 47 streaked during chromatographic purification leading to significant mass loss, 
however upon repeating the reaction the crude product was of sufficient purity to continue 
without purification to the next step in the synthesis. Crude 47 was subjected to base-mediated 
hydrolysis to give the desired linker 45 without the need for purification. 45 was obtained in a 
low 46% yield; although the reaction reached full conversion and only 45 was formed, the 
desired product was found to have a high aqueous solubility, leading to significant mass loss 




Scheme 40 The synthesis of control linker 45 via an amide coupling and ester hydrolysis. 
Peptide stapling of AMP2 with linker 45 was performed, with a minor modification due to the 
poor solubility of 45 when preparing a stock solution of the linker. Typically, linker stock 
solutions were prepared in DMF/MeCN (1:1), however it was found that a solvent system of 
equivalent volumes of DMF, DMSO and MES buffer (pH 6, 50 mM) were necessary to 
solubilise 45. Pleasingly, it was found that 45 had good solubility in the reaction solvent system 
(3:1 DMF/MES), and the stapling proceeded under the standard conditions to give AMP2-45 
after HPLC purification (Scheme 41).  
 





A novel, cleavable PDC was devised to target P. aeruginosa. The concept capitalised on the 
therapeutic potential of membrane-disrupting AMPs and drew inspiration from the fields of 
functionalised two-component STAMPs, and cleavable linkers which enable infection-
activated drug release. The final design of the PDC consisted of a STAMP, which was 
functionalised with a BL cleavable cephalosporin linker and small-molecule antibiotic 
ciprofloxacin.   
For the development of the PDC, literature reported AMPs were identified for an initial peptide 
screen. For this screen, an unfunctionalised model linker was synthesised, the stapling 
reaction conditions were optimised, and seven novel STAMPs were generated. A minimum 
inhibitory concentration (MIC) assay against P. aeruginosa strains and S. aureus showed that 
two peptides, AMP2-17 and AMP4-17 (Figure 81), displayed good MICs against P. 
aeruginosa, and gave selectivity over the Gram-positive strain S. aureus.   
 
Figure 81 The structures of novel peptides AMP2-17 and AMP4-17, identified as having good MIC values towards 
P. aeruginosa and selectivity over S. aureus in the initial peptide screen. 
Next, the synthesis of the PDC was explored. An initial route was developed towards the first 
generation PDC, and the possibility of connecting the DVP stapling moiety and the 
cephalosporin linker via CuAAC was investigated. In response to new information in the 
literature, the PDC design and synthesis was adapted, leading to the second generation 
PDC1, accessed via a shorter synthetic route. A key step in the synthesis of the desired 
stapling linker was a lipase-mediated deacetylation that proceeded in high conversion and 
gave only the desired product 39, requiring no purification. Overall, a 7-step synthesis 
generated the most advanced intermediate 37 (Scheme 42). Furthermore, investigations were 












3.5 Future work 
3.5.1 Synthesis and peptide characterisation  
To complete the synthesis of PDC1, the peptide stapling must be performed on a larger scale, 
and the tert-butyl ester deprotection performed under the literature conditions (Scheme 
43).235,257 The synthesis of control peptide AMP2-46 will proceed in the same manner.   
 
Scheme 43 The proposed synthetic route towards PDC1 and control peptide AMP2-46. AMP2 is stapled with 
intermediate 37 or 40. The tert-butyl ester protecting group can then be removed under the literature conditions.  
CD spectroscopy will be performed with PDC1 and the literature peptide sequence, AMP2, to 
ascertain the effect of peptide stapling on the α-helicity. The plasma stability of PDC1 and the 
linear analogue AMP2 will be determined; it is anticipated that the stapled peptide will have a 
greatly increased half-life, as the staple conformationally locks the peptide and increases 
resistance to proteolytic hydrolysis.67 Furthermore, an assay will be developed to analyse the 
BL hydrolysis of PDC1 in vitro with commercially available P. aeruginosa BLs. Using HPLC 





3.5.2 Biological testing 
For the assays described in this section, control peptides AMP2-45 and AMP2-46 will be 
included alongside PDC1 to identify how the cleavable linker and the conjugation of 
ciprofloxacin affects the activity. Biological testing of PDC1 will commence with a minimum 
inhibitory concentration (MIC) assay, as described in Section 3.3.2, and additionally the effect 
on bacterial growth will be assessed by measuring the OD600 continuously over 24 hours. To 
compare the activity of PDC1 with different concentrations of its constituent parts, AMP2-17 
and ciprofloxacin, a checkerboard assay will be performed.343 In a checkerboard assay, two 
compounds are serially-diluted along the rows and columns of a multi-well plate, leading to 
combinations of different concentrations which are incubated with bacteria and the inhibition 
of growth measured as previously described.344 To assess bacterial killing, rather than growth 
inhibition, the number of colony-forming units present after incubating bacteria with PDC1 will 
be measured.345  
Ideally, PDC1 will display activity towards P. aeruginosa but will be inert towards bacterial 
strains commonly found in the gut microbiota.346 To further determine the selectivity of PDC1, 
screening for growth inhibition against several clinical isolates of P. aeruginosa and standard 
strains of Enterococcus faecalis and Enterococcus coli (as representative gut microbes) will 
be performed.235 A wider screen against the ESKAPE pathogens,347 and other common Gram-
negative and -positive bacteria will be performed, to identify the spectrum of activity for PDC1. 
For AMPs, haemolysis often represents a significant barrier to their clinical utility as novel 
antimicrobials, and it has been shown in the literature that this problem can be exacerbated 
by RCM peptide stapling due to the lipophilic nature of the alkenyl staple increasing the overall 
lipophilicity of the STAMP.283,348 The haemolytic activity of PDC1 will be ascertained using a 
standard assay wherein the peptide is incubated with red blood cells at various concentrations, 
and haemoglobin release measured spectrophotometrically.349  
The sequence of unfunctionalised STAMP AMP2-17 is derived from a literature peptide, 
AMP2a.309 It has been shown in the literature that analogues of AMP2a disrupt bacterial 
membranes, however this has yet to be confirmed for AMP2a and AMP2-17.350 Membrane 
depolarisation assays will be performed to validate this proposed mechanism of action for 
AMP2-17 and PDC1, via measuring the uptake of fluorescent intercalating agent propidium 
iodide into bacterial cells.351 Specific disruption of  the outer membrane can be assessed by 
monitoring the uptake of fluorescent probe N-phenyl-1-naphthylamine, and depolarisation of 
the inner membrane assessed by measuring the release of dye DiSC3(5).352 Additionally, the 
Owens group have published lipid monolayers which mimic bacterial membranes, and are 
able to quantitatively measure the membrane-disruption of antimicrobials using organic 
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electrochemical transistor technology.353 A collaboration has been set up with the Owens 
group, wherein the membrane-disruption of AMP2, AMP2-17 and PDC1 will be measured 
using their published novel biomimetic electronic devices. If these assays confirm that AMP2-
17 and PDC1 cause membrane disruption, this can be visualised using transmission electron 
microscopy.310 
The ability of the unfunctionalised peptides AMP2-17 and AMP4-17 to prevent the formation 
of P. aeruginosa biofilms was assessed and discussed in Section 3.3.2. These data will be 
repeated to ensure the reliability of the data, and the effect of PDC1 and AMP2-17 on the 
disruption of pre-formed biofilms will be measured. It is anticipated that PDC1 will have a 
greater effect on biofilm formation than the unfunctionalised analogue AMP2-17, as 
ciprofloxacin provides an additional antibiotic effect.  
One potential application of PDC1 is to treat bacterial infections in the pulmonary fluid of cystic 
fibrosis patients, where there is typically a high salt concentration.281 This environment can 
reduce the activity of AMPs, so the MIC of AMP2-17 and PDC1 will be measured in different 
concentrations of NaCl and compared to the literature peptide AMP2a; it is anticipated that 
peptide stapling will improve the activity of the peptide in high salt environments.354 
 
3.5.3 Peptide-drug conjugate analogues  
The modular design of PDC1 provides a flexible platform for the targeting of different bacteria. 
To illustrate this modularity, the individual components (peptide, drug, release mechanism) 
can be varied to alter the mode of action of the PDC.  
 
3.5.3.1 Alternative antimicrobial peptides 
At the start of this project, there were no cysteine-stapled AMPs in the literature, only one 
component all-hydrocarbon STAMPs. Hence a screening approach was used to identify an 
active two-component stapled peptide. From the initial peptide screen, AMP2-17 was 
identified with a MIC of 64 µg/mL towards P. aeruginosa strains PAO1 and YM64. Whilst this 
was a reasonable MIC for P. aeruginosa, more active peptides amenable to cysteine stapling 
have since been reported in the literature. Further elucidation of the mechanism of action of 
the peptide is required prior to PDC optimisation, as the peptide may sensitise the bacteria to 
ciprofloxacin, or the two could a synergistic relationship. However, a more active peptide may 
be required for the success of PDC1.  
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DJK5 and DJK6 are short, cationic linear peptidest that eradicate P. aeruginosa biofilms and 
were reported in a patent in 2019: they have an MIC of 16 µg/mL against P. aeruginosa and 
a broad spectrum of activity, with lower MIC values against ESKAPE pathogens A. baumannii 
and K. pneumoniae.355 These peptides both displayed a synergistic relationship with 
ciprofloxacin and were shown to increase survival in an in vivo infection model. Another 
example is a two-component stapled peptide based on the sequence of CAP-1, a member of 
the cathelicidin AMP family published in 2018 (discussed in Section 3.1.4).291 This peptide 
was stapled between two cysteine residues with a perfluoroaryl linker, and inhibited the growth 
of P. aeruginosa at a concentration of 4 µM (~16 µg/mL).u As this linear sequence already 
contains cysteine residues at i,i+7 positions, it could easily be incorporated into the PDC by 
stapling the same linear peptide with linker 37. 
 
3.5.3.2 Alternative release mechanisms 
Various bacterial enzymes that selectively and efficiently modify or cleave a chemical motif 
have been explored for chemotherapy and prodrug applications.356 Accordingly, any of these 
chemical motifs that have two suitable handles for attachment of the stapling motif and 
antibiotic drug could be incorporated into the PDC design. By using different enzyme-
cleavable linkers, the properties of the PDC can be ‘tuned’ as desired. 
One example are aryl nitro compounds, which are selectively reduced by bacterial 
nitroreductases, and have been paired with self-immolative motifs in ciprofloxacin prodrugs.357 
One potential advantage of incorporating a nitroreductase-cleavable linker into the PDC 
design is that bacterial nitroreductases have wide substrate scopes and highly plastic active 
sites, therefore they are able to accommodate and cleave large species.358 Another possibility 
is the incorporation of cleavable, self-immolative linkers which are sensitive to mammalian β-
glucuronidases and aryl sulfatases, and have been used previously in antibody-drug 
conjugates.359,360 Bacterial β-glucuronidases have been shown to successfully release a 
glucuronide prodrug of anti-cancer drug 9-aminocamtothecin,361 and, as β-glucuronide 
prodrugs are actively transported into E. coli, incorporating a β-glucuronide-cleavable motif 
into the PDC design could promote cell penetration.362 Sulfatase activity has been 
documented in many different bacteria,363 including P. aeruginosa,364 and the utility of these 
enzymes has been illustrated by the development of sulfatase-activated fluorophores as 
diagnostic tools for identifying infections of mycobacteria.365 As the expression of sulfatases 
and β-lactamases differs depending on the bacterial strain and species, the two linkers provide 
 
t DJK5 and DKJ6 sequences: VQWRAIRVRVIR and VQWRRIRVWVIR respectively 
u Sequence: GGGLRKRLRKFRNKCKEKLKKCGQKIQGLLPKLA 
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differing specificities. Chemical motifs that are sensitive to these enzymes could be 
incorporated into the PDC design with a self-immolative linker, as shown in Scheme 44. 
Additionally, bacterial lipases represent another class of enzymes that could provide a different 
release mechanism, which will be discussed below.  
 
Scheme 44 The proposed structures of alternative enzyme-cleavable motifs (highlighted in red) which would be 
incorporated into PDC1. All could be linked to ciprofloxacin (shown in black) via a self-immolative linker (shown in 
blue). A) Nitroaryls are reduced by nitroreductases. B) β-Glucuronidase hydrolyses β-glucuronic acid. C) Sulfatases 
hydrolyse aryl sulfates. R = variable group.   
 
3.5.3.3 Alternative small-molecule antibiotics  
Due to the rapid development of AMR, it is necessary to investigate novel antimicrobial 
scaffolds as potential therapeutics, for example quorum sensing molecules. QS is a 
mechanism by which bacteria can orchestrate group behaviours, including those governing 
virulence and antibiotic resistance (e.g. the formation of biofilms).366 Quorum sensing inhibitors 
(QSIs) disrupt cell-to-cell communication, and due to the increasing prevalence of AMR they 
are being explored as potential therapeutics. QSIs are often based on the same scaffolds as 
the endogenous QS molecules. A key group of QSI are the acyl homoserine lactones (AHLs), 
which were shown to inhibit the formation of P. aeruginosa biofilms, for example the AHL 
analogues 7h and 7o reported by Blackwell and co-workers (Figure 82).367  
 
Figure 82 Selected examples of AHLs that affect biofilm formation and QS.367 
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Nielsen and co-workers developed functionalised PEG resins that release AHL QS molecules 
upon exposure to bacterial lipases, for applications in medical implants.368 Additionally, 
functionalised PEG resin beads were reported, which, upon exposure to bacterial lipases 
released ciprofloxacin; these resin beads were shown to significantly reduce the viability of 
wild-type P. aeruginosa.368 It is envisioned that the same cleavable motif could also be 
incorporated into an antimicrobial PDC (PDC-A, Scheme 45). Lipase hydrolysis would release 
ciprofloxacin and a functionalised STAMP (PDC-B), which can self-immolate to release an 
AHL QSI and an unfunctionalised STAMP (PDC-C). The proposed PDC would have similar 
advantages as PDC1: the STAMP targets specific bacteria and provides an additional 
mechanism of action, and the lipase-cleavable motif allows selective release of the QSI and 
ciprofloxacin. This species would have three distinct mechanisms of action as the STAMP 
disrupts bacterial membranes, ciprofloxacin targets DNA topoisomerases, and the QSI 
disrupts biofilm formation. As a proof-of-concept conjugate, PDC-A could be synthesised by 
incorporating the stapled peptide AMP2-17 reported in this section and a QSI with known P. 
aeruginosa activity. However, the modular nature of the design provides an opportunity to vary 
the peptide and QSI allowing different bacteria to be targeted, enabled by the wide substrate 




Scheme 45 The proposed structure and mechanism of release for the dual-functionalised STAMP, PDC-A. 
Exposure to bacterial lipase cleaves the ester linkage, releasing ciprofloxacin and PDC-B. PDC-B undergoes self-
immolation releasing the AHL QSI and unfunctionalised STAMP PDC-C. Ciprofloxacin is highlighted in green, the 




















4. Chapter 4 - Experimental details  
4.1 Chemistry experimental procedures  
All experiments were carried out in oven-dried glassware under an atmosphere of N2 unless 
otherwise stated.  Reaction temperatures of 0 °C were maintained using an ice-water bath and 
those below 0 °C using dry-ice and acetone; room temperature (rt) refers to 20-25 °C.  
Solvents: Distilled solvents were used unless otherwise stated. Diethyl ether was distilled 
from calcium hydride and lithium aluminium hydride. Tetrahydrofuran (THF) was dried over 
sodium wire and distilled from a mixture of lithium aluminium hydride and calcium hydride with 
triphenylmethane as the indicator. Acetonitrile (MeCN), CH2Cl2, hexane, methanol (MeOH), 
and toluene were all distilled from calcium hydride. Petroleum ether 40-60 (PE 40-60) refers 
to the petroleum fraction with boiling point of 40–60 ˚C. 
Reagents: Chemicals were purchased from commercial sources and used without further 
purification.  
Yield: refer to chromatographically and spectroscopically pure compounds unless otherwise 
stated and are reported as follows: mass, moles, percentage.  
Flash chromatography: Analytical thin layer chromatography was carried out on SiO2 Merck 
Kieselgel 60 F254 plates with visualisation either by UV light or staining with potassium 
permanganate or ninhydrin dips made using standard procedures. Retention factors (Rf) are 
quoted to 0.01. FCC was performed under a positive pressure of N2 or compressed air using 
slurry-packed Merck 9385 Kieselgel 60 SiO2 (230-400 mesh), or with a Combiflash Rf200 
automated chromatography system using Redisep® reverse-phase C18-silica flash columns 
(20-40 μm). 
Nuclear Magnetic Resonance (NMR): 1H, 13C and 19F NMR spectra were recorded using an 
internal deuterium lock at ambient probe temperatures on the following instruments: Bruker 
Avance III 400 MHz HD Smart Probe Spectrometer, Bruker Avance III 400 MHz HD 
Spectrometer, Bruker 400 MHz QNP Cryoprobe Spectrometer, Bruker 500 MHz DCH 
Cryoprobe Spectrometer, Bruker Avance III 500 MHz HD Smart Probe Spectrometer. The 
following deuterated solvents were used: chloroform (CDCl3) and dimethylsulfoxide (DMSO-
d6). 1H-NMR chemical shifts (δ) are quoted in ppm to the nearest 0.01 ppm, relative to the 
residual non-deuterated solvent peak and coupling constants (J) are quoted to the nearest 0.1 
Hertz (Hz). 13C NMR chemical shifts are quoted to the nearest 0.1 ppm, relative to the solvent 
peak and coupling constants are quoted to the nearest 0.1 Hz. 19F NMR chemical shifts are 
quoted to the nearest 0.1 ppm and coupling constants (J) are quoted to the nearest 0.1 Hertz 
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(Hz). Spectral data is reported as follows: chemical shift, integration, multiplicity (s, singlet; d, 
doublet; t, triplet; q, quartet; p, pentet; sept, septet; m, multiplet; br., broad; appt., apparent; 
(or a combination thereof), coupling constant(s) and assignment. The numbering system used 
in the assignments does not necessarily follow the IUPAC convention. Assignment of all 
spectra is supported by DEPT, COSY, HSQC and HMBC or done by analogy to fully assigned 
spectra of closely related compounds.  
Liquid chromatography-mass spectrometry (LCMS): LCMS was carried out using a 
Waters ACQUITY H-Class UPLC with an ESCi Multi-Mode Ionisation Waters SQ Detector 2 
spectrometer using MassLynx 4.1 software; ESI refers to the electrospray ionisation 
technique; LC system: solvent A: 2 mM NH4OAc in H2O/MeCN (95:5); solvent B: MeCN; 
solvent C: 2% formic acid; column: ACQUITY UPLC® CSH C18 (2.1 mm × 50 mm, 1.7 μm, 
130 Å) at 40 °C; gradient: 5 – 95% B with constant 5% C over 1 min at flow rate of 0.6 mL/min; 
Injection volume: 5 μL. Chromatographs were monitored by absorbance using diode array 
detection at a wavelength range of 190-600 nm, interval 1.2 nm.  
High resolution mass spectrometry (HRMS): HRMS was carried out using a Waters LCT 
Premier® Time of Flight mass spectrometer or the Waters Vion IMS Qtof mass spectrometer. 
Reported mass values are within the error limits of ± 5 ppm mass units. ESI refers to the 
electrospray ionisation technique.  
Analytical high-performance LC: Chromatographs were obtained on an Agilent 1260 
Infinity® using a reversed-phase Supelcosil ABZ+PLUS column (150 mm x 4.6 mm, 3 μm) 
eluting with a linear gradient system (solvent A: 0.05% (v/v) TFA in H2O, solvent B: 0.05% 
(v/v) TFA in MeCN) over 15 min, unless otherwise stated, at a flow rate of 1 mL/min. HPLC 
was monitored by UV absorbance at 220 and 254 nm.  
Preparative HPLC: Preparative HPLC was carried out on an Agilent 1260 Infinity® using a 
reversed-phase Supelcosil ABZ+PLUS column (250 mm x 21.2 mm, 5 μm) eluting with a linear 
gradient system (solvent A: 0.1% (v/v) TFA in H2O, solvent B: 0.05% (v/v) TFA in MeCN) over 
20 min at a flow rate of 20 mL/min. HPLC was monitored by UV absorbance at 220 and 254 
nm.  
Melting points: Melting points (mp) were measured using a Büchi melting point B545 
apparatus and are uncorrected. 
Infra-red spectroscopy (IR): Infra-red spectra were recorded neat on a Perkin Elmer 
Spectrum One FT-IR spectrometer fitted with an Attenuated Total Reflectance (ATR) sampling 
accessory. Selected absorption maxima (νmax) are quoted in wavenumbers (cm-1) with the 
following abbreviation: br, broad. 
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Optical rotations: Optical rotations were recorded on an Anton Parr MCD 100 Polarimeter. 
[α]D 25 values are reported in 10-1 deg cm2 g-1 at 589 nm, concentration (c) is given in g dL-1. 
4.1.1 Chemistry experimental procedures for Chapter 2 
3-Azidosulfonyl-3H-imidazol-1-ium hydrogen sulfate (1) 
 
To a suspension of sodium azide (13.0 g, 200 mmol, 1.01 eq.) in MeCN (160 mL) was added 
sulfuryl chloride (16.1 mL, 199 mmol) dropwise with ice cooling. The reaction mixture was 
stirred at rt for 16 h. Imidazole (25.9 g, 380 mmol, 1.91 eq.) was added portion-wise to the 
reaction mixture with ice cooling and the resulting slurry was stirred at rt for 5 h. The mixture 
was diluted with EtOAc (400 mL) and H2O (400 mL). The organic phase was washed with H2O 
(400 mL) and sat. aq. NaHCO3 solution (2 × 400 mL), then dried (MgSO4) and concentrated 
to 200 mL in vacuo. A solution of sulfuric acid (conc., 11 mL, 200 mmol, 1.01 eq.) in EtOAc 
(100 mL) was added dropwise with ice cooling over 30 min and the reaction mixture was stirred 
at rt for 16 h. The precipitate was filtered, washed with EtOAc (3 × 50 mL) and dried in vacuo 
to give the title compound as a white solid (32.7 g, 121 mmol, 61%). 
1H NMR (400 MHz, DMSO-d6) δ 8.57 (1H, s, H1), 7.96 (1H, s, H2), 7.32 (1H, s, H3); 13C NMR 
(101 MHz, DMSO-d6) δ 138.3 (CH, C1), 130.2 (CH, C2), 119.5 (CH, C3); IR (neat, cm-1) νmax 
2177 (strong, N=N=N stretch), 1586 (C=C bend), 1151 (S=O); HRMS (ESI): [M+Na]+ calcd. 
for [C3H5N5O6S2Na]+ 293.9579, observed 293.9583 (Δ = -2.0 ppm). 





To a stirred solution of Fmoc-Orn(Boc)-OH (2.50 g, 5.50 mmol) in 1,4-dioxane (8 mL) was 
added HCl (4 M in 1,4-dioxane, 4.00 mL, 16.00 mmol, 2.9 eq.). The reaction was stirred at rt 
for 21 h. The reaction mixture was diluted with diethyl ether (100 mL) and the precipitate was 
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filtered. The precipitate was washed with diethyl ether (4 × 50 mL) and dried in vacuo to give 
the title compound as a white powder (1.94 g, 4.96 mmol, 90%). 
1H NMR (400 MHz, DMSO-d6) δ 7.90 (5H, m, H13 and NH3), 7.74-7.68 (3H, m, H10 and H5), 
7.42 (2H, appt. t, J = 7.4 Hz, H12), 7.33 (2H, appt. t, J = 7.4 Hz, H11), 4.31-4.21 (3H, m, H7 
and H4), 3.97-3.93 (1H, m, H8), 2.83-2.72 (2H, m, H1), 1.86-1.71 (1H, m, H3), 1.70-1.53 (3H, 
m, H3 and H2); 13C NMR (101 MHz, DMSO-d6), 174.0 (C=O, C15), 156.6 (C=O, C6), 144.3 
(C, C9), 141.2 (C, C14), 128.1 (CH, C12), 127.6 (CH, C11), 125.7 (CH, C13), 120.6 (CH, C10), 
66.1 (CH2, C7), 53.9 (CH, C8), 47.1 (CH, C4), 38.9 (CH2, C1), 28.2 (CH2, C3), 24.4 (CH2, C2); 
IR (neat, cm-1) νmax 3015 (br, OH), 1730 (C=O), 1691 (C=O); HRMS (ESI): [M+H]+ calcd. for 
[C20H23N2O4]+ 355.1652, observed 355.1567 (Δ = -1.4 ppm); [α]D25 -1.00 (c = 1, DMSO). 
Data in accordance with previous literature reports.23 
 
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-azidopentanoic acid (3) 
 
2 (1.94 g, 5.00 mmol) was dissolved in a biphasic mixture of H2O (25 mL), MeOH (75 mL) and 
CH2Cl2 (50 mL). To the reaction mixture was added CuSO4∙5H2O (7.00 mg, 2.98 µmol, 0.006 
eq.) and 1 (4.31 g, 15.9 mmol, 3.18 eq.). The reaction mixture was adjusted to pH 9 with sat. 
aq. K2CO3 solution, then stirred vigorously at rt for 18 h. The reaction mixture was diluted with 
CH2Cl2 (50 mL) and the aqueous phase was separated. The organic phase was extracted with 
sat. NaHCO3 solution (2 × 60 mL). The combined aqueous extracts were washed with diethyl 
ether (2 × 60 mL). The ethereal extracts were discarded, and the aqueous layer was acidified 
to pH 2 with conc. HCl and extracted with diethyl ether (3 × 60 mL). The combined ethereal 
extracts were dried (MgSO4) and the solvent was removed in vacuo to give the title compound 
as a white solid (1.41 g, 3.71 mmol, 75%).  
Rf 0.38 (1% MeOH and 1% AcOH in CH2Cl2); 1H NMR (400 MHz, DMSO-d6) δ 7.92-7.87 (2H, 
d, J = 7.4 Hz, H2), 7.74-7.65 (3H, m, H5 and H10), 7.43 (2H, appt. t, J = 7.4 Hz, H3), 7.34 (2H, 
appt. dt, J = 7.4, 1.0 Hz, H4), 4.34-4.27 (2H, m, H8), 4.26-4.21 (1H, m, H11), 4.02-3.95 (1H, 
m, H7), 3.34 (2H, appt. t, J = 8.0 Hz, H15), 1.85-1.75 (1H, m, H14), 1.73-1.53 (3H, m, H14 
and H16); 13C NMR (101 MHz, DMSO-d6) δ 174.1 (C=O, C12), 156.6 (C=O, C9), 144.3 (C, 
C6 or C1), 141.2 (C, C6 or C1), 128.1 (CH, C3), 127.5 (CH, C4), 125.7 (CH, C5), 120.6 (CH, 
C2), 66.1 (CH2, C8), 53.8 (CH, C7), 50.7 (CH2, C11), 47.1 (CH, C16), 28.5 (CH2, C15), 25.6 
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(CH2, C14); IR (neat, cm-1) νmax 3065 (br. OH), 2095 (N=N=N stretch), 1700 (C=O), 1697 
(C=O), 1522 (C-C stretch); HRMS (ESI): [M+H]+ calcd. for [C20H21N4O4]+: 381.1518, observed 
381.1573 (Δ = 2.6 ppm); [α]D25 -3.6 (c = 1, MeOH, lit. [α]D -2.3).369  




A solution of N-bromosuccinimide (23.1 g, 130 mmol, 2.17 eq.) in DMF (150 mL) was added 
dropwise to an ice-cold suspension of carbazole (10.0 g, 59.8 mmol) in toluene (50 mL). The 
reaction mixture was warmed to rt, stirred for 30 min then poured onto H2O (500 mL). The 
precipitate that formed was washed with H2O (100 mL) and cold MeOH (100 mL). The crude 
product was triturated with cold MeOH/hexanes (1:1) to give the title compound as a cream 
solid (12.8 g, 39.6 mmol, 66%).  
Rf 0.31 (20:80 EtOAc/Hexanes); 1H NMR (500 MHz, DMSO-d6) δ 11.60 (1H, s, NH, H1), 8.44 
(2H, d, J = 1.8 Hz, H6), 7.54 (2H, dd, J = 8.6, 1.8 Hz, H4), 7.48 (2H, d, J = 8.6 Hz, H3); 13C 
NMR (101 MHz, DMSO-d6) δ 139.3 (C, C2), 129.2 (CH, C6), 123.8 (CH, C4), 123.8 (C, C5), 
113.7 (CH, C3), 111.5 (C, C7); IR (neat, cm-1) νmax 3420 (NH stretch), 1430 (C=C stretch); 
HRMS (ESI): [M+H]+ calcd. for [C12H879Br2N]+ 325.9003, observed 325.1504 (Δ = -0.9 ppm).   




A suspension of 4 (5.0.0 g, 15.5 mmol), Pd(PPh3)2Cl2 (500 mg, 0.775 mmol, 0.05 eq.), CuI 
(100 mg, 0.465 mmol, 0.026 eq.), trimethylsilylacetylene (10.0 mL, 69.8 mmol, 4.5 eq.), and 
PPh3 (100 mg, 0.388 mmol, 0.025 eq.) in NEt3 (160 mL) was heated to reflux for 18 h. The 
reaction mixture was filtered through Celite®, washed with H2O (50 mL) and brine (50 mL), 
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dried (Na2SO4) and concentrated in vacuo. The residue was purified by FCC on SiO2 (0-60% 
EtOAc in PE 40-60) to give the title compound as an orange solid (4.02 g, 11.2 mmol, 72%).  
Rf 0.37 (15% EtOAc/PE 40-60); 1H NMR (400 MHz, CDCl3) δ 8.19-8.16 (3H, m, H1 and H6), 
7.54 (2H, dd, J = 8.4, 1.5 Hz, H4), 7.32 (2H, d, J = 8.4 Hz, H3), 0.29 (18H, s, H10); 13C NMR 
(101 MHz, CDCl3) δ 139.6 (C, C2), 130.4 (CH, C4), 124.8 (CH, C6), 122.9 (C, C7), 114.6 (C, 
C5), 110.8 (CH, C3), 106.3 (C, C8), 92.3 (C, C9), 0.28 (CH3, C10); IR (neat, cm-1) νmax 3362 
(NH stretch), 2956 (C-H aromatic stretch), 2138 (C≡C stretch), 1481 (C=C stretch); HRMS 
(ESI): [M+H]+ calcd. for [C22H26NSi2]+ 360.1604, observed 360.1604 (Δ = -4.7 ppm).  




A suspension of 5 (321 mg, 0.892 mmol) and K2CO3 (469 mg, 3.39 mmol, 3.8 eq.) in MeOH 
(30 mL) was stirred at rt for 18 h. The reaction mixture was evaporated in vacuo and the 
residue purified by FCC on SiO2 (40% CH2Cl2 in PE 40-60) to give the title compound as a 
beige solid (156 mg, 0.725 mmol, 81%).  
Rf 0.28 (25% EtOAc/hexanes); 1H NMR (400 MHz, DMSO) δ 11.70 (1H, s, H1), 8.37 (2H, s, 
H6), 7.51-7.48 (4H, m, H3 and H4), 4.04 (2H, s, H8); 13C NMR (101 MHz, DMSO-d6) δ 140.4 
(C, C2), 130.1 (CH, C4), 125.0 (CH, C6), 122.4 (C, C7), 112.6 (C, C5), 112.0 (CH, C3), 85.4 
(C, C8), 79.0 (CH, C9); IR (neat, cm-1) νmax 3404 (NH stretch), 3269 (C≡C-H stretch), 2103 
(C≡C stretch), 1601 (C=C stretch); HRMS (ESI): [M+H]+ calcd. for [C16H10N]+ 216.0813, 
observed 216.0818 (Δ = 2.3 ppm).  










6-(3,6-Diethynyl-9H-carbazol-9-yl)hexanoic acid (7) 
 
Freshly ground KOH (1.25 g, 22.2 mmol, 7.9 eq.) was suspended in DMF/DMSO (1:1, 5.6 mL) 
and stirred for 1.5 h. 6 (1.00 g, 2.80 mmol) was added and the reaction mixture was stirred at 
rt for 20 min. 6-Bromohexanoic acid (1.09 g, 5.60 mmol, 2.0 eq.) was added and the reaction 
mixture was stirred at rt for 20 min then irradiated with 37 kHz ultrasonic waves for 1.5 h. The 
reaction mixture was acidified to pH 4 with 2 N HCl and the aqueous phase was extracted with 
EtOAc (3 × 10 mL). The combined organics were dried (MgSO4) and concentrated in vacuo. 
The residue was purified by FCC on SiO2 (0-100% EtOAc in hexane, then 0-10% MeOH in 
EtOAc) to yield the title compound as an orange oil which solidified on standing (580 mg, 1.76 
mmol, 63%).  
Rf 0.12 (50% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 8.21 (2H, s, H11), 7.60 (2H, d, J 
= 8.5 Hz, H9), 7.32 (2H, d, J = 8.5 Hz, H8), 4.28 (2H, t, J = 7.2 Hz, H6), 3.09 (2H, s, H14), 
2.32 (2H, t, J = 7.4 Hz, H2), 1.88 (2H, appt. p, J = 7.6 Hz, H5), 1.67 (2H, appt. p, J = 7.5 Hz, 
H3), 1.46-1.37 (2H, m, H4); 13C NMR (101 MHz, CDCl3) δ 178.9 (C, C1), 140.6 (C, C7), 130.2 
(CH, C9), 124.8 (CH, C11), 122.3 (C, C12), 112.8 (C, C10), 108.9 (CH, C8), 84.7 (C, C13), 
75.5 (CH, C14), 43.0 (CH2, C6), 33.6 (CH2, C2), 28.6 (CH2, C5), 26.6 (CH2, C3), 24.3 (CH2, 
C4); IR (neat, cm-1) νmax 3260 (C≡C-H stretch), 2926 (OH stretch), 1699 (CO carbonyl stretch), 
1480 (C=C aromatic stretch); HRMS (ESI): [M+H]+ calcd. for [C22H20NO2]+ 330.1494, observed 
330.1489 (Δ = -1.5 ppm).  
 
Methyl 3,5-bis((trimethylsilyl)ethynyl)benzoate (9) 
 
To a solution of methyl 3,5-dibromobenzoate (900 mg, 3.10 mmol), 
tris(dibenzylideneacetone)dipalladium(0) (54.0 mg, 59.0 µmol, 0.19 eq.), CuI (11.5 mg, 6.00 
µmol, 0.0019 eq.) and PPh3 (77.5 mg, 0.290 mmol, 0.094 eq.) in anhydrous NEt3 (15 mL) was 
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added trimethylsilylacetylene (6.00 mL, 42.2 mmol, 13.6 eq.). The reaction was heated to 
reflux for 18 h. The solvent was removed under N2 and the crude product was purified by FCC 
on SiO2 (0-5% EtOAc/PE 40-60) to yield the title compound as an orange oil which solidified 
on standing (977 mg, 2.97 mmol, 96%).  
Rf 0.45 (1% EtOAc/PE 40-60); 1H NMR (400 MHz, CDCl3) δ 8.04 (2H, d, J = 1.6 Hz, H4), 7.72 
(1H, t, J = 1.6 Hz, H6), 3.91 (3H, s, H1), 0.24 (18H, s, H9); 13C NMR (101 MHz, CDCl3) δ 
165.7 (C, C2), 139.1 (CH, C6), 132.7 (CH, C4), 130.7 (C, C3), 124.0 (C, C5), 103.1 (C, C7), 
96.2 (C, C8), 52.5 (CH3, C1), -0.1 (CH3, C9); IR (neat, cm-1) νmax 2956 (C-H aromatic stretch), 
2155 (C≡C stretch), 1730 (C=O, carbonyl stretch), 1588 (C=C aromatic stretch); HRMS (ESI): 
[M+H]+ calcd. for [C18H25Si2O2]+ 329.1393, found: 329.1474 (Δ = 3.3 ppm).  
Data in accordance with previous literature reports.23 
 
3,5-Diethynylbenzoic acid (10) 
 
To a solution of 9 (2.85 g, 8.68 mmol) in THF (50 mL) was added 6 N KOH solution (8.50 mL, 
50 mmol, 5.76 eq.). The reaction was stirred at rt for 48 h. The volatile solvents were removed 
in vacuo and the remaining aqueous solution was diluted with H2O (20 mL) and acidified to 
pH 2 using 2 N HCl. The mixture was extracted with diethyl ether (3 × 30 mL) and the combined 
organics were dried (MgSO4) and evaporated in vacuo. The crude product was recrystallised 
from CHCl3 to give the title compound as pale orange crystals (1.25 g, 7.35 mmol, 84% yield). 
Rf 0.40 (1% MeOH/CH2Cl2 with 1% AcOH); Mp (CHCl3) 200 °C decomp. (lit. mp 250 °C 
decomp.);23 1H NMR (400 MHz, DMSO-d6) δ 7.95 (2H, d, J = 1.4 Hz, H4), 7.80 (1H, t, J = 1.5 
Hz, H6), 4.40 (2H, s, H8); 13C NMR (101 MHz, DMSO-d6) δ 170.8 (C, C2), 143.4 (C, C6), 
137.6 (CH, C4), 128.9 (C, C3), 128.1 (C, C5), 87.9 (C, C7), 86.7 (CH, C8); IR (neat, cm-1) νmax 
3286 (C≡C-H stretch), 2599 (OH), 1684 (C=O carbonyl stretch), 1443 (C=C aromatic stretch); 
HRMS (ESI): [M-H]- calcd. for [C11H5O2]- 169.0295, observed 169.0290 (Δ = -2.9 ppm).  




4.1.2 Chemistry experimental procedures for Chapter 3 
General method 1 - SNAr reaction: To a solution of chloro-aryl (1.0 eq.) and amine (1.2 eq.) 
in acetone was added NEt3 (2.5 eq.) with ice cooling. The reaction was stirred with ice cooling 
for 2 h and then warmed to rt and stirred for 1 h. The reaction mixture was diluted with EtOAc, 
washed with H2O (× 3), dried (MgSO4) and evaporated in vacuo. The residue was purified by 
FCC on SiO2 to give the title compound. 
General method 2 - Suzuki-Miyaura coupling67: A suspension of di-chloroaryl (1.0 eq.), 
potassium vinyltrifluoroborate (3.0 eq.) and K2CO3 (6.0 eq.) in 1,4-dioxane/H2O (9:1) was 
degassed under N2 for 5 min. PdCl2(dppf)·CH2Cl2 (0.1 eq.) was added to the reaction mixture 
at rt and the reaction was heated to reflux for 18 h. The reaction mixture was filtered through 
Celite® and evaporated in vacuo to give the crude product which was purified by FCC to give 
the desired product.   
General method 3 - Ethyl ester hydrolysis: To a solution of ethyl ester (1.0 eq.) in THF/H2O 
(1:1, reaction molarity 0.07 M) at 0 °C was added LiOH·H2O (1.1 eq.) and the reaction was 
stirred at rt until the starting material was fully consumed. The reaction mixture was diluted 
with H2O, washed with Et2O (× 1) and the pH was adjusted with 1N HCl. The aqueous was 
extracted with CH2Cl2 (× 4) and the combined organics were dried (Na2SO4) to give the crude 
product.  
 
Ethyl N-(2,6-dichloropyrimidin-4-yl)-N-methylglycinate (12) 
 
To a solution of cyanuric chloride (5.00 g, 27.1 mmol) and sarcosine ethyl ester hydrochloride 
(4.16 g, 27.1 mmol, 1.0 eq.) in acetone (100 mL) at 0 °C was added DIPEA (9.45 mL, 54.2 
mmol, 2.0 eq.) dropwise. The reaction was stirred at 0 °C for 2 h, then poured onto ice water 
(100 mL). The aqueous was extracted with CH2Cl2 (3 × 50 mL), dried (MgSO4) and evaporated 
in vacuo to give the title compound as a yellow solid (6.57 g, 24.9 mmol, 92%) which was 
taken on without further purification. 
Rf 0.26 (20% EtOAc/PE 40-60); 1H NMR (400 MHz, CDCl3) δ 4.35 (2H, s, H2), 4.22 (2H, q, J 
= 7.2 Hz, H4), 3.25 (3H, s, H1), 1.28 (3H, t, J = 7.2 Hz, H5); 13C NMR (101 MHz, CDCl3) δ 
170.4 (C=O, C3), 170.0 (C, C6), 167.9 (C, C7), 165.5 (C, C8), 61.8 (CH2, C2), 50.8 (CH2, C4), 
36.5 (CH3, C1), 14.2 (CH3, C5); IR (neat, cm-1) νmax 2992 (aliphatic C-H, stretch), 1735 (ester 
C=O, stretch), 1480 (aliphatic C-H, bend), 1215 (ester C-O, stretch), 794 (aromatic C-Cl, 
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stretch); HRMS (ESI): [M+H]+ calcd. for [C8H11Cl2N4O2]+ 265.0259, observed 265.0249 (Δ = -
3.8 ppm).  
Data in accordance with previous literature reports.67 
 
Ethyl N-(4,6-divinyl-1,3,5-triazin-2-yl)-N-methylglycinate (13) 
 
Prepared following general method 2 using 12 (2.50 g, 9.43 mmol), potassium 
vinyltrifluoroborate (3.80 g, 28.4 mmol, 3.0 eq.), K2CO3 (7.80 g, 56.7 mmol, 6.0 eq.) and 
PdCl2(dppf)·CH2Cl2 (770 mg, 0.945 mmol, 0.1 eq.) in 1,4-dioxane/H2O (9:1, 128 mL). The 
reaction was complete after 2 h. The crude product was purified by FCC on SiO2 (0-25% 
EtOAc in PE 40-60) to give the title compound as a clear oil (1.20 g, 4.83 mmol, 51%).  
Rf 0.52 (25% EtOAc/PE 40-60); 1H NMR (400 MHz, CDCl3) δ 6.78-6.52 (4H, m, H9 and H12), 
5.75 (2H, dd, J = 2.1, 10.2 Hz, H8 and H11), 4.38 (2H, s, H2), 4.18 (2H, q, J = 7.2 Hz, H4), 
3.29 (3H, s, H1), 1.25 (3H, t, J = 7.2 Hz, H5); 13C NMR (101 MHz, CDCl3) δ 170.7 (C=O, C3), 
170.2 (C, C6), 169.6 (C, C7 or C10), 165.5 (C, C7 or C10), 136.2 (CH, C8 or C11), 136.0 (CH, 
C8 or C11), 126.2 (CH2, C9 or C12), 126.0 (CH2, C9 or C12), 61.1 (CH2, C2), 50.7 (CH2, C4), 
35.7 (CH3, C1), 14.2 (CH3, C5); IR (neat, cm-1) νmax 2983 (alkene C-H, stretch), 1742 (ester 
C=O, stretch), 1637 (alkene C=C, stretch), 1186 (ester C-O, stretch), alkene C-H, bend); 
HRMS (ESI) [M+H]+ calcd. for [C12H17N4O2]+ 249.1352, observed 249.1352 (Δ = -0.4 ppm). 




Prepared following general method 3, using 13 (100 mg, 0.403 mmol) and LiOH·H2O (19.0 
mg, 0.453 mmol, 1.1 eq.) in THF/H2O (1:1, 6 mL). The starting material was consumed after 
18 h. After washing with Et2O (1 × 5 mL), the pH was adjusted to 7 with 1N HCl and the 
aqueous was extracted with CH2Cl2 (4 × 5 mL). The combined organics were dried (Na2SO4), 
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evaporated and triturated with cold PE 40-60 to give the title compound as a white solid (50.0 
mg, 22.7 mmol, 56%).  
Rf 0.17 (10% MeOH/CH2Cl2); 1H NMR (400 MHz, DMSO-d6) δ 6.74-6.49 (4H, m, H7 and 10), 
5.89-5.81 (2H, m, H6 and 9), 4.36 (2H, s, H2), 3.21 (3H, s, H1); 13C NMR (101 MHz, DMSO-
d6) δ 171.1 (C=O, C3), 170.4 (C, C4), 170.0 (C, C5 or C8), 165.6 (C, C5 or C8), 136.4 (CH2, 
C7 or 10), 136.3 (CH2, C7 or 10), 127.3 (CH, C6 or 9), 127.3 (CH, C6 or 9), 50.5 (CH3, C1), 
35.9 (CH2, C2); IR (neat, cm-1) νmax 2495 (alkene C-H, stretch), 1711 (acid C=O, stretch), 1640 
(alkene C=C, stretch), 1224 (acid C-O, stretch); LRMS (ESI) [M+H]+ calcd. for [C10H13N4O2]+ 
221.1 observed 221.2.   




Prepared following general method 1 using 2,4,6-trichloropyrimidine (1.57 mL, 13.6 mmol), 3-
phenyl-1-propylamine (2.30 mL, 16.4 mmol, 1.2 eq.) and NEt3 (4.80 mL, 34.2 mmol, 2.5 eq.) 
in acetone (70 mL). The crude product was purified by FCC on SiO2 (25% EtOAc in PE 40-
60) to give the title compound as a yellow solid (1.62 g, 5.74 mmol, 42%).  
Rf 0.63 (25% EtOAc/PE 40-60); 1H NMR (400 MHz, CDCl3) δ 7.34-7.21 (5H, m, H1 and H2 
and H3), 6.62 (1H, s, H11), 5.45 (1H, appt. s, H8), 3.48 (2H, q, J = 6.8 Hz, H7), 2.72 (2H, t, J 
= 7.5 Hz, H5), 1.97 (2H, p, J = 7.5 Hz, H6); 13C NMR (101 MHz, CDCl3) δ 161.6 (C, C9 and 
C10), 141.1 (C, C4), 128.5 (CH, C2), 128.3 (CH, C3), 126.1 (CH, C1), 108.9 (CH, C11), 41.1 
(CH2, C7), 33.0 (CH2, C5), 30.8 (CH2, C6); IR (neat, cm-1) νmax 3271 (N-H, stretch), 3122 
(aromatic C-H, stretch), 2934 (aliphatic C-H, stretch), 1600 (N-H, bend), 1518 (aromatic C=C, 
stretch), 1450 (aliphatic C-H, bend), 696 (C-Cl, stretch); HRMS (ESI) [M+H]+ calcd. for 











Prepared following general method 2 using 15 (1.00 g, 3.55 mmol), potassium 
vinyltrifluoroborate (1.42 g, 10.6 mmol, 3.0 eq.), K2CO3 (2.94 g, 21.2 mmol, 6.0 eq.) and 
PdCl2(dppf)·CH2Cl2 (290 mg, 0.346 mmol, 0.1 eq.) in 1,4-dioxane/H2O (9:1, 50 mL). The crude 
product was purified by FCC on SiO2 (0-25% EtOAc in PE 40-60) to give the title compound 
as a pale yellow oil (659 mg, 2.49 mmol, 70%).  
Rf 0.44 (25% EtOAc/PE 40-60); 1H NMR (400 MHz, CDCl3) δ 7.33-7.18 (5H, m, H1 and H2 
and H3), 6.61 (2H, dd, J = 17.4, 10.6 Hz, H13), 6.56 (1H, s, H11), 6.38 (2H, dd, J = 17.3, 0.8 
Hz, H14’), 5.59 (2H, dd, J = 10.6, 1.4 Hz, H14), 5.24 (1H, appt. s, H8), 3.54 (2H, q, J = 6.8 Hz, 
H7), 2.75 (2H, t, J = 7.5 Hz, H5), 1.99 (2H, p, J = 7.4 Hz, H6); 13C NMR (101 MHz, CDCl3) δ 
163.8 (C, C10 and C12), 162.7 (C, C9), 142.0 (C, C4), 136.0 (CH, C13), 128.6 (CH, C2 or 
C3), 128.5 (CH, C2 or C3), 126.0 (CH, C1), 121.6 (CH2, C14), 105.7 (CH, C11), 41.1 (CH2, 
C7), 33.4 (CH2, C5), 31.5 (CH2, C6); IR (neat, cm-1) νmax 3027 (aromatic C-H, stretch), 2937 
(alkene C-H, stretch), 1636 (alkene C=C, stretch), 1541 (aromatic C=C, stretch), 1325 (C-N, 
stretch), 907 (alkene C=C, bend); HRMS (ESI) [M+H]+ calcd. for [C17H20N3]+ 266.1657, 




Prepared following general method 2 using 2-amino-4-chloropyrimidine (200 mg, 1.54 mmol), 
K2CO3 (1.28 g, 9.24 mmol, 6.0 eq.), potassium vinyltrifluoroborate (620 mg, 4.63 mmol, 3.0 
eq.), and PdCl2(dppf)·CH2Cl2 (126 mg, 0.154 mmol, 0.1 eq.) in 1,4-dioxane/H2O (9:1, 26 mL). 
The crude product was adsorbed onto Fluorosil® and purified by FCC on SiO2 (1% NEt3 in 
EtOAc) to give the title compound as a beige solid (75.0 mg, 0.619 mmol, 40%).  
Rf 0.46 (1% NEt3/EtOAc); 1H NMR (400 MHz, CDCl3) δ 8.26 (1H, d, J = 5.1 Hz, H3), 6.63 (1H, 
d, J = 5.1 Hz, H4), 6.57 (1H, dd, J = 17.4, 10.6 Hz, H6), 6.34 (1H, dd, J =  17.4, 1.0 Hz, H7’), 
5.61 (1H, dd, J = 10.6, 1.0 Hz, H7), 5.12 (2H, br. s, H1); 13C NMR (101 MHz, CDCl3) δ 164.4 
(C, C5), 162.3 (C, C2), 157.4 (CH, C3), 135.4 (CH, C6), 123.2 (CH2, C7), 108.7 (CH, C4); IR 
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(neat, cm-1) νmax 3328, 3168, 2352, 1650, 1548, 1451, 1337, 1217; HRMS (ESI) [M+H]+ calcd. 
for [C6H8N3]+ 122.0718 observed 122.0715 (Δ = 1.5 ppm).  




A suspension of 2-amino-4,6-dichloropyrimidine (400 mg, 2.44 mmol, 1.0 eq.), potassium 
vinyltrifluoroborate (980 mg, 7.32 mmol, 3.0 eq.), Pd(dppf)Cl2·CH2Cl2 (200 mg, 0.244 mmol, 
0.01 eq.) and K2CO3 (2.02 g, 14.64 mmol, 6.0 eq.) in THF/H2O (10:1, 6.6 mL) was heated to 
70 °C for 18 h. The reaction mixture was filtered through Celite® and concentrated in vacuo. 
The crude residue was purified by FCC on SiO2 (20-40% EtOAc/PE 40-60) to give the title 
compound as a yellow solid (190 mg, 1.29 mmol, 53%).  
Rf 0.33 (50% EtOAc/PE 40-60); 1H NMR (400 MHz, CDCl3) δ 6.67 (1H, s, H4), 6.61 (2H, dd, 
J = 17.4, 10.7 Hz, H5), 6.36 (2H, dd, J = 17.4, 1.3 Hz, H6), 5.62 (2H, dd, J = 10.7, 1.3 Hz, 
H6’); 13C NMR (101 MHz, CDCl3) δ 164.2 (C, C3), 163.2 (C, C2), 135.6 (CH, C5), 122.0 (CH2, 
C6), 106.2 (CH, C4); IR (neat, cm-1) νmax 3329 (N-H, stretch), 1648 (C=C stretch, alkene), 1558 
(N-H bending), 1457 (C=C aromatic, stretch), 1223 (C-N stretch); LRMS (ESI) [M+H]+ calcd. 
for [C8H10N3]+ 148.1 observed 148.2. 




To a solution of 24 (190 mg, 1.29 mmol) in DMF (5.6 mL) was added 6-iodo-1-hexyne (850 
µL, 6.45 mmol, 5.0 eq.). To the reaction mixture was added sodium hydride (60% in mineral 
oil, 260 mg, 6.45 mmol, 5.0 eq.) portion-wise. The reaction mixture was stirred at rt for 18 h, 
then diluted with H2O (50 mL) and extracted with CH2Cl2 (3 × 20 mL). The combined organics 
were dried (MgSO4) and the solvent removed in vacuo. The crude product was purified by 
151 
 
FCC on SiO2 (20-40% EtOAc/PE 40-60) to give the title compound as an orange oil (100 mg, 
0.440 mmol, 34%).  
Rf 0.4 (30% EtOAc/PE 40-60); 1H NMR (400 MHz, CDCl3) δ 6.60 (2H, dd, J = 17.4, 10.6 Hz, 
H2), 6.54 (1H, s, H4), 6.37 (2H, appt. d, J = 17.4 Hz, H1’), 5.57 (2H, dd, J = 10.6, 1.4 Hz, H1), 
5.20 (1H, br. s, H6), 3.51 (2H, q, J = 6.7 Hz, H7), 2.28-2.24 (2H, m, H12), 1.97 (2H, t, J = 2.6 
Hz, H10), 1.79-1.72 (2H, m, H8 or H9), 1.68-1.63 (2H, m, H8 or H9); 13C NMR (101 MHz, 
CDCl3) δ 163.7 (C, C3), 162.7 (C, C5), 136.0 (CH, C2), 121.3 (CH2, C1), 105.5 (CH, C4), 84.3 
(C, C11), 68.5 (CH, C12), 40.8 (CH2, C7), 28.8 (CH2, C8), 25.8 (CH2, C9), 18.2 (CH2, C10); 
IR (neat, cm-1) νmax 3349 (N-H, stretch), 3211 (C-C alkyne, stretch), 1632 (C=C stretch, 
conjugated alkene), 1558 (N-H bending), 1219 (C-N stretch); LRMS (ESI) [M+H]+ calcd. for 
C14H18N3+ 228.1 observed 228.3. 
Data in accordance with previous literature reports.371 
 
(6R,7R)-7-Amino-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-
carboxylic acid (28) 
 
To a suspension of 7-ACA (184 mg, 0.676 mmol) in MeOH/H2O (2 mL, 1:1) at -30 °C was 
added sodium hydroxide (3 N, 0.3 mL, 1.3 eq.) dropwise. The reaction mixture was stirred at 
-30 °C for 4 h then warmed to 0 °C and acidified to pH 2 with 1 N HCl. The resulting precipitate 
was filtered and washed with MeOH to give the title compound as an orange solid (63.0 mg, 
0.274 mmol, 40%). 
1H NMR (400 MHz, DMSO-d6) δ 4.93 (1H, d, J = 4.0 Hz, H7), 4.73 (1H, d, J = 4.0 Hz, H6), 
4.21-4.20 (2H, m, H10), 3.56 (1H, d, J = 18, H2), 3.48 (1H, d, J = 18 Hz, H2); 13C NMR (400 
MHz, DMSO-d6) 170.0 (C=O, C8), 163.8 (C=O, C9), 129.5 (C, C3), 79.6 (C, C4), 63.5 (CH, 
C6), 60.0 (CH2, C10), 59.0 (CH, C7), 25.2 (CH2, C2); IR (neat, cm-1) vmax 3377 (O-H, stretch), 
3146 (N-H, stretch), 1783 (C=O lactam, stretch), 1616 (C=O acid, stretch), 1535 (alkene C=C, 
stretch).  






4-Azidobenzoyl chloride (29) 
 
To a suspension of 4-azidobenzoic acid (720 mg, 4.41 mmol) in CH2Cl2 (3 mL) at rt was added 
oxalyl chloride (225 μL, 2.66 mmol, 0.6 eq.). The reaction mixture was stirred for 20 min then 
DMF (15 μL, cat.) was added dropwise. The reaction mixture was stirred at rt for 18 h, then 
the solvent removed in vacuo to give the crude product as a beige solid (786 mg, 4.33 mmol, 
98%) which was used without further purification.  
Rf 0.29 (2% MeOH/CH2Cl2); 1H NMR (400 MHz, DMSO-d6) δ 7.97-7.95 (2H, m, H2), 7.22-7.19 
(2H, m, H3); 13C NMR (101 MHz, DMSO-d6) δ 167.0 (C=O, C5), 144.4 (C, C4), 131.7 (CH, 
C2), 127.7 (C, C1), 119.6 (CH, C3); IR (neat, cm-1) vmax cm-1 2122 (N=N=N), 1762 (C=O, 
stretch), 1572 (aromatic C-H, bend).  





tert-Butyl acetate (9.25 mL) was sparged for 5 min then 7-ACA (500 mg, 1.84 mmol) was 
added. BF3.OEt2 (1.40 mL, 11.0 mmol, 6.0 eq.) was added dropwise and the reaction mixture 
was stirred at rt for 2 h. Upon the formation of a homogenous solution the reaction mixture 
was poured into ice water (50 mL) and extracted with EtOAc (4 x 30 mL). The combined 
organics were dried (MgSO4) and the solvent was removed in vacuo to yield the crude product 
(473 mg, 1.44 mmol, 78%) as a beige gum which was used without further purification.  
Rf 0.29 (50% EtOAc/PE with 1% NEt3); 1H NMR (400 MHz, DMSO-d6) δ 4.98 (1H, d, J = 5.1 
Hz, H7), 4.89 (1H, d, J = 12.6 Hz, H10), 4.79 (1H, d, J = 5.1 Hz, H6), 4.60 (1H, d, J = 12.6 Hz, 
H10’), 3.58 (1H, d, J = 18.2 Hz, H2), 3.43 (1H, d, J = 18.1 Hz, H2’), 2.02 (3H, s, H12), 1.46 
(9H, s, H14); 13C NMR (101 MHz, DMSO-d6) δ 170.3 (C=O, C9), 170.1 (C=O, C11), 160.8 
(C=O, C8), 127.1 (C, C3), 122.1 (C, C4), 82.6 (C, C13), 63.8 (CH, C6), 62.8 (CH2, C10), 59.3 
(CH, C7), 27.5 (CH3, C14), 25.4 (CH2, C2), 20.7 (CH3, C12); IR (neat, cm-1) vmax 2957 (N-H 
stretch), 1777 (C=O lactam, stretch), 1699 (C=O ester, stretch), 1678 (C=O ester, stretch), 
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1150 (C-O ester, stretch); LRMS (ESI) [M+H]+ calcd. for [C14H20N2O5SNa]+ 351.1 observed 
351.4.  





To a solution of 30 (416 mg, 1.27 mmol) in THF (31.2 mL) was added 29 (291 mg, 1.61 mmol, 
1.2 eq.) and NEt3 (229 μL, 1.61 mmol, 1.2 eq.). The reaction was stirred at rt for 2 h then a 
further 0.5 eq. of 29 (121 mg, 0.670 mmol, 0.5 eq.) was added to the reaction mixture. The 
reaction mixture was stirred for 1 h then the solvent was removed under reduced pressure. 
The crude product was purified by FCC on SiO2 (0-50% EtOAc in PE 40-60) to give the title 
compound (315 mg, 0.665 mmol, 52%) as a yellow oil.  
Rf 0.53 (50% EtOAc/PE 40-60); 1H NMR (CDCl3, 400 MHz) δ 7.83 (2H, d, J = 8.6 Hz, H19 or 
18), 7.08 (2H, d, J = 8.6 Hz, H19 or 18), 6.99 (1H, d, J = 8.7 Hz, H15), 6.01 (1H, dd, J = 4.8, 
8.7 Hz, H7), 5.12 (1H, d, J = 13.3 Hz, H10), 5.07 (1H, d, J = 4.9 Hz, H6), 4.81 (1H, d, J = 13.3 
Hz, H10), 3.59 (1H, d, J = 18.5 Hz, H2), 3.39 (1H, d, J = 18.5 Hz, H2), 2.09 (3H, s, H12), 1.53 
(9H, s, H14); 13C NMR (101 MHz, CDCl3) δ 170.7 (C=O, C9), 166.4 (C=O, C11), 164.5 (C=O, 
C16), 160.3 (C=O, C8), 144.3 (C, C20), 129.2 (CH, C19), 129.1 (C, C17), 127.3 (C, C3), 123.9 
(C, C4), 119.2 (CH, C18), 83.9 (C, C13), 63.1 (CH2, C10), 59.7 (CH, C6), 57.5 (CH, C7), 27.8 
(CH3, C14), 26.4 (CH2, C2), 20.8 (CH3, C12); IR (neat, cm-1) vmax 2987 (N-H, stretch), 2124 
(N=N=N), 1776 (C=O lactam, stretch), 1735 (C=O, stretch), 1704 (C=O, stretch), 1646 (C=O, 
stretch), 1603 (aromatic C-H, stretch), 1148 (C-O ester, stretch); HRMS (ESI) [M+Na]+ calcd. 











To a suspension of ciprofloxacin (1.00 g, 3.02 mmol) in 1 N NaOH (10 mL) and THF (20 mL) 
was added a solution of di-tert-butyl dicarbonate (720 mg, 3.32 mmol, 1.1 eq.) in THF (20 mL) 
dropwise at rt. The reaction mixture was stirred at rt for 18 h, then the solvent was removed 
under reduced pressure. The residue was taken up in H2O (20 mL) and the pH adjusted to 7 
with sat. aq. NH4Cl solution. The resulting precipitate was filtered and washed with H2O (1 × 
10 mL) to give a white solid. The solid was suspended in MeOH/0.1 N NaOH (60 mL, 1:1) and 
heated to 30 °C for 45 min. The solvent was removed under reduced pressure, and the residue 
taken up in EtOH/H2O (20 mL, 99:1) and evaporated 3 times. The solid was taken up in CH2Cl2 
(20 mL) and the solvent removed under reduced pressure to give the title compound as a 
white solid (1.30 g, 2.87 mmol, 95%).  
1H NMR (400 MHz, CDCl3) δ 8.76 (1H, s, H15), 8.02 (1H, d, J = 12.8 Hz, H8), 7.36 (1H, d, J 
= 7.0 Hz, H11), 3.67 (4H, appt. br. s, H4), 3.53 (1H, appt. br. s, H16), 3.29 (4H, appt. br. s, 
H5), 1.50 (9H, s, H1), 1.40-1.39 (2H, m, H17 or H17’), 1.21-1.23 (2H, m, H17 or H17’); 13C 
NMR (125 MHz, CDCl3) δ 177.1 (C, C12), 166.9 (C, C14), 154.5 (C, C3), 153.6 (C, d, J = 
250.4 Hz, C7), 147.5 (CH, C15), 145.8 (C, d, J = 11.25 Hz, C6), 139.0 (C, C10), 120.2 (C, d, 
J = 6.8 Hz, C9), 112.6 (CH, d, J = 23.6 Hz, C8), 108.2 (C, C13), 105.0 (CH, C11), 80.4 (C, 
C2), 49.8 (CH2, C4 and C5), 35.3 (CH, C16), 28.4 (CH3, C1), 8.3 (CH2, C17 and C17’); 19F 
NMR (376 MHz, CDCl3) δ -121.0; IR (neat, cm-1) vmax 2977 (carboxylic acid O-H, stretch), 1777 
(C=O unsaturated, stretch), 1701 (C=O, stretch), 1681 (C=O, stretch), 1455 (O-H, bend), 1367 
(aromatic C-N, stretch); LRMS (ESI) [M+H]+ calcd. for [C22H2719FN3O5]+ 432.2 observed 432.1.  
Data in accordance with previous literature reports.333 
 
Ethyl 4-((4,6-dichloropyrimidin-2-yl)amino)butanoate (43) 
 
Prepared following general method 1, using 2,4,6-trichloropyrimidine (1.00 g, 5.45 mmol), 
ethyl-4-aminobutyrate hydrochloride (1.10 g, 6.54 mmol, 1.2 eq.) and NEt3 (1.90 mL, 13.6 
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mmol, 2.5 eq.) in acetone (34 mL). The crude product was purified by FCC on SiO2 (20-70% 
EtOAc in PE 40-60) to give the title compound as a light yellow solid (469 mg, 1.69 mmol, 
31%).  
Rf 0.48 (25% EtOAc/PE 40-60); 1H NMR (400 MHz, CDCl3) δ 6.59 (1H, s, H10), 5.87 (1H, br. 
s, H1), 4.14 (2H, q, J = 7.1 Hz, H6), 3.49 (2H, q, J = 6.7 Hz, H2), 2.39 (2H, t, J = 7.2 Hz, H4), 
1.94 (2H, p, J = 7.1 Hz, H3), 1.25 (3H, t, J = 7.1 Hz, H7); 13C NMR (101 MHz, CDCl3) δ 173.2 
(C, C5), 161.9 (C, C8), 161.8 (C, C9), 109.1 (CH, C10), 60.7 (CH2, C6), 41.1 (CH2, C2), 31.6 
(CH2, C4), 24.7 (CH2, C3), 14.3 (CH3, C7); IR (neat, cm-1) vmax cm-1 2980 (aliphatic C-H 
stretch), 1705 (ester C=O stretch), (aliphatic C-H bend), 1375 (C-N stretch), 788 (aromatic C-
Cl stretch); HRMS (ESI) [M+H]+ calcd. for [C10H1435Cl2N3O2]+ 278.0463 observed 278.0456 (Δ 
= -2.5 ppm) 
Data in accordance with previous literature reports.69 
 
Ethyl 4-((4,6-divinylpyrimidin-2-yl)amino)butanoate (42) 
 
Prepared following general method 2, using 43 (301 mg, 1.08 mmol), K2CO3 (897 mg, 6.50 
mmol, 6.0 eq.), potassium vinyl trifluoroborate (434 mg, 3.24 mmol, 3.0 eq.) and 
PdCl2(dppf)·CH2Cl2 (90.0 mg, 0.110 mmol, 0.1 eq.)  in 1,4-dioxane (13 mL) and H2O (1.4 mL). 
The crude product was purified by FCC on SiO2 (25-50% EtOAc in PE 40-60) to give the title 
compound as a yellow oil (283 mg, 1.08 mmol, quant.).  
Rf 0.58 (25% EtOAc/PE 40-60); 1H NMR (400 MHz, CDCl3) δ 6.56 (2H, dd, J = 17.4, 10.6 Hz, 
H11), 6.51 (1H, s, H10), 6.34 (2H, d, J = 17.4 Hz, H12’), 5.54 (2H, dd, J = 10.6, 1.3 Hz, H12), 
5.14 (1H, br. s, H1), 4.11 (2H, q, J = 7.2 Hz, H6), 3.52 (2H, q, J = 6.6 Hz, H2), 2.40 (2H, t, J = 
7.4 Hz, H4), 1.95 (2H, p, J = 7.1 Hz, H3), 1.23 (3H, t, J = 7.2 Hz, H7); 13C NMR (101 MHz, 
CDCl3) δ 173.5 (C, C5), 163.7 (C, C8), 162.6 (C, C9), 135.9 (CH, C11), 121.4 (CH2, C12), 
105.7 (CH, C10), 60.4 (CH2, C6), 40.7 (CH2, C2), 31.8 (CH2, C4), 25.1 (CH2, C3), 14.2 (CH3, 
C7); IR (neat, cm-1) vmax 2977 (aromatic C-H, stretch), 2901 (alkene C-H, stretch), 1728 (C=O 
ester), 1539 (aromatic C=C, stretch), 936 (alkene C=C, bend); HRMS (ESI) [M+H]+ calc. for 
[C14H20N3O2]+ 262.1556 observed 262.1554 (Δ = – 0.8 ppm). 
Data in accordance with previous literature reports.69 
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4-((4,6-Divinylpyrimidin-2-yl)amino)butanoic acid (41) 
 
Prepared following general method 3, using 42 (190 mg, 0.727 mmol) and LiOH·H2O (93.0 
mg, 2.18 mmol, 3.0 eq.) in THF/H2O (10 mL, 1:1). The reaction mixture was diluted with H2O 
(5 mL), acidified to pH 5 with 1 N HCl and extracted with CH2Cl2 (3 × 10 mL). The combined 
organics were dried (MgSO4) and evaporated under reduced pressure to give the title 
compound as a cream solid (100 mg, 0.430 mmol, 60%).  
Rf 0.27 (EtOAc); 1H NMR (400 MHz, CDCl3) δ 6.84-6.76 (1H, m, H1), 6.60-6.48 (3H, m, H9 
and H10), 6.35-6.17 (2H, m, H11’), 5.59-5.57 (2H, m, H11), 3.59 (2H, q, J = 6.0 Hz, H4), 2.46 
(2H, t, J = 6.8 Hz, H2), 2.02 (2H, p, J = 6.7 Hz, H3); 13C NMR (101 MHz, CDCl3) 177.7 (C, 
C5), 163.9 (C, C8), 162.2 (C, C7), 135.3 (CH, C10), 122.4 (CH2, C11), 104.0 (CH, C9), 40.9 
(CH2, C2), 32.4 (CH2, C4), 25.0 (CH2, C3); IR (neat, cm-1) vmax 3279 (N-H, stretch), 2929 
(aromatic C-H stretch), 1702 (C=O ester, stretch), 1562 (aromatic C=C, stretch), 928 (alkene 
C=C, bend); LRMS (ESI) [M-H]- calc. for [C12H14N3O2]- 232.4 observed 232.1.  





To a solution of 41 (808 mg, 3.47 mmol) in DMF (50 µL) was added DIPEA (1.205 mL, 6.94 
mmol, 2.0 eq.) and HATU (2.415 g, 4.16 mmol, 1.2 eq.). To this was added 30 (1.138 g, 3.47 
mmol, 1.0 eq.), and the reaction mixture was stirred at rt for 2 h. The reaction mixture was 
diluted with H2O and the organic layer was washed with brine, then dried (MgSO4) and 
concentrated in vacuo to give the crude product. The crude product was purified by FCC (C18 
silica, eluted with 5-95% acetonitrile in 0.1 M NH4OH) to give the title compound as a yellow 
oil (614 mg, 1.13 mmol, 47%).  
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Rf 0.24 (2% MeOH/CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 6.96 (1H, s, H4), 6.73 (2H, dd, J = 
17.3, 10.6 Hz, H2),  6.50 (2H, dd, J = 17.3, 1.1 Hz, H1’), 5.68 (2H, dd, J = 10.6, 1.1 Hz, H1), 
5.04 (1H, d, J = 12.8 Hz, H21), 4.94 (1H, d, J = 5.2 Hz, H12), 4.85-4.74 (3H, m, H21’ and H14), 
4.16-4.10 (2H, m, H7), 3.55 (1H, d, J = 18.2 Hz, H19), 3.35 (1H, d, J = 18.2 Hz, H19’), 2.70-
2.62 (2H, m, H9), 2.15-2.10 (2H, m, H8), 2.08 (3H, s, H23), 1.54 (9H, s, H18); 13C NMR (101 
MHz, CDCl3) δ 174.2 (C=O), 173.3 (C=O), 171.2 (C=O), 170.6 (C=O), 164.0 (C, C3), 162.5 
(C, C5), 135.2 (CH, C2), 127.4 (C, C20), 123.0 (CH2, C1), 121.5 (C, C15), 110.6 (CH, C4), 
83.8 (C, C17), 63.1 (CH2, C21), 59.3 (CH, C14), 57.5 (CH, C12), 48.1 (CH2, C7), 33.7 (CH2, 
C9), 27.8 (CH3, C18), 26.5 (CH2, C8), 25.6 (CH2, C19), 20.8 (CH3, C23); IR (neat, cm-1) vmax 
2971 (aromatic, C-H stretch), 2923 (N-H, stretch), 1780 (C=O, stretch), 1719 (C=O, stretch), 
1684 (C=O, stretch), 1635 (conjugated C=C, stretch); HRMS (ESI) [M+H]+ calcd. for 





40 (65 mg, 0.120 mmol) was dissolved in anhydrous THF (640 µL) and anhydrous hexanes 
(5.77 mL) were added to make a suspension. To this was added s-BuOH (213 µL, 2.28 mmol, 
19.0 eq.), CAL B lipase (267 mg) and 4 Å molecular sieves (54 mg). The reaction mixture was 
heated to 50 °C in a heated incubator for 3 days. The reaction mixture was diluted with CH2Cl2 
(1 mL), filtered and the filtrate was evaporated under reduced pressure to give the crude 
product as an orange oil (47 mg, 0.0934 mmol, 78%) which was taken on without further 
purification. 
Rf 0.45 (25% EtOAc/PE 40-60); 1H NMR (400 MHz, MeOD) δ 6.72 (1H, s, H4), 6.64 (2H, dd, 
J = 17.4, 10.7 Hz, H2), 6.39 (2H, appt. d, J = 16.8 Hz, H1’), 5.74-5.4 (3H, m, H1 and H14), 
5.13-5.27 (1H, m, H22), 5.07-4.94 (1H, m, H12), 4.43-4.08 (2H, m, H21), 3.54-3.48 (2H, m, 
H7), 3.55-3.47 (2H, m, H19), 2.45-2.37 (2H, m, H9), 2.09-1.93 (2H, m, H8); 13C NMR (125 
MHz, CDCl3) δ 169.9 (C=O),168.0 (C=O), 166.6 (C=O), 164.7 (C, C3), 164.0 (C, C5), 135.1 
(CH, C2), 129.7 (C, C20), 123.5 (C, C15), 123.3 (CH2, C1), 110.6 (CH, C4), 84.2 (C, C17), 
65.1 (CH, C14), 60.2 (CH, C12), 53.5 (C19), 48.1 (CH2, C7), 33.7 (CH2, C9), 29.7 (CH3, C18), 
28.0 (CH2, C8), 22.7 (CH2, C19); IR (neat, cm-1) vmax 2925 (aromatic, C-H stretch), 2920 (N-
H, stretch), 1757 (C=O, stretch), 1681 (C=O, stretch), 1660 (C=O, stretch), 1640 (conjugated 
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C=C, stretch); HRMS (ESI) [M+H]+ calcd. for [C24H32N5O5S]+ 502.2124 observed 502.2122 (Δ 





Ciprofloxacin hydrochloride (500 mg, 1.36 mmol) was dissolved in EtOH (9 mL) and sulfuric 
acid (conc., 200 μL, cat.) was added dropwise. The reaction mixture was heated to reflux for 
48 h then cooled to rt. The solvent was removed under N2 and the residue taken up in sat. aq. 
NaHCO3 and extracted with CH2Cl2 (4 × 5 mL). The combined organics were dried (MgSO4) 
and evaporated under reduced pressure to give the title compound as a cream solid (328 mg, 
0.913 mmol, 67%)  
1H NMR (400 MHz, CDCl3) δ 8.49 (1H, s, H12), 7.98 (1H, d, J = 13.4 Hz, H8), 7.25 (1H, d, J 
= 7.2 Hz, H5), 4.37 (2H, q, J = 7.2 Hz, H16), 3.44 (1H, sept., J = 4.0 Hz, H13), 3.26-3.21 (4H, 
m, H3), 3.13-3.07 (4H, m, H2), 1.40 (3H, t, J = 7.2 Hz, H17), 1.35-1.29 (2H, m, H14), 1.17-
1.11 (2H, m, H14); 13C NMR (101 MHz, CDCl3) δ 173.1 (C=O, d, J = 2.2 Hz, C10), 165.7 (C=O, 
C15), 153.3 (C, d, J = 249.5 Hz, C9), 148.0 (CH, C12) 144.9 (C, d, J = 10.6 Hz, C4), 137.9 (C, 
d, J = 1.2 Hz, C6), 122.8 (C, d, J = 7.1 Hz, C7), 113.1 (CH, d, J = 23.3 Hz, C8), 110.2 (C, 
C11), 104.7 (CH, d, J = 3.2 Hz, C5), 60.7 (CH2, C16), 51.0 (CH2, d, J = 4.5 Hz, C3), 45.9 (CH2, 
C2), 34.4 (CH, C13), 14.4 (CH3, C17), 8.0 (CH2, C14); 19F NMR (376 MHz, CDCl3) δ -123.6; 
IR (neat, cm-1) vmax cm-1 2988 (alkene C-H, stretch), 2901 (N-H, stretch), 1718 (C=O, stretch), 
1617 (C=O, stretch), 1589 (C=C, stretch), 1254 (ester C-O, stretch); LRMS (ESI) [M+H]+ calcd. 
for [C19H23FN3O3]+ 360.2 observed 360.5.  












dihydroquinoline-3-carboxylic acid (37) 
 
Step 1: 39 (145 mg, 0.290 mmol) was dissolved in DMF (1.4 mL) and DIPEA (252 mL, 1.97 
mmol, 5.0 eq.) and bis(4-nitrophenyl)carbonate (176 mg, 0.580 mmol, 2.0 eq.) were added. 
The reaction mixture was stirred at rt for 48 h then diluted with H2O. The organic layer was 
washed with brine, sat. aq. NaHCO3, 1 N KOH (1 × 1 mL each), the organic layer was dried 
(MgSO4) and concentrated in vacuo to give a dark brown residue.  
Step 2: A suspension of ciprofloxacin (101 mg, 0.305 mmol, 1.05 eq.) and NaHCO3 (122 mg, 
1.45 mmol, 5.0 eq.) in H2O (1.8 mL) was heated to 45 °C for 40 min then cooled to rt. To this 
was added a solution of the dark brown residue from step 1 in 1,4-dioxane (1.8 mL). The 
reaction was stirred at rt for 2 h then H2O (1 mL) and diethyl ether (1 mL) were added. The 
aqueous portion was extracted with diethyl ether, CH2Cl2 and EtOAc (2 × 1 mL of each), and 
the combined organics were dried (MgSO4) and evaporated in vacuo. The resulting residue 
was purified by FCC on C18 silica (eluted with 5-95% MeCN in 0.1 N NH4OH) and lyophilised 
to give the title compound as a cream solid (10.0 mg, 0.0116 mmol, 4%).    
Rf 0.55 (25% EtOAc/PE 40-60); 1H NMR (400 MHz, CDCl3) δ 8.81-8.76 (1H, m, H35), 8.30-
8.22 (1H, m, H27), 8.12-8.02 (1H, m, H27),  7.35-7.28 (1H, m, H30), 6.63-6.46 (3H, m, H2 and 
H4), 6.40-6.30 (3H, m, H1b and H30), 5.69-5.62 (1H, m, H12), 5.61-5.54 (2H, m, H1’), 5.32-
5.28 (1H, m, H14), 5.09-4.90 (2H, m, H19 or 21), 4.75-4.55 (2H, m, H19 or 21), 3.76-3.66 (1H, 
br. s, H36), 3.61-3.49 (4H, m, H23), 3.50-3.02 (4H, m, H24), 2.41-2.35 (2H, m, H7), 2.09-1.94 
(2H, m, H9); 1.54-15.1 (9H, m, H18); 1.44-1.35 (2H, m, H37), 1.30-1.20 (2H, m, H37); 13C 
NMR (101 MHz, CDCl3) δ 173.0 (C=O, C31), 172.7 (C10), 170.5 (C=O, C16), 166.0 (C=O, 
C33), 165.9 (C=O, C13), 164.9 (C, C3), 164.4 (C, C5), 160.4 (C=O, C22), 154.5 (C, C26), 
148.2 (CH, C35), 145.6 (C, C25), 135.7 (C, C29), 135.7 (CH, C2), 125.2 (C, C20), 125.0 (C, 
C15), 122.2 (C, C28), 121.5 (CH2, C1), 119.6 (CH, C27), 108.3 (C, C32), 105.5 (CH, C4), 
105.4 (CH, C30), 83.9 (C, C17), 65.5 (CH2, C21), 60.4 (CH, C12 or C14), 53.5 (CH, C12 or 
C14), 50.8 (CH2, C24), 50.7 (CH2, C24), 40.5 (CH2, C7), 40.5 (CH2, C23), 35.3 (CH, C36), 
33.3 (CH2, C9), 27.9 (CH3, C18), 26.4 (CH2, C19), 25.5 (CH2, C8), 8.2 (CH2, C37); IR (neat, 
cm-1) vmax 3121 (O-H stretch), 2937 (N-H, stretch), 1779 (C=O, stretch), 1723 (C=O, stretch), 
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1719 (C=O, stretch), 1626 (C=O, stretch), 1545 (C=C, stretch), 1457 (O-H, bend), 1209 (C-F, 






To a suspension of 41 (50.0 mg, 0.215 mmol), 44 (69.0 mg, 0.193 mmol, 0.9 eq.) and NEt3 
(75 μL, 0.539 mmol, 2.0 eq.) in DMF (2.2 mL) was added T3P (50% in DMF, 192 μL, 0.323 
mmol, 1.5 eq.). The reaction mixture was stirred at rt for 18 h. The reaction mixture was poured 
onto H2O (30 mL) and washed with sat. aq. NaHCO3 solution (1 × 5 mL), 10% aq. citric acid 
solution (1 × 5 mL), 5% aq. LiCl solution (10 × 5 mL). The organic layer was dried (MgSO4) 
and evaporated in vacuo to give the crude product as a cream solid (42.0 mg, 0.0731 mmol, 
34%), which was used without further purification.  
Rf 0.10 (2% MeOH/CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 8.53 (1H, s, H21), 8.06 (1H, d, J = 
13.2 Hz, H15), 7.24 (1H, d, J = 7.0 Hz, H18), 6.60-6.52 (3H, m, H4 and H2), 6.35 (2H, d, J = 
17.3 Hz, H1’), 5.55 (2H, dd, J = 10.6, 1.4 Hz, H1), 5.26-5.19 (1H, m, H6), 4.39 (2H, q, J = 7.12 
Hz, H23), 3.84 (2H, t, J = 4.6 Hz, H11), 3.64 (2H, t, J = 4.2 Hz, H11), 3.57 (2H, q, J = 6.4 Hz, 
H7), 3.40 (1H, appt. s, J = 3.2 Hz, H25), 3.20 (4H, t, J = 4.9 Hz, H12), 2.50 (2H, t, J = 7.3 Hz, 
H9), 2.03 (2H, p, J = 6.8 Hz, H8), 1.40 (3H, t, J = 7.1 Hz, H24), 1.35-1.27 (2H, m, H26), 1.16-
1.10 (2H, m, H26); 13C NMR (125 MHz, CDCl3) δ 173.1 (C=O, C19), 171.3 (C=O, C10), 165.9 
(C=O, C22), 163.7 (C, C3), 162.7 (C, C5), 153.3 (C, d, J = 247.1 Hz, C14), 148.2 (CH, C21), 
144.0 (C, d, J = 10.6 Hz, C13), 138.0 (C, d, J = 1.1 Hz, C17), 135.9 (CH, C2), 123.6 (C, d, J 
= 7.0 Hz, C16), 121.5 (CH2, C1), 113.6 (CH, d, J = 22.9 Hz, C15), 110.7 (C, C20), 105.7 (CH, 
C4), 105.0 (CH, d, J = 2.6 Hz, C18), 61.0 (CH2, C23), 50.5 (CH2, d, J = 5.6 Hz, C12), 49.6 
(CH2, d, J = 2.9 Hz, C12), 45.4 (CH2, C11), 41.3 (CH2, C11), 41.0 (CH2, C7), 34.5 (CH, C25), 
30.6 (CH2, C9), 25.2 (CH2, C8), 14.4 (CH3, C24), 8.2 (CH2, C26); 19F NMR (376 MHz, CDCl3) 
δ -123.9; IR (neat, cm-1) vmax 2988 (aromatic C-H, stretch), 2901 (N-H, stretch), 1777 (C=O, 
stretch), 1735 (C=O, stretch), 1709 (C=O, stretch), 1647 (conjugated C=C, stretch), 1380 (C-
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fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (45) 
 
Prepared following general method 3, with 47 (25.0 mg, 0.0436 mmol) and LiOH·H2O (2.00 
mg, 0.0477 mmol, 1.1 eq.) in THF/H2O (1:1, 588 μL). The reaction mixture was washed with 
diethyl ether (1 × 1 mL), the aqueous phase acidified to pH 4 using 1 N HCl and extracted with 
CH2Cl2 (5 × 2 mL). The combined organics were dried and evaporated to give the title 
compound as a cream solid (11.0 mg, 0.0201 mmol, 46%). 
Rf 0.08 (2% MeOH/CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 14.91 (1H, s, H23), 8.79 (1H, s, 
H21), 8.06 (1H, d, J = 12.9 Hz, H15), 7.34 (1H, d, J = 6.6 Hz, H18), 6.61-6.52 (3H, dd and s, 
J = 17.4, 10.7 Hz, H2 and H4), 6.35 (2H, d, J = 17.0 Hz, H1’), 5.56 (2H, dd, J = 10.6, 1.4 Hz, 
H1), 5.40-5.33 (1H, m, H6), 3.89-3.83 (2H, m, H11), 3.70-3.64 (2H, m, H11), 3.58 (2H, q, J = 
6.4 Hz, H7), 3.55-3.49 (1H, m, H24), 3.32-3.24 (4H, m, H12), 2.51 (2H, t, J = 7.3 Hz, H9), 2.04 
(2H, p, J = 6.9 Hz, H8), 1.43-1.53 (2H, m, H25), 1.23-1.17 (2H, m, H25); 13C NMR (101 MHz, 
CDCl3) δ 177.2 (C=O, C19), 171.3 (C=O, C10), 166.9 (C=O, C22), 163.7 (C, C3), 162.6 (C, 
C5), 153.6 (C, d, J = 249.2 Hz, C14), 147.6 (CH, C21), 145.4 (C, d, J = 10.1 Hz, C13), 139.0 
(C, d, J = 1.0 Hz, C17), 135.8 (CH, C2) 121.6 (C, C16), 120.5 (CH2, C1), 112.7 (CH, d, J = 
23.7 Hz, C15), 108.4 (C, C20), 105.6 (CH, C4), 105.0 (CH, d, J = 3.3 Hz, C18), 50.2 (CH2, d, 
J = 6.3 Hz, C12), 49.4 (CH2, d, J = 2.7 Hz, C12) 45.2 (CH2, C11), 41.2 (CH2, C11), 41.0 (CH2, 
C7), 35.3 (CH, C24) 30.5 (CH2, C9), 25.1 (CH2, C8), 8.3 (CH2, C25);  19F NMR (376 MHz, 
CDCl3) δ -121.16; IR (neat, cm-1) vmax 3038 (aromatic C-H, stretch), 2922 (N-H, stretch), 1732 
(C=O, stretch), 1728 (C=O, stretch), 1625 (C=O, stretch), 1556 (C=C, stretch), 1212 (C-F, 
stretch); HRMS (ESI) [M+H]+ calcd. for [C29H3219FN6O4]+ 547.2469 observed 547.2470 (Δ = 




4.1.3 Peptide synthesis and stapling procedures 
Solid Phase Peptide Synthesis (SPPS): For all peptides, a Rink Amide MBHA low-loading 
resin (0.19-0.51 mmol/g, 100−200 mesh) was used to afford C-terminal amides upon cleavage 
from the resin. Fmoc-protected amino acids were employed and the following side chain 
protecting groups were used: 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Arg), 
triphenylmethyl (Asn, Gln, Cys), tert-butyl (Asp, Glu, Ser, Thr, Tyr) and Boc (His, Lys, Trp). 
The chloranil qualitative amine test was used to assess the completion of coupling and 
deprotection reactions: colourless resin indicated an Fmoc-protected peptide, a blue/green 
resin colour indicated a free N-terminus.170  
Manual SPPS: Amide coupling was conducted using Fmoc-protected amino acids (5.0 eq.), 
HATU (5.0 eq.), DIPEA (10.0 eq.) in the minimum amount of DMF at rt with agitation. Fmoc 
deprotection was carried out with 20% piperidine in DMF at rt with agitation. If required, N-
terminal capping was performed with acetic anhydride or octanoyl chloride (5.0 eq.) and 
DIPEA (10.0 eq.) in CH2Cl2 at rt with agitation.  
Automated SPPS: Automated SPPS was carried out on solid-phase using a Fmoc-protecting 
group strategy on a CEM Liberty Blue® automated microwave peptide synthesiser. Arginine 
was coupled using double couplings for 15 min each without microwave irradiation. All other 
amino acids were coupled using double couplings with 25 W power at 75 oC for 15 min. Fmoc 
deprotection was carried out with 20% piperidine in DMF, using 45 W power at 75 oC over 3 
min. If required, the N-terminus of the peptide was capped by acetylation using 20% acetic 
anhydride or octanoyl chloride solution in DMF solution at rt for 20 min.  
Resin cleavage: Peptides were cleaved from the resin in either a TFA cocktail containing 
TFA/H2O/TIPS/CH2Cl2 (92.5:2.5:2.5:2.5) or TFA/TIPS/H2O/EDT (94:1:2.5:2.5). Cleavage was 
performed at 40 ˚C for 45 min, and the resin filtered. The eluate was dried, and the cleaved 
peptide was precipitated with cold diethyl ether and dried. The crude peptide was purified by 
preparative HPLC. The purified peptides were lyophilised, the mass analysed by LCMS and 
the purity determined by analytical HPLC. 
General procedure for two-component CuAAC peptide stapling: The double-click 
reaction was used to cross-link the azido functionalised peptides with dialkynyl functionalised 
linkers. All solvents for the reaction were degassed with N2 for 30 min before use. The dialkynyl 
linker (1.1 eq.) was added to the diazido peptide in H2O/tert-butanol (1:1) under N2 before the 
addition of a solution of CuSO4·5H2O (1.0 eq.), tris(3-hydroxypropyltriazolylmethyl)amine 
(THPTA, 1.0 eq.), and sodium ascorbate (3.0 eq.) in H2O. The reaction mixture was stirred at 
rt and monitored by LCMS and HPLC. One the starting material had been consumed, the 
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reaction was lyophilised, and the crude product purified by preparative HPLC. The purified 
stapled peptide was lyophilised and analysed by LCMS and analytical HPLC. 
General procedure for Cys-DVP peptide stapling: The Cys-DVP reaction was used to 
cross-link the cysteine-containing peptides with DVP linkers. The peptide was dissolved in 
MES buffer (pH 6, 50 mM) and DMF (1:3, 2 mg/mL of peptide). The DVP linker (1.1 eq.) was 
added as a stock solution (5- mg/mL, DMF/MES buffer (pH 6, 50 mM), 1:1). The reaction was 
stirred at rt and monitored by analytical HPLC and LCMS. Additional linker was added if 
necessary. Once the starting material had been consumed the solvent was removed under 
N2, and the crude product purified by preparative HPLC. The purified stapled peptide was 














4.1.4 Peptide analysis 
4.1.4.1 Peptide mass spectrometry data 
Table 24 Peptide sequence, mass spectrometry and analytical HPLC data for Chapter 2 peptides. All peptides are 
C-terminal amides and acetyl capped. X = Orn(N3), X6, X10 and X11 = stapled between Orn(N3) with linkers 6, 10 
and 11 respectively. ND = purity not determined.  










P1 Ac-IARKLQCIADQFHRL 1853.2 927.6 927.6 [M+2H]2+ >99 7.9 
P2 Ac-IGAQLRRMADDLNAQY 1876.1 939.0 939.1 [M+2H]2+ >99 7.9 
P3 Ac-CATQLRRFGDKLNFR 1866.1 934.0 934.1 [M+2H]2+ >99 6.9 
P4 Ac-IAXKLQCIADQFHXL 1819.9 911.6 911.0 [M+2H]2+ >99 9.3 
P5 Ac-IGXQLRRMADDLNXQY 2013.0 2013.4 2013.0 [M+H]+ 94 8.3 
P6 Ac-CAXQLRRFGDKLNXR 1897.0 950.3 949.5 [M+2H]2+ >99 9.3 
P4-6 Ac-IAX6KLQCIADQFHX6L 1993.0 997.7 997.5 [M+2H]2+ 92 9.3 
P5-6 Ac-IGX6QLRRMADDLNX6QY 2229.5 1115.8 1115.5 [M+2H]2+ 90 8.5 
P6-6 Ac-CAX6QLRRFGDKLNX6R 2113.4 1057.7 1057.5 [M+2H]2+ ND†† 7.3 
P8 Ac-IARKLQXIADQFHXL 1874.2 1875.0 1875.2 [M+H]+ >99 8.6 
P9 Ac-IGAXLRRMADXLNAQY 1913.2 957.7 957.5 [M+2H]2+ 94 9.6 
P10 Ac-CATQLRXFGDKLNXR 1843.1 922.5 922.5 [M+2H]2+ 95 9.6 
P11 Ac-IATQLRXFGDKLNXR 1853.1 1854.6 1854.1 [M+H]+ 92 8.5 
P8-10 Ac-IARKLQX10IADQFHX10L 2044.4 1023.4 1023.2 [M+2H]2+ >99 10.4 
P9-10 Ac-IGAX10LRRMADX10LNAQY 2083.4 1042.9 1042.7 [M+2H]2+ 97 8.9 
P11-10 Ac-IATQLRX10FGDKLNX10R 2023.3 1012.7 1012.6 [M+2H]2+ 94 8.0 
P8-11 Ac-IARKLQX11IADQFHX11L 2739.3 1370.6 1370.5 [M+2H]2+ 92 8.4 
P9-11 Ac-IGAX11LRRMADX11LNAQY 2777.3 1390.0 1389.6 [M+2H]2+ 91 8.3 
P11-11 Ac-IATQLRX11FGDKLNX11R 2717.2 907.1 906.7 [M+3H]3+ >99 7.5 
11 10-Ahx-Ahx-(D)R-(D)R-(D)R 864.1 864.9 864.0 [M+H]+ 97 7.4 
†Purity and retention time determined by analytical HPLC (5-95% MeCN in H2O run over 15 min). 
††Due to the broad signal an accurate purity could not be determined. See Appendix 2 for HPLC spectrum.  
 
Table 25 Peptide sequence, mass spectrometry and analytical HPLC data for Chapter 3 peptides. All peptides are 
C-terminal amides and have an uncapped N-terminus unless otherwise specified; Ac = acetyl capped, C8 = capped 
with octanoyl chloride. C17 = stapled with linker 17. C18 = Cys capped with reagent 18, C45 = stapled with linker 45.  








AMP1 Ac-TLKQFCKGVGKWCVK 1766.2 884.4 884.1 [M+2H]2+ 84 6.9 
AMP2 FCKWAFKWCKK 1473.9 738.1 738.0 [M+2H]2+ 86 9.9 
AMP3 Ac-WCLKKFRGCF 1328.7 665.4 665.3 [M+2H]2+ 85 7.9 
AMP4 RFRRLCKKWRKRCKKI 2204.8 735.9 735.9 [M+3H]3+ >99 5.9 
AMP5 C8-GCLKFIKKCL 1277.7 1278.8 1278.7 [M+H]+ 95 10.2 
AMP6 KWVQNYCKHLGRKCHTLKT 2341.2 1171.6 1171.4 [M+2H]2+ >99 6.0 
AMP7 NLFRKLCHRLFRRCFGYTLR 2599.2 867.2 867.4 [M+3H]3+ 95 5.7 
AMP1-17 Ac-TLKQFC17KGVGKWC17VK 2031.1 1016.7 1016.6 [M+2H]2+ 94 8.5 
AMP2-17 FC17KWAFKWC17KK 1737.9 1739.8 1739.2 [M+H]+ 97 7.6 
AMP3-17 Ac-WC17LKKFRGC17F 1592.8 1594.5 1594.0 [M+H]+ 98 9.0 
AMP4-17 RFRRLC17KKWRKRC17KKI 2470.2 1236.3 1236.1 [M+2H]2+ 95 9.4 
AMP5-17 C8-GC17LKFIKKC17L 1541.9 1543.5 1543.1 [M+H]+ 98 7.0 
AMP6-17 KWVQNYC17KHLGRKC17HTLKT 2607.4 2608.8 2608.2 [M+H]+ 82 7.8 
AMP7-17 NLFRKLC17HRLFRRC17FGYTLR 2864.5 1433.3 1433.3 [M+2H]2+ >99 8.9 
AMP1-18 Ac-TLKQFC18KGVGKWC18VK 2008.5 1005.2 1005.0 [M+2H]2+ >99 6.9 
AMP2-18 FC18KWAFKWC18KK 1716.2 858.9 858.4 [M+2H]2+ >99 6.7 
AMP3-18 Ac-WC18LKKFRGC18F 1571.0 786.2 786.5 [M+2H]2+ 87 7.2 
AMP4-18 RFRRLC18KKWRKRC18KKI 2447.1 816.6 816.3 [M+3H]3+ >99 6.0 
AMP5-18 C8-GC18LKFIKKC18L 1520.0 1518.8 1518.9 [M-H]- >99 7.5 
AMP6-18 KWVQNYC18KHLGRKC18HTLKT 2583.4 1291.3 1291.6 [M-2H]2- >99 6.0 
AMP7-18 NLFRKLC18HRLFRRC18FGYTLR 2841.5 711.3 711.4 [M+4H]4+ 96 7.8 
AMP2a FAKWAFKWLKK 1451.9 1452.8 1452.8 [M+H]+ 93 4.8 
AMP4a RFRRLRKKWRKRLKKI 2268.9 757.1 757.3 [M+3H]+ 90 6.3 
AMP6a KWVQNYMKHLGRKAHTLKT 2339.8 1170.9 1170.5 [M+2H]2+ 96 6.4 
AMP2-45 FC45KWAFKWC45KK 2021.5 2021.0 2021 [M+H]+ >99 7.5 




Table 26 SPPS yields for linear peptides after HPLC purification.  
Peptide Amount of resin used  
(mg) 
Amount of resin 
used (mmol) 
Yield of peptide 
(mg) 
Yield of peptide 
(%) 
P1 294 0.1 21* 22* 
P2 294 0.1 19* 20* 
P3 294 0.1 25 13 
P4 301 0.1 15 8 
P5 301 0.1 20 10 
P6 400 0.1 4.2 2 
P8 735 0.25 81 17 
P9 735 0.25 154 22 
P10 735 0.25 9.2 2 
P11 301 0.1 15 8 
11 758 0.25 52* 48* 
AMP1 490 0.25 57 13 
AMP2 490 0.25 78 21 
AMP3 490 0.25 51 15 
AMP4 490 0.25 30 5 
AMP5 490 0.25 29 9 
AMP6 490 0.25 14 2 
AMP7 490 0.25 35 5 
AMP2a 196 0.1 21* 28* 
AMP4a 196 0.1 19* 16* 
AMP6a 196 0.1 13* 11* 
*Yield of peptide cleaved and purified from half of the resin. The % yield has been multiplied by 2 to correct for 
this.  
 
4.1.4.2 Circular dichroism spectroscopy 
Circular dichroism spectroscopy was performed with an Aviv 410 circular dichroism spectro-
polarimeter. Data was collected between 185-250 nm at 298 K with the following parameters: 
1.0 nm bandwidth, 0.5 s averaging time, 1.0 nm wavelength step in a quartz cuvette with a 1 
mm path length. Pure, lyophilised peptides were dissolved in either MeCN/H2O (1:1), SDS (30 
mM), TFE (50% aq. solution) or NaPi (10 mM, pH 7.4) to an approximate concentration of 100 
µL. The recorded spectra are a smoothed average of three scans, normalised against the 
solvent used.  
The ellipticity recorded was normalised against the ellipticity recorded at 207 nm, and the α-
helicity calculated using the following equation, where E193 and E211 are the ellipticities 
recorded at these wavelengths (in nm):176,175 
 
% 𝛼 ℎ𝑒𝑙𝑖𝑐𝑖𝑡𝑦 = 27.58 − (14.46 × 𝐸193) + (1.86 × 𝐸193










4.2 General biological procedures 
4.2.1 Flow cytometry assay procedures  
Ethical approval was obtained from the Faculty Research Ethics Committee at Anglia Ruskin 
University, Cambridge, UK where the experiments were carried out. Unless otherwise stated, 
the experiments were performed on no fewer than three separate occasions using platelets 
from different donors. Data were analysed using AccuriC6 BD Software and GraphPad Prism. 
The following reagents were used: Annexin-V-PE (BD Biosciences, UK), anti-PAC-1 (BD 
Biosciences, UK), anti-CD62P (BD Pharmingen, UK), or anti-CD63 (BD Pharmingen, UK). 
Peptides and ABT737 were stored as 1 mM DMSO stock solutions.  
Preparation of washed platelet suspension:v Human blood was collected from healthy 
volunteers, who had not taken medication for two weeks, following informed consent in 
accordance with the Declaration of Helsinki. Blood was collected into 11 mM sodium citrate 
and washed platelets were prepared as follows: Platelet-rich plasma was obtained by 
centrifugation (240 g, 15 min). Prostaglandin E1 (2 μM) was added to prevent premature 
platelet activation, and the plasma was centrifuged at 640 g for 15 min. Platelets were 
suspended in calcium-free Tyrode‘s buffer (CFT buffer, containing: 140 mM NaCl, 5 mM KCl, 
10 mM HEPES, 5 mM glucose, 0.42 mM NaH2PO4, 12 mM NaHCO3, titrated to pH 7.4 with 
NaOH) to a final concentration of 2×108 platelet/mL and rested at 37 °C for 1 h.  
Flow cytometry: Treated washed platelet suspensions were analysed by flow cytometry 
using a C6 Accuri Flow Cytometer (Beckton Dickinson, UK). At least 10,000 events were 
acquired per experiment. In all the experiments, the entire platelet population was primarily 
gated by forward scatter (FSC). Untreated platelets (no fluorescent markers, no compounds) 
were analysed by flow cytometer on the laser of interest and the measurement used as zero. 




v Performed by Dr. Niaz Ahmed, Anglia Ruskin University.  
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Figure 83 Data normalisation for flow cytometry of washed platelet suspensions. A) An example of untreated 
platelets with gating applied. B) A threshold is set using the fluorescence of untreated platelets. C) After treatment, 
‘positive platelets’ are defined as platelet populations that appear to the right of the threshold.  
Phosphatidyl serine (PS) exposure: PS exposure was assessed after incubation of washed 
platelet suspensions (50 μL) at 37 °C in Tyrode’s solution (pH 7.4, 445 μL) with either the 
peptide (5 μL of 1 mM stock solution in DMSO), DMSO (5 μL) or ABT737 (5 μL of 1 mM stock 
solution in DMSO). At t = 1, 2 and 3 h, 25 μL of the suspension was added to 25 μL of an 
annexin V solution (10% in Tyrode‘s solution), and the sample was protected from direct light 
and analysed by flow cytometry.  
Platelet activation markers: Platelet activation markers (PAC-1, CD62P and anti-CD63) 
were assessed after incubation of washed platelet suspensions (3 μL) in CFT buffer (pH 7.4, 
105 μL) with the desired antibody (1.2 μL) and peptide (1.1 μL of 1 mM DMSO stock solution) 
at 37 °C for 1 h. The suspensions were analysed by flow cytometry at t = 1 h.  
 
4.2.2 Microbiology assay procedures 
All compounds were stored as 25.6 mg/mL stock solutions in DMSO/H2O (1:1). Colistin was 
used as a positive control and was stored as a 25.6 mg/mL stock solution in water. 
Antimicrobial testing was performed according to EUCAST guidelines in microdilution.316 
Compounds were tested against P. aeruginosa strains PAO1,317 YM64,318 and 
Staphylococcus aureus. Unless otherwise stated, each result was duplicated on the same 
plate and each test repeated in triplicate on separate days.  
Initial MIC testing: Bacterial cultures were grown overnight at 37 °C in Lysogeny broth (LB).w 
The suspension was diluted to OD600 0.1 in cation-adjusted Muller-Hinton broth (MH-B). Into 
each well of a 96-well plate was added 99 μL of bacterial suspension, leaving the outer 
columns empty in case of evaporation. To the desired wells 1 μL of compound stock solution 
was added. Some wells left untreated as a negative control, colistin was added to some wells 
as a positive control, and some wells contained only cation-adjusted MH-B to check for 
contamination of the broth. The plate was sealed with a gas-permeable membrane and 
incubated at 37 °C with 50 revolutions per minute (rpm) shaking for 18 h. The optical density 
at 600 nm (OD600) was measured, and the MIC was determined as the lowest concentration 
of compound which prevented visible growth.  
Serial dilution MIC testing: Bacterial suspensions were made up to OD600 0.1 in MH-B as 
previously described. Into the first well of a 96-well plate was added 99 μL of broth and 1 μL 
 
w Preparation of bacterial cultures performed by Thomas O’Brien, University of Cambridge.  
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of compound (stock solution = 25.6 mg/mL in DMSO/H2O 1:1). Into the second well was added 
199 μL of broth and 1 μL of compound (stock solution = 25.6 mg/mL in DMSO/H2O 1:1). To 
the remaining wells was added 99 μL of broth. 100 μL of solution was taken from the second 
well and added to the third with mixing and this was continued along the row until the minimum 
desired concentration was achieved: the excess 100 μL was discarded. Each well was 
inoculated with 50 μL of bacterial suspension. The same controls were included as previously 
described. The plate was sealed with a gas-permeable membrane and incubated at 37 °C 
with 50 rpm shaking for 18 h. The absorbance at 600 nm was measured, and the MIC was 
determined as the lowest concentration of compound which prevented visible growth. 
Biofilm crystal violet assay: The protocol for ‘Initial MIC testing’ was followed, with sub-
inhibitory concentrations of the desired peptides. Untreated bacteria and bacteria treated with 
inhibitory and sub-inhibitory concentrations of colistin were included as controls. The bacterial 
supernatant was aspirated off, and the cells were washed with deionised H2O (2 × 120 µL). 
Crystal violet (0.1% aq. solution, 120 µL) was added to each well and the plate was incubated 
at rt for 15 min. The crystal violet was aspirated off, the wells washed with deionised H2O (3 × 
120 µL) and the plate was inverted and dried in the oven for 10 min. To each well was added 
acetic acid (30% aq. solution, 120 µL) and the plate was vortexed gently. The absorbance at 
595 nm of each well was measured.  
 
4.2.3 Computational methodsx 
Peptides were modelled using Chimera. For peptides in Chapter 3, the staple was placed so 
that the overall cationic charge and amphipathicity, both of which are linked to antimicrobial 
activity, were preserved.98,312 Additionally, any potentially unstable residues (Met) were 
replaced by the staple where possible. Where possible, molecular dynamics simulations were 
performed using AMBER 14 on the linear and stapled peptides to predict the ability of the 
staple to maintain peptide helicity. The force fields ff14SB and GAFF were used to describe 
the peptide and staple respectively during the simulations. 
  
 
x All computational experiments described in this dissertation were performed by Dr. Yaw Sing Tan, A*STAR 
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6.2 Appendix 2 - Selected analytical HPLC traces  
Gradients are given as % of MeCN in H2O with a 0.01% formic acid additive. The spectra 
shown were recorded at a wavelength of 220 nm. A peak at 2 min corresponds to DMSO 
which was added to aid the solubility of the peptide.  
P1 5-95%        P1 30-80%   
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